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Summary 
Interactions between proteins are central to essentially all cellular processes. Many methods for 
the investigation of proteins have been developed in the last years, requiring either removal of 
the proteins from their normal cellular environment, perturbation of the cells or costly 
instrumentation and high technical expertise. Therefore we aimed at designing assays for in 
vivo studies of protein interaction, distribution, dynamics, characterization, manipulation and 
enzyme activity focusing on proteins essential for DNA methylation. 
During this thesis we developed a novel fluorescent two-hybrid (F2H) assay for a direct analysis 
of protein-protein interactions in real-time in mammalian cells using a simple co-localization 
read-out of fluorescent bait and prey proteins at a stably integrated chromosomal lac operator 
array. The F2H assay can in principle be automated and therefore be used for high-throughput 
protein-protein interaction analysis in living cells. 
To study localization and mobility of endogenous proteins inside cells we took advantage of 
antibodies derived from alpacas (Lama pacos). Alpacas and other Camelidae posses so-called 
heavy-chain antibodies that lack light chains. We isolated the heavy chain variable domain 
(VHH) of these single chain antibodies, fused this antigen-binding fragment to a fluorescent 
protein and expressed the resulting chimeric protein (referred to as chromobody) in cells. 
Chromobodies allow for the first time targeting and tracing of endogenous antigens, i.e. 
proteins as well as non-protein components in living cells. 
An additional, highly versatile application of VHHs is to couple them on solid support for 
biochemical methods or to fuse them to a structural protein. We generated a VHH against the 
green fluorescent protein GFP (referred to as GFP-binding protein; GBP) and tethered it to the 
nuclear lamina (referred to as GFP-nanotrap). With this intracellular GFP-nanotrap we could 
ectopically capture GFP-fusion proteins and their interacting endogenous factors. Such directed 
manipulation of cellular components opens up new possibilities to study protein dynamics, 
function and regulation including the role and organization of nuclear architecture. 
To gain insight into the regulation and maintenance of cytosine-5 methylation by DNA 
methyltransferases (Dnmts), an epigenetic hallmark leading to transcriptional silencing, we 
developed an in vivo trapping assay that directly visualizes the activity and subnuclear targeting 
of Dnmts in the context of dynamic chromatin structures and simultaneously ongoing DNA 
replication. The trapping assay offers an approach to test new types of Dnmt inhibitors 
including small molecules. 
In summary, we developed new, simple, versatile and efficient methods and tools to study the 
regulation and function of proteins involved in complex cellular processes such as DNA 
methylation in living cells in real-time. 
  Summary 
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CHAPTER I. Introduction 
The understanding of cellular processes and regulatory networks requires quantitative data on 
all cellular components including their concentration, modifications, interactions, distributions, 
dynamics and activity in living cells. Biological processes such as DNA replication or DNA 
methylation are strictly coordinated and mostly take place in complex, dynamic networks and 
clusters where many proteins are involved. In the case of DNA replication, being an essential 
part of the cell cycle, this implies assembly of several thousand replication clusters throughout 
the cell which comprise specialized proteins to unwind the DNA, stabilize the single strand 
state and precisely duplicate each and every base pair of the genome exactly one time on the 
leading strand as well as on the lagging strand where in addition, maturation of Okazaki 
fragments is required (Sclafani and Holzen, 2007). At the same time countless processes occur 
within cells involving an only partly known number of cellular factors. To gain an insight into 
such cellular events it is necessary to identify the involved factors, their functions and their 
interactions. 
Closely associated with the highly complex task of DNA replication is the maintenance of 
epigenetic information, i.e. DNA methylation and specific histone modifications during each 
cell cycle. Epigenetic information is defined as the information, which is inherited through 
mitosis or meiosis but is not contained within the basic sequence of DNA. So far, we owe part 
of our basic knowledge about DNA methylation, the most common epigenetic modification, to 
classical biochemical in vitro approaches, which cannot reproduce the complexity of living, 
mammalian cells. Therefore, the body of this thesis project aimed at developing new methods 
and tools to study proteins involved in DNA methylation, more precisely DNA 
methyltransferase 1 (Dnmt1) in their normal environment of living cells. First, we aimed at 
designing a new assay to directly visualize protein-protein interactions in living cells, including 
detection of interactions between Dnmt1 and proteins involved in DNA replication 
independently of cell cycle progression. The next objective was to generate a novel, versatile 
tool to recognize, trace and manipulate proteins in vivo. This tool should also be applicable to 
isolate proteins for biochemical and functional studies e.g. to determine enzymatic activity in 
vitro or chromatin immunoprecipitations (ChIPs). A further goal was to develop a method to 
directly visualize DNA methyltransferase activity in living cells, particularly to monitor kinetic 
properties of Dnmt1 in its native environment. 
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I.1. How to detect protein interactions? 
I.1.1. Antibodies and derivates thereof to identify proteins 
Many methods that are applied to detect and gain insight into biological functions depend on 
the recognition of an antigen by a specific antibody. Conventional antibodies are heteromeric 
molecules composed of light (L) and heavy (H) chains with constant and variable domains. The 
combination of variable domains of an H- and L-chain considerably diversifies the antigen-
binding repertoire of conventional antibodies (Fig. 1a). 
Antibodies are widely used as detection reagents in many biochemical, cellular and 
histological applications. However, despite being generally applied, conventional antibodies 
yield fundamental disadvantages. Antibodies are naturally designed to function in the 
extracellular milieu. Essential disulfide bonds are formed through a complex process of 
assembly. Therefore, antibodies expressed inside cells (within the reducing environment of the 
cytoplasm) are folded improperly and prone to aggregation. Additionally, batch-to-batch 
variations in monoclonal antibody quality and their limited amount of availability are common 
problems. To circumvent these limitations recombinant antibody formats such as antigen 
binding fragments (Fab fragments) or single chain variable fragments (scFvs) are being 
developed. Currently, widely used recombinant antibody-derivates are scFvs, a fusion of the 
variable heavy and light chains of immunoglobulins (Ig), linked together with a short, usually 
serine-glycine-linker (Fig. 1a). Nevertheless, scFvs and other formats do not solve all problems 
of conventional antibodies, as antigen recognition of scFvs in living cells also mostly is 
impaired by aggregation (Cardinale et al., 2004). 
Interestingly, camelids (Bactrian camels, dromedaries and llamas) developed in addition to their 
conventional antibodies, so-called heavy-chain antibodies solely composed of truncated H-
chains (Hamers-Casterman et al., 1993). Isolation of the variable domain of these single-chain 
antibodies yields the smallest intact antigen-binding fragment (15 kDa), the heavy chain 
variable (VHH) domain (Fig. 1b) (Muyldermans et al., 1994; Muyldermans and Travers, 1994). 
Sequence analysis and elucidation of the crystal structure revealed that VHHs contain four 
framework regions forming the core structure of the immunoglobulin domain and three 
complementarity-determining regions (CDRs) involved in antigen binding (Desmyter et al., 
2001; Desmyter et al., 1996; Harmsen et al., 2000). It has been shown that VHHs bind their 
antigen specifically with nanomolar affinity (Muyldermans and Lauwereys, 1999). Furthermore, 
VHHs are highly soluble and stable because of unique hydrophilic residues in their structural 
region (Davies and Riechmann, 1995; Muyldermans, 2001; van der Linden et al., 1999; Vu et 
al., 1997). 
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Fig. 1(a) Schematic outline of conventional antibodies composed of heavy (H) and light (L) chains with 
variable (v) and constant (c) domains. Recombinant derivates thereof are Fab fragments and single chain 
variable fragments (scFv). (b) In comparison, a Camelidae-derived heavy-chain antibody and the isolated 
heavy chain variable (VHH) domain. Within the crystal structure of the VHH, the three antigen binding 
loops (CDRs) are shown in yellow, cyan and green. Adapted from (Harmsen and De Haard, 2007) 
In contrast to scFvs, VHHs are encoded by only one gene, so they can easily be amplified by 
one RT-PCR reaction from total mRNA isolated from antibody producing cells (lymphocytes). 
For efficient selection of specific VHHs, the VHH repertoire of one animal is cloned in a phage 
display vector leading to a library. This library can then be screened for antigen-binding VHHs 
using the phage display technology. Several rounds of affinity purification and amplification 
lead to the isolation of candidate-VHHs, which then can be tested by e.g. enzyme-linked 
immunosorbent assay (ELISA) and further characterized through Biacore measurements (Fig. 2). 
Once, specific VHHs are identified and selected they can easily be produced as recombinant 
proteins in bacteria in infinite amounts with constant quality (Muyldermans, 2001). 
 
 
Fig. 2Workflow of the isolation of specific VHHs from an immunized alpaca. Adapted from 
(Muyldermans, 2001) 
We show in chapter II.2 that fluorescently labeled VHHs (chromobodies) are capable to detect 
and visualize antigens in living cells. In chapter II.3 we demonstrate that immobilized VHHs 
(nanotraps) can also be applied for biochemical and functional studies as well as a tool to 
manipulate cellular proteins. 
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I.1.2. Biochemical methods to study protein interactions 
Widely used biochemical methods to analyze proteins and interacting factors are affinity 
purification, immunoprecipitation (IP), co-immunoprecipitation (Co-IP) or pull-down assays. 
These methods are all based on the binding of a specific antibody or a ligand to the protein of 
interest and require removal of the proteins from their native environment. The antibody/ligand 
is immobilized on a solid support and binds specifically the protein of interest from a complex 
protein mixture. After elution of the isolated protein (Fig. 3) it can be further analyzed by e.g. 
gel electrophoresis, western blotting or mass spectrometry. With these techniques the presence, 
molecular mass, quantity, enzymatic activity or post-translational modifications of the protein 
of interest but especially interactions with other proteins can be determined. Presumably the 
most significant method to identify a specifically precipitated protein and interacting 
components is western blotting. After protein-isolation, gel electrophoresis is uses to separate 
proteins according to their size. The proteins are then transferred to a membrane, where they 
are detected with specific antibodies. This reveals their presence, quantity, size and also 
provides information about potential interaction partners. A further method to identify proteins, 
particularly unknown proteins and interactors is mass spectrometry. The protein of interest is 
precipitated together with interacting proteins and separated by gel electrophoresis. Candidate 
bands are cut out and the masses of proteolytic peptides in that protein band determined. 
Subsequent in silico data analysis and comparison with protein databases provides the best 
match proteins. 
 
 
Fig. 3Schematic representation of precipitation of a particular protein (green) from a crude mixture of 
proteins by binding to a specific antibody (or ligand) immobilized on solid support. Interacting proteins 
(yellow) can be co-precipitated. 
Dependant on the properties of the analyzed proteins detergent solubilization of cells during 
biochemical studies can promote artificial protein-aggregation leading to false positive results 
(Pfleger and Eidne, 2003). Artificial introduction of expression vectors into cells can induce 
overexpression of the corresponding protein of interest, which then may lead to protein-
aggregation. Additionally, it is not possible to distinguish between direct and indirect 
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interactions when the protein of interest is assembled in a large multi-component complex. The 
disassembly of complexes may then lead to disruption of the protein interactions to be assayed 
for, giving false negatives. Slight variation of protocols may therefore lead to contrary results. To 
some extend proteins can be embedded in complexes in such a way, so that the specific 
antibody has no access to and can therefore not detect its epitope. Furthermore, it is very 
demanding to detect weak respectively transient interactions between proteins or very low 
abundant proteins. Nevertheless biochemical approaches to detect protein interactions are 
mostly considered to be the “gold standard” among the diversity of present techniques (Cho et 
al., 2004). 
 
I.1.3. Genetic yeast two-hybrid screens to detect protein-protein 
interactions 
Another frequently used technique is the genetic identification of protein-protein interactions 
with yeast two-hybrid (Y2H) screens. The Y2H technique uses two protein domains of a 
transcriptional activator that have specific functions: a DNA-binding domain (DB), which 
recognizes and binds to a defined promoter sequence upstream of a reporter gene and an 
activation domain (AD) which interacts with the RNA polymerase II complex, thereby 
activating transcription. 
For a Y2H screen, first, a cDNA encoding the protein of interest (X) is cloned into a bait vector, 
creating a fusion of the DB and X. Second, a cDNA encoding an interacting protein Y (or a 
library of cDNAs encoding an entire collection of different potential interactors) is cloned into a 
prey vector, creating a fusion of the AD and Y. Finally, bait and prey protein are expressed in 
yeast and if they interact, the AD is recruited to a reporter gene, creating a hybrid transcription 
factor. The downstream reporter gene, e.g. an auxotrophic marker such as HIS3 or ADE2 or a 
colony color marker like lacZ, is transcribed (Fig. 4). Yeast cells expressing HIS3 or ADE2 
protein are able to grow on selective medium lacking the amino acid histidine or the 
metabolite adenine, respectively. Expression of -galactosidase (LacZ) results in blue coloration 
of the yeast cells growing on medium containing X-gal (Durfee et al., 1993; Fields and Song, 
1989; Vidal et al., 1996b; Vojtek et al., 1993). Thus, the interaction of two proteins is measured 
by the reconstitution of a transcription factor and the consequent activation of a set of specific 
reporter genes. (Vidal et al., 1996a). 
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Fig. 4Schematic representation of the yeast two hybrid screen. The bait protein (X) is fused to the DNA-
binding domain (DB) of a transcription factor. The prey protein (Y) is fused to the transcription activation 
domain (AD) of a transcription factor. Reporter gene expression can then efficiently be selected for in 
yeast. Modified from (Vidal and Legrain, 1999) 
Although Y2H screens are very suitable to identify whole protein networks and to develop 
interactome maps in an efficient and inexpensive high-throughput manner (Vidal, 2005) they 
also have some disadvantages: (I) Y2H screens yield a high number (up to 50%) of false positive 
or false negative identifications (Deane et al., 2002); (II) mammalian proteins expressed in yeast 
can be misfolded and therefore dysfunctional; (III) lack of some post-translational modifications 
of mammalian proteins in yeast may prevent interactions; (IV) no spatial or dynamic resolution 
where and when the detected interactions normally occur in higher eukaryotic cells is obtained 
(Kim et al., 2007). Additionally, before performing Y2H screens self-activation of transcription 
by the bait proteins has to be tested for. Modification of the classical Y2H screen like forward 
or reverse ‘n’ -hybrid screens (reviewed in (Vidal and Legrain, 1999)) and combinations thereof 
have been made to further improve the reliability of the screens. However, a second line of 
evidence for confirmation of interactions by higher confidence assays such as Co-IPs remains 
necessary (Uetz et al., 2004). 
An analogous system to the yeast two-hybrid screen is the bacterial two-hybrid (B2H) selection 
system, which facilitates the rapid interaction analysis of large libraries (more than 108 in size), 
due to the higher transformation efficiency and faster growth rate of E.coli (Hu et al., 2000; 
Joung et al., 2000).  
 
I.1.4. Fluorescently labeled proteins and applications in living cells 
The combined use of genetic and biochemical approaches has led to the identification of 
thousands of potential protein interactions, but the cell specificity and the subcellular 
localization of these interactions often remain unknown. Therefore more and more cellular 
approaches are being developed and applied in order to investigate distribution and dynamics 
of fluorescently labeled proteins as well as interactions between proteins in their physiological 
environment with minimal perturbation. Kinetic data on protein localization and mobility 
acquired from live cell microscopic methods can be modeled to quantify biophysical properties 
of molecules and processes (Phair and Misteli, 2001). Generally, with fusion proteins it has to 
be taken into account that they are artificially introduced into cells. Controls, including 
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antibody stainings against the endogenous protein are therefore crucial to assure that the fusion 
protein is distributed and regulated like its endogenous counterpart. Furthermore, potential 
influences on cellular properties and interference with cellular processes such as cell cycle 
have to be considered (Sporbert et al., 2005). 
 
Photomanipulation to measure protein dynamics 
The mobility of fluorescently labeled proteins can be measured with fluorescence recovery after 
photobleaching (FRAP) and fluorescence loss in photobleaching (FLIP). Both techniques involve 
deliberate photobleaching an area with a short intense laser beam that results in localized 
destruction of fluorophores. For FRAP evaluation the time it takes for fluorescence to recover in 
the bleached area is measured. In a FLIP experiment the selected area is repeatedly bleached 
and the time it takes for adjacent areas to loose fluorescence is measured (Fig. 5). The kinetics 
of the fluorescence recovery respectively loss provide a quantitative measure of the mobility of 
the labeled proteins. 
 
 
Fig. 5Graphical presentations of FRAP and FLIP experiments. The arrow indicates photobleaching with 
an intense laser beam (in the outlined area); M the region where fluorescence intensity is measured. 
Photoactivatable (PA) fluorescent proteins generally display little or no initial fluorescence 
under excitation at the imaging wavelength. After activation by irradiation at a different (usually 
shorter) wavelength they dramatically increase their fluorescence intensity. Photoconvertible 
(PC) proteins, on the other hand, undergo a change in the fluorescence emission profile upon 
optically-induced changes (a strong laser pulse) to the chromophore. These effects result in a 
direct and controlled highlighting of distinct molecular pools within the cell and changes in 
fluorescent protein distribution can then be monitored and evaluated (Lippincott-Schwartz et 
al., 2003). 
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FRAP, FLIP, PA and PC are all based on conventional laser scanning microscopy. This enables 
the detection of localization of fluorescently labeled molecules within the optical spatial 
resolution defined by the diffraction limit (Abbe limit), at best 200 nanometers (Abbe, 1873). 
However, in order to understand the physical interactions between protein partners involved in 
a typical biomolecular process, the relative proximity of the molecules must be determined 
more precisely than diffraction-limited optical imaging methods permit. Techniques such as 
fluorescence resonance energy transfer (FRET), bimolecular fluorescence complementation 
(BiFC) or fluorescence correlation spectroscopy (FCS) permit determination of the vicinity 
between two molecules within several nanometers, a distance sufficiently close for molecular 
interactions to occur. 
 
Fluorescence energy transfer as a measure for protein interactions 
Förster radius energy transfer, mostly called fluorescence resonance energy transfer (FRET) is a 
non-destructive spectroscopic method that can monitor the proximity and relative angular 
orientation of fluorophores in vivo by the energy transfer between two fluorophores (Miyawaki 
et al., 1997). For monitoring the complex formation between two molecules in cells, one 
molecule is labeled with a donor-fluorophore and the other with an acceptor. The donor 
fluorescent dye has shorter excitation/emission wavelengths that allow excitation of the 
acceptor fluorescence dye. Typically two fluorophores with overlapping emission and 
excitation wavelengths are used, classically cyan fluorescent protein (CFP) and yellow 
fluorescent protein (YFP) (Mc Intyre et al., 2007) (Fig. 6a). An alternative technique to FRET is 
bioluminescence resonance energy transfer (BRET), a very similar technique, based on a 
bioluminescent donor and a fluorescent acceptor. 
When the donor and acceptor are in close proximity (1-10 nm) on account of an interaction of 
the two analyzed molecules, the donor transfers the excitation energy directly to the second 
fluorochrome (the acceptor) without the emission of a photon. Therefore, if energy transfer 
occurs, the donor channel signal will be quenched and the acceptor channel signal will be 
increased (Periasamy, 2001) (Fig. 6a). 
FRET quantification is most often based on measuring changes in fluorescence intensity or 
fluorescence lifetime upon changing the experimental conditions. The fluorescence lifetime 
refers to the average time the molecule stays in its excited state before emitting a photon. A 
common FRET microscopy and quantification technique is photo acceptor bleaching. To this 
end images of donor emission are taken with the acceptor being present. The acceptor is then 
bleached, such that it is incapable of accepting energy transfer. Further donor emission images 
are then acquired. A pixel-based quantification should then reveal a brighter fluorescence or a 
longer fluorescence lifetime of the donor in case of interaction (Sekar et al., 2003). 
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Fig. 6 (a) Principle of fluorescence resonance energy transfer (FRET). Interaction between proteins X and 
Y fused to cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) respectively results in 
FRET between the donor and the acceptor fluorophore. Plot: excitation (ex) / emission (em) spectra with 
maxima at 434nm / 476, 505nm (CFP) and 514nm / 527nm (YFP) (b) Head- or tail-fusions of fluorescent 
proteins can result in a distance larger than the FRET radius. (c) The fusion to the fluorescent protein may 
mask the interaction site and thus prevent an interaction that occurs under normal conditions. 
However, the quantitative or semi-quantitative determination of protein interactions with FRET 
is very complex and extensive positive as well negative controls are crucial (Miyawaki et al., 
1997). Fluorescent proteins fusion to the studied proteins can be N- or C-terminal. Opposite 
orientations of the fusions can easily result in a distance between the two fluorophores too large 
for a detectable FRET effect (Fig. 6b). Depending on the geometry of interactions fluorophore 
fusions can inhibit interactions, which occur under normal conditions (Fig. 6c). Therefore many 
potential protein-protein interactions might not be detected. Recently, it has been confirmed 
that photobleaching of YFP induces photoconversion of the protein and generation of a 
fluorescent byproduct emitting CFP-like fluorescence (Kirber et al., 2007; Valentin et al., 2005). 
On account of these results, this mainly used FRET pair appears to be less suitable for 
interaction studies or at least careful controls need to be done. 
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Fluorescence complementation to visualize protein interactions 
A more recent approach to determine protein-protein interactions in living cells is the 
bimolecular fluorescence complementation (BiFC) assay. This approach is based on the 
complementation between two non-fluorescent fragments of e.g. the yellow fluorescent protein 
(YFP). Reconstruction of the fluorescent protein due to interactions between the proteins fused 
to each of the fragments then recovers the fluorescence (Hu et al., 2002) (Fig. 7). 
In the last years complementation assays based on fragments of different proteins including 
other GFP variants (Magliery et al., 2005), monomeric red fluorescent protein 1 (mRFP1) (Jach 
et al., 2006), firefly luciferase (Paulmurugan et al., 2002), Gaussia luciferase (Remy and 
Michnick, 2006) or TEV protease (Wehr et al., 2006) have been developed. These various 
complementary fragments differ in their functional characteristics and cover a wide range of 
possible applications. Therefore, interactions between peptides, nuclear proteins, membrane 
proteins or proteins involved in signaling cascades in mammalian cells, E.coli or several other 
organisms could be visualized (an extended list of described interaction is available at: 
http://sitemaker.umich.edu/kerppola.bifc). A further modification of the BiFC assay is the 
simultaneous monitoring of expression and interaction of proteins (Wolff et al., 2006). 
 
 
Fig. 7Principle of bimolecular fluorescence complementation (BiFC). Non-fluorescent fragments of YFP 
(FR1 and FR2) are fused to the proteins X and Y to be tested. Interaction of X and Y bring the two 
fragments together thereby reconstituting the yellow fluorescent protein YFP 
The BiFC approach is capable to detect protein-protein interactions in living cells however, 
steric constraints can prevent the association of the fragment with the interactors. The present 
generation of fluorescence complementation assays has proven to be versatile, but they have 
some characteristics limiting their usage. One of these limitations is the irreversible association 
of the fluorescent protein fragments (Kerppola, 2006b). A second limitation is the intrinsic 
ability of fluorescent-protein fragments to associate with each other independently of an 
interaction between the proteins that are fused to the fragments. Finally, the chemical reactions 
required for fluorophore formation are very slow and temperature-sensitive making it so far 
impossible to directly visualize the protein-protein interactions in real-time (reviewed in 
(Kerppola, 2006a)). 
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Analysis of single fluorescent molecules in living cells 
In fluorescence correlation spectroscopy (FCS) diffusion and interaction of fluorescent 
molecules are studied by analyzing fluorescence intensity fluctuations arising from single 
molecules diffusing in and out of the illuminated volume of a focused laser beam (Magde et al., 
1974). An important extension of FCS is the simultaneous detection of two color channels, 
using two spectrally distinct dyes (Schwille et al., 1997). With two-color FCS, a cross-
correlation (FCCS) analysis can be made, where the signals of the two channels are time-
correlated with each other and the interaction between two molecules results in a positive 
cross-correlation amplitude. Single molecule tracing (SMT) allows the direct observation of 
movements in the nanometer-scale. This makes it possible to discriminate between specific 
classes of mobility, such as diffusion, binding, direct transport or motion confined to spatially 
restricted zones (Grunwald et al., 2006). 
Measuring fluorescence of single molecules is a highly complex task demanding a very 
specialized microscopic instrumentation optimized for highest sensitivity and acquisition 
speed. Furthermore, in living cells the signal-to-noise ratio is largely influenced by auto-
fluorescence and scattering. Additionally, the big complexity of the biological systems under 
investigation requires individual adaptation, optimization and extensive testing of each 
experimental setup (Haustein and Schwille, 2007). On account of the huge amounts of data 
generated during any of the methods and the lack of robust automated evaluation software 
additional expertise in data analysis and interpretation is required. 
In summary, numerous cell biological methods based on microscopy of fluorescent proteins, 
biochemical or genetic approaches are available for addressing whether proteins interact or 
not. However many of these methods can be technically very demanding, can be limited by the 
strength of the interaction, or cannot resolve whether the interaction indeed occurs inside cells. 
To this end our goal was to develop new and simple assays that are adaptable to high-
throughput formats primarily to study function, regulation and inhibition of DNA methylation 
as well as interactions between proteins involved in this process. 
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I.2. DNA methylation in mammalian cells 
In mammalian organisms cells differ dramatically in their function, shape and organization 
despite of an identical genetic information. During development cellular differentiation is 
established by epigenetic modifications such as DNA methylation and histone tail 
modifications regulating the expression of cell-type specific sets of genes (Berger, 2007; Bird, 
2002; Bird, 2007; Leonhardt and Cardoso, 2000; Reik, 2007; Robertson, 2002). DNA 
methylation pattern changes along with cellular differentiation and once established, it is stably 
inherited from one cell generation to the next. 
Addition of methyl groups to the 5-position of cytosine residues in palindromic cytosine-
guanine dinucleotides (CpGs) in the vertebrate genome (Gruenbaum et al., 1981) is a 
postreplicative modification catalyzed by DNA (cytosine-5-)-methyltransferases (Dnmts). CpG 
dinucleotides are not randomly distributed in the mammalian genome; instead, they are highly 
enriched at promoter regions while being greatly under-represented in the rest of the genome. 
About 70% of CpGs in mammalian genomes are methylated (Ehrlich et al., 1982), 
predominantly in repressive heterochromatic region and in repetitive sequences (Baylin and 
Bestor, 2002; Yoder et al., 1997). Cytosine methylation generally is associated with 
transcriptional inactivation (Bird and Wolffe, 1999; Kass et al., 1997) partly through inhibition 
of sequence-specific DNA binding factors (Tate and Bird, 1993). Additionally, the recruitment 
of methyl binding proteins, which interact with histone deacetylases to modify histones, creates 
a chromatin structure refractory to transcriptional initiation (Jones et al., 1998; Nan et al., 
1998). In the promoters of about half of all human genes, clusters of CpG-rich regions termed 
CpG islands are present (Bird, 1986; Gardiner-Garden and Frommer, 1987). These CpG islands 
represent about 15% of all CpG sites and were found to be mostly unmethylated (Shen et al., 
2007; Weber et al., 2007). Therefore, the role of CpG island methylation in normal 
development however remains poorly understood. It is now widely held that CpG islands 
associated with both housekeeping and tissue-specific genes are unmethylated at any 
developmental stage, except when associated with certain imprinted genes and genes subject 
to X inactivation (Saxonov et al., 2006). 
Controversially discussed aspects of mammalian development are the molecular mechanisms 
underlying the two major waves of genome-wide demethylation and remethylation: one during 
germ-cell development and the other after fertilization (reviewed in (Reik et al., 2001)). The 
genome-wide demethylation could either occur passively through the lack of maintenance 
methylation following DNA replication and cell division (Howlett and Reik, 1991; Rougier et 
al., 1998) or could be due to an active process (Oswald et al., 2000). Recently, it has been 
shown that Gadd45a (growth arrest and DNA-damage-inducible protein 45 alpha), a nuclear 
protein involved in maintenance of genomic stability, DNA repair and suppression of cell 
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growth, promotes active DNA demethylation by interaction with DNA repair endonuclease 
XPG (Barreto et al., 2007). 
In contrast to developmental genes, which need to be epigenetically regulated with flexibility, 
imprinted genes need to be stably silenced. To imprint genes, DNA methylation is introduced 
during gametogenesis, by the de novo methyltransferases Dnmt3a (Chedin et al., 2002; Jia et 
al., 2007; Kaneda et al., 2004) and/or Dnmt3b and their cofactor Dnmt3L (for Dnmt3-like) 
(Hata et al., 2002; Margot et al., 2003; Suetake et al., 2004). Dnmt3L is closely related to 
Dnmt3 but appears to be inactive on its own (Bourc'his et al., 2001). After fertilization, the 
methylation is later on stably maintained by Dnmt1 (Goll and Bestor, 2005; Reik, 2007). The 
importance of maintaining DNA methylation patterns is underlined by the observation that 
homozygous null deletions of mouse Dnmt1 result in an 80% reduction of global genomic 
methylation in embryonic stem cells and embryos and are lethal early in development (Lei et 
al., 1996; Li et al., 1992). 
As mentioned, CpG islands in the promoter region of many genes on the inactive copy of the X 
chromosome are methylated (Panning and Jaenisch, 1996). However, it has been shown that 
on a chromosome-wide scale, the active copy is actually more highly methylated, mostly 
occurring within the bodies of genes (the transcribed regions), rather than in upstream 
promoters or intergenic areas (Hellman and Chess, 2007; Lock et al., 1986; Viegas-Pequignot et 
al., 1988; Weber et al., 2005b). 
DNA methylation has also been postulated to play a role in cancer for many decades since 
methylation patterns are significantly altered in many tumor types. In cancer cells, the 
transcriptional silencing of tumor-suppressor genes by CpG island promoter hypermethylation 
correlates with tumor development (Hanahan and Weinberg, 2000; Jones and Baylin, 2002). 
Another effect of hypermethylation is a higher frequency of point mutations; CpGs are mutation 
hotspots. This results from increased deamination of 5-methylcytosine (5mC) to thymine, 
resulting in a CT transition mutation, which is not recognized and repaired before the next 
round of DNA replication (Jones et al., 1992; Laird and Jaenisch, 1994). In contrast, 
spontaneous deamination of cytosine forms uracil, which is efficiently recognized and removed 
by DNA repair enzymes like uracil DNA glycosylases (Craig and Bickmore, 1994; Sved and 
Bird, 1990). Additionally, genome-wide hypomethylation in cancer cells induces chromosomal 
instability and promotes insertional mutagenesis by retroviral elements (such as IAPs) (Brown 
and Robertson, 2007; Eden et al., 2003; Gaudet et al., 2003; Gaudet et al., 2004; Howard et 
al., 2007; Walsh et al., 1998). In summary, DNA methylation and the maintenance of proper 
DNA methylation plays a central role in the epigenetic control of mammalian gene expression 
during development and is required for X inactivation (Beard et al., 1995), genomic imprinting 
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(Li et al., 1993) and silencing of retroviral elements (Jaenisch and Bird, 2003; Jones and Takai, 
2001). 
In mammals DNA methylation is catalyzed by a family of four active DNA methyltransferases: 
Dnmt1, Dnmt2, Dnmt3a and Dnmt3b where Dnmt2 mainly methylates aspartic acid transfer 
RNA (tRNA(Asp)) (Goll et al., 2006) but is not required for DNA methylation (Okano et al., 
1998b). Dnmt3a and Dnmt3b are essential for the methylation of previously unmethylated 
DNA (de novo methylation) during development (Okano et al., 1999; Okano et al., 1998a). 
The most abundant DNA methyltransferase in mammals is Dnmt1 designated as the 
maintenance methyltransferase, ensuring the established methylation patterns are preserved 
over many cell divisions (Bestor, 2000; Li, 2002; Robertson and Wolffe, 2000). 
 
I.2.1. Function and localization of Dnmt1 
DNA methylation occurs in the context of other epigenetic modifications and once established 
it needs to be maintained over many cell division cycles. This means that both, genetic and 
epigenetic information have to be faithfully duplicated, implying a tight coordination between 
the DNA replication machinery and epigenetic regulators. The first eukaryotic DNA 
methyltransferase to be identified and cloned was later named Dnmt1 (Bestor et al., 1988; 
Bestor, 1988; Bestor and Ingram, 1983; Bestor and Ingram, 1985). Dnmt1 is ubiquitously 
expressed in mammalian cells, and considered to be the key maintenance methyltransferase 
(reviewed in (Goll and Bestor, 2005)). It predominantly methylates hemimethylated CpG 
dinucleotides in the genome. In vitro assay show a 10- to 40-fold higher activity of Dnmt1 on 
hemimethylated DNA as compared with unmethylated substrates (Pradhan et al., 1999). 
The enzyme comprises 1620 amino acids. The first 1100 amino acids constitute the regulatory 
domain and the remaining residues form the catalytic domain containing the 10 conserved 
motifs (I-X). These motifs are characteristic for cytosine-5-methyltransferases including the 
invariant catalytic center (Pro-Cys-/PC-motif) in motif IV (Leonhardt and Bestor, 1993). The 
substitution of the PC dipeptide has been shown to result in a loss of enzymatic activity (Hsieh, 
1999). The regulatory and catalytic domain are joined by seven Lys-Gly repeats (Fig. 8). 
Mouse oocytes and preimplantation embryos express an oocyte-specific variant called Dnmt1o. 
At the mouse Dnmt1 locus an oocyte-specific promoter initiates translation at the second, 
downstream ATG. This yields the shortened Dnmt1o, lacking 118 amino acids at the N-
terminus (Carlson et al., 1992; Gaudet et al., 1998; Mertineit et al., 1998). The truncated 
Dnmt1o is retained in the cytoplasm of mouse oocytes and early embryos (Cardoso and 
Leonhardt, 1999; Doherty et al., 2002; Howell et al., 2001) with restricted mobility, while it 
has a higher mobility in the nucleus of preimplantation embryos (Grohmann et al., 2005). Apart 
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from the development specific isoforms of Dnmt1 also proliferation dependent mRNA 
expression has been described (Robertson et al., 2000b). 
The postreplicative maintenance of methylation patterns is mediated and secured by 
association of Dnmt1 with the replication machinery throughout S phase (Chuang et al., 1997; 
Leonhardt et al., 1992; Robertson et al., 1999). Replication-independent loading on (peri-
)centromeric heterochromatin from mid-late S to G2 and M phase has also been described 
(Easwaran et al., 2004) (Fig. 8). During S phase Dnmt1 transiently interacts with the central 
loading platform PCNA at replication foci. This interaction was shown not to be essential for 
methylation activity but to increase the maintenance activity in a twofold manner (Schermelleh 
et al., 2007; Spada et al., 2007). 
 
 
Fig. 8Structure of DNA methyltransferase 1 (Dnmt1). In the regulatory domain the PCNA binding 
domain (PBD) and the targeting sequence (TS) mediate association of Dnmt1 with chromatin during the 
cell cycle. The catalytic domain contains 10 conserved motifs (I-X) characteristic for C5-
methyltransferases and the catalytic center (red line in motif IV). Regulatory and catalytic domains are 
joined by seven Lys-Gly repeats (KG)7.  
Furthermore, it has been suggested that the recruitment of Dnmt1 to DNA damage sites (via the 
PCNA binding domain; PBD) is responsible for coupling DNA repair and subsequent 
restoration of DNA methylation patterns (Mortusewicz et al., 2005). Many additionally 
interactions of Dnmt1 with a range of nuclear proteins including UHRF1, G9a, pRb, DMAP1, 
E2F1, HDAC 1/2, MeCP2, p23, PARP-1, Annexin V, p53, SUV39H1 and HP1b and the 
nucleolar chromatin remodeling complex Tip5/Snf2h have also been described (Bostick et al., 
2007; Esteve et al., 2006; Fuks et al., 2000; Fuks et al., 2003; Geiman et al., 2004a; Geiman et 
al., 2004b; Kimura and Shiota, 2003; Reale et al., 2005; Robertson et al., 2004; Robertson et 
al., 2000a; Robertson et al., 2000b; Santoro et al., 2002; Smallwood et al., 2007). The 
regulation of Dnmt1 during development and cell cycle as well as disease related defects are 
reviewed in more detail in chapter II.5. 
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In summary, Dnmt1 interacts with a large number of various proteins. These interactions 
involve different types of proteins ranging from transcription factors to histone 
methyltransferases. This places Dnmt1 at the center of a complex network connecting two 
epigenetic pathways - both resulting in the establishment and maintenance of transcriptionally 
inactive chromatin - DNA methylation and histone modification. All interactions occur in a 
highly dynamic fashion and are mainly cell cycle dependently regulated. Our aim was now to 
develop new in vivo assays and tools to analyze which of them occur where and when and 
what their functional consequences are.  
 
I.2.2. Molecular mechanism of DNA methylation 
Having a closer look at DNA methylation being a postreplicative process reveals an interesting 
problem. DNA replication is highly processive taking about ~2 kbp/ min (Jackson and Pombo, 
1998). A certain discrepancy emerges since in vitro steady-state kinetic analysis of purified 
recombinant Dnmt1 revealed a much lower turn-over rate of about 70–450 s per methyl group 
transfer (Bacolla et al., 1999; Pradhan et al., 1999). Assuming in vivo DNA methylation to be 
faster, it is still not likely to come close to the 30–40 times faster DNA replication, especially 
taking into account cytosine-methylation being a highly complex reaction (Fig. 9). 
The methyl transfer reaction process is initiated with nonspecific binding of Dnmts to DNA, 
recognition of specific hemimethylated CpG sites and recruitment of the methyl group donor S-
adenosyl methionine (SAM) to the active site of the enzyme (Chiang et al., 1996). Dnmts 
transfer a methyl group onto carbon 5 of cytosines through a covalent intermediate between the 
PC dipeptide in the active site and the carbon 6 of the target cytosine (Bestor and Verdine, 
1994; Chen et al., 1991; Santi et al., 1983). During this covalent complex formation, the 
cytidine base is flipped out of the DNA doublehelix into an active site pocket of the enzyme 
(Horton et al., 2004; Klimasauskas et al., 1994). The base pairing hydrogen bonds are broken 
and the stacking interactions with the adjacent base pairs are lost (Cheng and Roberts, 2001; 
O'Gara et al., 1996). Through the methyl group transfer the cofactor SAM is transformed into 
the demethylated S-adenosyl homocysteine (SAH). Subsequently, an unidentified enzyme base 
or water molecule abstracts a proton from the cytosine-5 position, which allows release of free 
enzyme by -elimination (Erlanson et al., 1993). 
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Fig. 9Schematic representation of the methylation reaction catalyzed by Dnmts (green). A covalent 
complex is formed between the sulfhydryl group of cysteine in the PC dipeptide in the active site of 
Dnmts and the carbon 6 position of the cytosine base ring. Then a methyl group is transferred from S-
adenosyl methionine (SAM) followed by the release of S-adenosyl homocysteine (SAH) and the enzyme. 
Adapted from (Goll and Bestor, 2005). 
The enzymatic activity of Dnmts can be measured in vitro. For this, isolated protein is mixed 
with [3H]-SAM and hemimethylated double stranded DNA. The methylation reaction catalyzed 
by Dnmt, transfers labeled methyl groups on the DNA template. The incorporation of 3H into 
the DNA can then be measured by (liquid) scintillation counting. Various other methods are 
available to determine global methylation levels of genomic DNA or local levels at certain 
promoters. 
A very common and efficient technique is the treatment of DNA with bisulfite (i.e. sodium 
bisulfite), which converts non-methylated cytosine residues in DNA to uracil, whereas 5-
methylcytosine remains unaltered (Shapiro et al., 1973; Shapiro et al., 1974). In a PCR 
amplification of the region of interest the uracil is subsequently replaced by a thymine, which 
can be detected by DNA sequencing (bisulfite sequencing) (Frommer et al., 1992). The 
combined bisulfite restriction analysis (COBRA) is an alternative detection method to 
quantitatively determine methylation levels of CpG dinucleotides at specific gene loci (Xiong 
and Laird, 1997). Bisulfite treatment of DNA and PCR amplification introduces different 
restriction sites for specific enzymes in methylated DNA and unmethylated DNA, which then 
can be analyzed by restriction analysis. 
A different approach to analyze CpG methylation is methylation sensitive restriction enzyme 
digestion of DNA with enzyme pairs like HpaII and its methylation insensitive isoschizomer 
MspI. Methylated and unmethylated DNA is digested and the resulting restriction fragments can 
be detected by southern blotting or PCR (Sadri and Hornsby, 1996). Immunostainings with 
specific 5mC-antibodies visualize the overall distribution of methylation pattern inside single 
cells. With the recently developed methyl-DIP technique methylated DNA is 
immunoprecipitated with 5mC-antibodies followed by hybridization to genomic microarrays, 
allowing the identification of methyl-CpG-rich sequences (Keshet et al., 2006; Weber et al., 
2005a; Zhang et al., 2006). However, none of the methods listed is capable of visualizing the 
enzymatic activity or monitoring protein interactions in living cells.  
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During this work we developed new, versatile methods and tools for in vivo and in vitro 
approaches, which all can be applied to study DNA methylation in its natural environment. 
With our novel trapping assay we are able to study DNA methyltransferase activity in defined 
chromatin domains e.g. heterochromatin or euchromatin in living cells. Furthermore we 
designed a fluorescent two-hybrid assay, which enables us to easily analyze interactions of 
Dnmts, mutant Dnmts or isolated domains of Dnmts with other proteins in real-time in vivo. 
Additionally, we generated small antigen-binding proteins (VHHs) and labeled them 
fluorescently (chromobodies) to trace protein in living cells. Furthermore, we immobilized 
VHHs on a matrix (nanotrap) to precipitate proteins for biochemical studies respectively to alter 
their ectopic localization in cells. The applicability of these new methods is not restricted to 
research on DNA methylation but can generally be implemented to obtain data on proteins 
including their concentrations, modifications, interactions, distributions, dynamics and activity 
in living cells to help understanding cellular processes and regulatory networks. 
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Abbreviations 
aa: amino acid 
BAH: bromo adjacent homology domain 
BiFC: bimolecular fluorescence complementation 
BHK: baby hamster kidney 
CFP: enhanced cyan fluorescent protein 
Co-IP: co-immunoprecipitation 
DAPI: 4',6-diamidino-2-phenylindole 
DDP1: deafness dystonia peptide 1 
Dnmt1: DNA methyltransferase 1 
DPSS: Diode-Pumped Solid-State 
FP: fluorescent protein 
FRET: fluorescence resonance energy transfer 
GFP: enhanced green fluorescent protein 
HEK: human embryonic kidney cell line 
IMS: intermembrane space 
NLS: nuclear localization signal 
PARP: Poly (ADP-ribose) polymerase 
PBD: PCNA binding domain 
PBHD: polybromo homology domain 
PCNA: proliferating cell nuclear antigen 
RFP: monomeric red fluorescent protein 
SUMO3: small ubiquitin-related modifier 3 
TS: targeting sequence (of Dnmt1) 
Vim: Vimentin 
XRCC1: X-ray repair cross-complementing protein 1 
Y2H: yeast two-hybrid 
YFP: enhanced yellow fluorescent protein 
ZnF: Zn2+-binding region 
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Summary 
Genetic high-throughput screens have yielded large sets of potential protein-protein 
interactions now to be verified and further investigated. Here we present a simple 
assay to directly visualize protein-protein interactions in single living cells. Using a 
modified lac repressor system, we tethered a fluorescent bait at a chromosomal lac 
operator array and assayed for co-localization of fluorescent prey fusion proteins. 
With this fluorescent two-hybrid (F2H) assay we successfully investigated the 
interaction of proteins from different subcellular compartments including nucleus, 
cytoplasm and mitochondria. In combination with an S phase marker we also studied 
the cell cycle dependence of protein-protein interactions. These results indicate that 
the F2H assay is a powerful tool to investigate protein-protein interactions within their 
cellular environment and to monitor the response to external stimuli in real-time.  
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Introduction 
After sequencing the human genome the next challenge is now to analyze the 
complex protein-networks underlying cellular functions. In the last decade a wide 
variety of methods to study protein-protein interactions ranging from biochemical to 
genetic or cell-based approaches have been developed. Biochemical methods like 
affinity purification or co-immunoprecipitation (Co-IP) allow the detection of protein 
complexes in vitro. Genetic methods, such as the yeast two-hybrid (Y2H) system (1), 
enable efficient high-throughput screening of interactions within the cellular 
environment (2). The analysis of mammalian protein interactions in yeast may, 
however, suffer from the absence or insufficient conservation of cellular factors 
modulating protein-protein interactions, e.g. through posttranslational modifications 
(3). 
In recent years new fluorescence-based methods for in-cell visualization of protein-
protein interactions have been introduced. Two established techniques, fluorescence 
resonance energy transfer (FRET) (4, 5) and bimolecular fluorescence 
complementation (BiFC) (6), are based on the expression of fluorescently labeled 
proteins or fragments thereof. However, FRET requires costly instrumentation and 
advanced technical expertise, while BiFC is based on the irreversible 
complementation and slow maturation of fluorophores which does not allow real-time 
detection of protein-protein interactions (6).  
All these methods have inherent shortcomings and are typically combined to obtain 
more reliable results. We have now developed a novel fluorescent two-hybrid (F2H) 
assay for the direct visualization of protein-protein interactions in living mammalian 
cells. The simple optical readout of this F2H assay allows observation of protein-
protein interactions in real time and should also be suitable for high-throughput 
screens.
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Experimental Procedures 
Expression constructs 
The LacI encoding sequence was PCR amplified from the p3’SS EGFP-LacI 
expression vector (7) using the following primers: forward primer 5’-TCT AGA AAG 
CTT TCC ATG GTG AAA CCA GTA-3’ and reverse primer 5’-CCA TGC CCG GGA 
CAG GCT GCT TCG GGA AAC-3’ (restriction sites in italic). This PCR fragment was 
digested with HindIII and XmaI and cloned into the same sites of two Dnmt1-YFP 
expression vectors (MTNY.2 and PBHD-YFP)(8) generating PBD-LacI-YFP and 
PBD-LacI-YFP. The NLS-PCNA-LacI-RFP and XRCC1-LacI-RFP constructs were 
generated by PCR amplification of the PCNA and XRCC1 cDNA using the following 
primers (restriction sites in italic):  
PCNA forward 5´- CCCCCTCGAGATGTTCGAGGCGCGC -3´ 
PCNA reverse 5´- GGGGAAGCTTGGAGATCCTTCTTCATCCTC- 3` 
XRCC1 forward 5´- CCCCAGATCTATGCCGGAGATCCGC -3´ 
XRCC1 reverse 5´- GGGGGAATTCGGGGCTTGCGGCACCAC -3´ 
 
Subsequently the PCR fragments were cloned into a LacI-RFP expression vector 
using the XhoI/HindIII sites for the NLS-PCNA-LacI-RFP and the BglII/EcoRI sites for 
the XRCC1-LacI-RFP expression vector. 
All other F2H constructs were generated by PCR amplification of coding cDNAs and 
subsequent ligation into the AsiSI and NotI sites of the bait and prey expression 
vectors described in Fig. 1a. The following primers were used with the restriction site 
indicated in italics: 
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DDP1 forward 5´-CCCCGCGATCGCGATTCCTCCTCCTCTTCCTC-3´ 
DDP1 reverse 5´-CCCCGCGGCCGCTCAGTCAGAAAGGCTTTCTG-3´ 
TIMM13 forward 5´-CCCCGCGATCGCGAGGGCGGCTTCGGCTCC-3´ 
TIMM13 reverse 5´-CCCCGCGATCGCGAGGGCGGCTTCGGCTCC-3´ 
HZFH forward 5´-GGGGGCGATCGCCACGCCCGCTTCC-3´ 
HZFH reverse 5´-CCCCGCGGCCGCTTAGTCGTCTATACAGATCACCTCC-3´ 
SUMO3 forward 5´-CCCCGCGATCGCGCCGACGAAAAGCCCAAG-3´ 
SUMO3 reverse 5´-CCCCGCGGCCGCTCAGTAGACACCTCCCG-3´ 
Vim forward 5´-GGGGTGTACAGCGATCGCATGTCGACCCACGCGT-3´ 
Vim reverse 5´-CCCCGAATTCGCGGCCGCTTATTCAAGGTCATCGTGATGCT-3´ 
 
Mammalian expression constructs encoding translational fusions of human DNMT1, 
DNA Ligase I, DNA Ligase III, p21, FEN I, Polymerase  p66 subunit, PARP-1, 
PARP-2 and PCNA were previously described (9-14). Deletion constructs and 
isolated domains of DNA Ligase I and III were described in Mortusewicz et al (15). 
Immunoprecipitations were performed with a GFP-nanotrap (16) as described before 
(15). All fusions constructs were tested for correct expression and localization. 
 
Cell culture and transfection 
Transgenic BHK cells (clone #2) and U2OS cells (clone 2-6-3) containing lac 
operator repeats were cultured under selective conditions in DMEM supplemented 
with 10% fetal calf serum and 150 μg/ml hygromycin B (PAA Laboratories) as 
described (17, 18). For microscopy cells were grown to 50-70% confluence either on 
18x18 glass coverslips or in -slides (ibidi, Munich, Germany) and then co-
transfected with the indicated expression constructs using Polyplus transfection 
reagent jetPEI™ (BIOMOL GmbH, Hamburg, Germany) according to the 
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manufacturer’s instructions. After 6-10 hours the transfection medium was changed 
to fresh culture medium and cells were then incubated for another 12-24 hours 
before live cell microscopy or fixation with 3.7% formaldehyde in PBS for 10 min at 
room temperature. Fixed cells were permeabilized with 0.2% Triton X-100 in PBS for 
3 min, counterstained with DAPI and mounted in Vectashield (Vector Laboratories, 
CA, USA). 
 
Microscopy 
Live or fixed cells expressing fluorescent proteins were analyzed using a Leica TCS 
SP2 AOBS or a Leica TCS SP5 confocal microscope equipped with a 63x/1.4 NA 
Plan-Apochromat oil immersion objective. Fluorophores were excited with a 405 nm 
Diode laser, a 488 nm and a 514 nm argon laser and a 561 nm Diode-Pumped Solid-
State (DPSS) laser. Confocal image stacks of living or fixed cells were typically 
recorded with a frame size of 512x512 pixels, a pixel size of 50-100 nm, a z-step size 
of 250 nm and the pinhole opened to 1 Airy unit. A maximum intensity projection of 
several mid z-sections was generated with ImageJ (Version 1.38, 
http://rsb.info.nih.gov/ij/). 
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Results 
To visualize protein-protein interactions in living cells in real time we developed a 
fluorescent two-hybrid (F2H) assay. The rationale for the F2H assay is based on the 
fact that proteins are freely roaming the cell unless interactions with other cellular 
components immobilize them at specific structures (19). 
We used a previously described BHK and an U2OS cell line, which both harbor a 
stable integration of about 200-1000 copies of a plasmid carrying 256 copies of the 
lac operator sequence (17, 18). We generated an expression construct encoding a 
fluorescent bait protein consisting of a fluorescent protein (FP), the lac repressor 
(LacI) and the protein X to be tested for interactions (bait) resulting in the triple fusion 
protein FP-LacI-X (Fig. 1a) or X-LacI-FP. This fusion protein binds to the operator 
array, which then becomes visible due to the focal enrichment of the FP signal. A 
second, differently labeled fusion protein (FP-Y, prey) may either interact with the bait 
protein X leading to co-localization of the FP signals (Fig. 1b) or may not interact, 
resulting in a dispersed distribution of the prey fluorescence (Fig. 1c). 
 
Visualization of interactions between DNA repair proteins 
To test the F2H assay, the previously described interaction between the two DNA 
repair proteins DNA Ligase III and XRCC1 (20, 21) was analyzed and the results 
were compared with data obtained from pull down assays. We have previously 
shown that this interaction is mediated by the BRCT domain of DNA Ligase III which 
targets it to DNA repair sites (15). We generated a bait fusion protein consisting of 
XRCC1 followed by the LacI and the monomeric red fluorescent protein RFP 
(mRFP). As expected this fusion protein localized at the lac operator array in 
transiently transfected BHK cells (Fig. 2a). Both, the full length GFP-tagged DNA 
Ligase III as well as the isolated GFP-labeled BRCT domain co-localize with XRCC1 
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at the lac operator array, while a fusion protein missing the BRCT domain shows a 
dispersed distribution. Notably, the highly homologous DNA Ligase I, which catalyzes 
the same reaction as DNA Ligase III, does not bind to XRCC1 (Fig. 2a and 
supplementary Fig. 1). A direct comparison of the F2H data with data obtained from 
Co-IP experiments reveals that these two methods gave similar results (Fig. 2b). In 
addition, we could also observe the recently described interaction of XRCC1 with 
PCNA (22) and the two DNA-damage dependent PARPs, PARP-1 and PARP-2 (23, 
24) (supplementary Fig. 2). These results demonstrate that the F2H assay is well 
suited to study protein-protein interactions in living cells.  
 
Analysis of cell cycle dependence of protein-protein interactions 
A challenge in the analysis of protein-protein interactions is to monitor transient 
changes caused by for example cell cycle progression or other external stimuli. We 
analyzed the previously described interaction between DNA methyltransferase 1 
(Dnmt1) and PCNA which is mediated by the PCNA binding domain (PBD) and 
targets Dnmt1 to sites of DNA replication in S phase (8, 25). These findings raised 
the question whether this interaction occurs only in S phase at replication foci or 
throughout the cell cycle. We generated two bait-proteins comprising parts of Dnmt1 
fused to the LacI and YFP. One bait (PBD-LacI-YFP) comprises aa 118-427 of 
Dnmt1 including the PBD, while the second bait (PBD-LacI-YFP) lacks the PBD and 
comprises aa 629-1089 of Dnmt1 (Fig. 3a). As a prey-protein we used RFP-PCNA, 
which in addition marks sites of DNA replication allowing the identification of cells in 
S phase (9, 26). The binding possibilities of these fusion proteins at the lac operator 
array and the replication fork are summarized in Fig. 3b.  
In non S phase the LacI part of the bait proteins only binds to the chromosomally 
integrated lac operator array, which – dependent on the ploidy of the cell – becomes 
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visible as one or two fluorescent spots in the nucleus. Interaction of RFP-PCNA with 
the PBD part of the bait protein results in co-localization of the fluorescent signals at 
the lac operator array (Fig. 3c upper panel), while deletion of the PBD in the bait 
protein leads to a dispersed distribution of RFP-PCNA in non S phase cells (Fig. 3d 
upper panel). This clearly illustrates that the PBD-dependent interaction of Dnmt1 
with PCNA also occurs outside of S phase. 
In S phase cells, RFP-PCNA localizes at sites of ongoing DNA replication and in 
addition is recruited to the lac operator array by the PBD-LacI-YFP bait protein (Fig. 
3c lower panel). In contrast, when RFP-PCNA is co-expressed together with a bait 
protein lacking a functional PBD (PBD-LacI-YFP), RFP-PCNA is exclusively 
enriched at DNA replication sites and not at the lac operator array highlighted by 
PBD-LacI-YFP (Fig. 3d lower panel). 
These results clearly show that the localization of RFP-PCNA (prey) at the lac 
operator array depends on the presence of the PBD in the bait construct and that this 
interaction is not restricted to S phase. 
 
Next, we analyzed the interaction of other PBD-containing proteins with PCNA. We 
generated a bait fusion protein comprising PCNA fused to an additional NLS followed 
by LacI and RFP (NLS-PCNA-LacI-RFP). When co-expressed with GFP-Ligase I, 
both fusion proteins localized to the lac operator array indicating interaction between 
PCNA and DNA Ligase I. Deletion of the PBD lead to a dispersed distribution of DNA 
Ligase I, while the PBD of DNA Ligase I alone was sufficient for binding to PCNA at 
the lac operator array (supplementary Fig. 3). This is in agreement with previous 
studies showing that the PBD of DNA Ligase I is necessary and sufficient for its 
targeting to DNA replication and repair sites (15, 27, 28). Notably, using the F2H 
assay we could demonstrate that DNA Ligase I, as well as the isolated PBD are 
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capable of binding to PCNA also outside of S phase. Likewise we could show binding 
of various additional replication and repair proteins like FEN1, p21 and the 
Polymerase  subunit p66 to PCNA in non S phase cells (supplementary Fig. 4). 
Taken together we could show that the interaction between replication proteins and 
PCNA is not limited to S phase but also occurs in non S phase cells and outside the 
replication machinery. This illustrates that the F2H assay offers the unique potential 
to analyze cell cycle specific changes in protein-protein interactions in living cells. 
 
Detection of interactions between proteins related to Huntington´s disease  
To investigate whether the F2H assay can also detect protein-protein interactions 
taking place in other cellular compartments, we tested the F2H assay with protein 
interactions identified in the context of Huntington´s disease by yeast two-hybrid 
(Y2H) assays (29). We analyzed the interaction of one cytoplasmatic (Vimentin) and 
two nuclear (HZFH and SUMO3) proteins. Vimentin has been described to be a 
cytoskeleton component and participates in transport processes, whereas HZFH and 
SUMO3 are involved in transcriptional regulation and DNA maintenance (29). These 
proteins were either fused with a red fluorescent mCherry-LacI-NLS or with NLS-GFP 
to generate sets of bait and prey proteins. BHK cells carrying a lac operator array 
were transfected with all possible combinations of expression constructs and 
subjected to microscopic analysis. We could detect an interaction between Vimentin 
and HZFH independent of whether these two proteins were used as bait or prey 
(Fig.4 and data not shown). We could also detect the reported interaction between 
SUMO3 and HZFH while Vimentin and SUMO3 did not interact, as previously 
described (Fig. 4) (29). These results show that interactions of nuclear and 
cytoplasmic proteins can be studied with the F2H assay. 
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Detection of interactions between mitochondrial proteins 
Next, we investigated whether the F2H assay is also suitable to detect protein-protein 
interactions occurring in other cellular organelles. To this end, we analyzed the 
interaction between two mitochondrial proteins, DDP1 (deafness dystonia peptide 1) 
and TIMM13. Both proteins are nuclear encoded and imported into the mitochondrial 
intermembrane space (IMS) forming a hexameric complex (Fig. 5a). Within the IMS 
the DDP1-TIMM13 complex facilitates the import of hydrophobic proteins of the 
mitochondrial import machinery into the mitochondrial innermembrane (30). A 
mutation of the DDP1 gene was associated with the Mohr-Tranebjaerg-Syndrome, 
which is a progressive, neurodegenerative disorder (31). This C66W missense 
mutation is known to cause a full blown phenotype and affects the highly conserved 
Cys(4) motif of DDP1. Previous studies have shown, that this amino acid exchange 
abolishes the interaction between DDP1 and TIMM13 in the IMS (32). 
Using a red fluorescent bait fusion protein comprising LacI-NLS-TIMM13 and GFP-
tagged wildtype (GFP-DDP1) or mutant DDP1 (GFP-DDP1C66W) prey proteins we 
analyzed this specific mitochondrial protein interaction with the F2H assay. We found 
that GFP-DDP1 co-localizes with TIMM13 at the lac operator array (Fig. 5b), while 
GFP-DDP1C66W was evenly distributed (Fig. 5c). These results demonstrate that the 
F2H assay is also suitable for the analysis of protein-protein interactions occurring 
outside the nucleus and the characterization of disease related point mutations 
disrupting these interactions. 
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Discussion 
Here we describe a new method to detect and visualize protein-protein interactions in 
living cells, which we termed fluorescent two-hybrid assay (F2H). This method is 
based on the immobilization of a fluorescently labeled bait protein at a distinct 
subcellular structure enabling the detection of protein-protein interactions as co-
localization of a differently labeled prey protein at this defined structure. The F2H 
assay described takes advantage of cell lines with a stable integration of a lac 
operator array to immobilize a lac repressor fused to fluorescently labeled proteins of 
interest (bait). Readily usable cell lines have already been described for human, 
mouse, hamster and Drosophila (7, 17, 18, 33-35). To be independent of specific 
transgenic cell lines this assay could be modified by using various cellular structures 
like the lamina, the cytoskeleton or centrosomes as anchoring structures to locally 
immobilize bait proteins.  
Like other genetic two-hybrid methods also the F2H assay may yield false positive or 
false negative results, which need to be controlled for. Prey proteins that bind to the 
lac operator array in the absence of a bait protein can be identified by an initial 
screen and then be only used as baits. We analyzed more than 20 protein-protein 
interactions from different subcellular compartments with the F2H assay and 
obtained identical results as previously described with other genetic or biochemical 
methods. Only one protein (SUMO3) was found to bind by itself to the lac operator 
array and could therefore only be used as a bait protein. These results show that the 
F2H assay is a reliable and broadly applicable method to study protein-protein 
interactions. 
In some cases, proteins may accumulate at subnuclear foci and thus complicate the 
F2H analysis. To bypass this problem, the lac operator array could be visualized and 
identified with a third fluorescent fusion protein like CFP-LacI. 
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In summary, this new F2H assay allows the direct visualization of protein-protein 
interactions and should be ideally suited to investigate cell cycle or differentiation 
dependent changes in real-time in living cells. A significant advantage of the F2H 
assay over other cell-based techniques is its simplicity that does neither require 
costly instrumentation nor advanced technical expertise. The simple optical read-out 
of the F2H assay additionally offers the possibility to use this assay in automated 
high-throughput screens to systematically analyze the protein interactome in living 
cells.  
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-41- 
Acknowledgements 
We thank D.L. Spector for providing BHK clone#2 and U2OS.2-6-3 cells containing a 
lac operator array, V. Schreiber for GFP-tagged PARP-1 and PARP-2 constructs and 
R.Y. Tsien for mRFP1 and mCherry cDNA. We thank L. Schermelleh and F. Spada 
for helpful comments and suggestions. We are grateful to G. Li for help in plasmid 
construction. This work was supported by the Center for NanoScience (CeNS), by 
the Nanosystems Initiative Munich (NIM) and by grants from the Deutsche 
Forschungsgemeinschaft (DFG) to M.C.C and H.L. 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-42- 
References 
1. Fields, S., and Song, O. (1989) A novel genetic system to detect protein-
protein interactions. Nature 340, 245-246. 
2. Rual, J. F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., 
Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., Klitgord, N., 
Simon, C., Boxem, M., Milstein, S., Rosenberg, J., Goldberg, D. S., Zhang, L. V., 
Wong, S. L., Franklin, G., Li, S., Albala, J. S., Lim, J., Fraughton, C., Llamosas, E., 
Cevik, S., Bex, C., Lamesch, P., Sikorski, R. S., Vandenhaute, J., Zoghbi, H. Y., 
Smolyar, A., Bosak, S., Sequerra, R., Doucette-Stamm, L., Cusick, M. E., Hill, D. E., 
Roth, F. P., and Vidal, M. (2005) Towards a proteome-scale map of the human 
protein-protein interaction network. Nature 437, 1173-1178. 
3. Parrish, J. R., Gulyas, K. D., and Finley, R. L., Jr. (2006) Yeast two-hybrid 
contributions to interactome mapping. Curr Opin Biotechnol 17, 387-393. 
4. Sekar, R. B., and Periasamy, A. (2003) Fluorescence resonance energy 
transfer (FRET) microscopy imaging of live cell protein localizations. J Cell Biol 160, 
629-633. 
5. Miyawaki, A. (2003) Visualization of the spatial and temporal dynamics of 
intracellular signaling. Dev Cell 4, 295-305. 
6. Kerppola, T. K. (2006) Visualization of molecular interactions by fluorescence 
complementation. Nat Rev Mol Cell Biol 7, 449-456. 
7. Robinett, C. C., Straight, A., Li, G., Willhelm, C., Sudlow, G., Murray, A., and 
Belmont, A. S. (1996) In vivo localization of DNA sequences and visualization of 
large-scale chromatin organization using lac operator/repressor recognition. J Cell 
Biol 135, 1685-1700. 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-43- 
8. Easwaran, H. P., Schermelleh, L., Leonhardt, H., and Cardoso, M. C. (2004) 
Replication-independent chromatin loading of Dnmt1 during G2 and M phases. 
EMBO Rep 5, 1181-1186. 
9. Sporbert, A., Domaing, P., Leonhardt, H., and Cardoso, M. C. (2005) PCNA 
acts as a stationary loading platform for transiently interacting Okazaki fragment 
maturation proteins. Nucleic Acids Res 33, 3521-3528. 
10. Mortusewicz, O., Schermelleh, L., Walter, J., Cardoso, M. C., and Leonhardt, 
H. (2005) Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl 
Acad Sci U S A. 
11. Schermelleh, L., Spada, F., Easwaran, H. P., Zolghadr, K., Margot, J. B., 
Cardoso, M. C., and Leonhardt, H. (2005) Trapped in action: direct visualization of 
DNA methyltransferase activity in living cells. Nat Methods 2, 751-756. 
12. Cazzalini, O., Perucca, P., Riva, F., Stivala, L. A., Bianchi, L., Vannini, V., 
Ducommun, B., and Prosperi, E. (2003) p21CDKN1A does not interfere with loading 
of PCNA at DNA replication sites, but inhibits subsequent binding of DNA 
polymerase delta at the G1/S phase transition. Cell Cycle 2, 596-603. 
13. Maeda, Y., Hunter, T. C., Loudy, D. E., Dave, V., Schreiber, V., and Whitsett, 
J. A. (2006) PARP-2 interacts with TTF-1 and regulates expression of surfactant 
protein-B. J Biol Chem 281, 9600-9606. 
14. Meder, V. S., Boeglin, M., de Murcia, G., and Schreiber, V. (2005) PARP-1 
and PARP-2 interact with nucleophosmin/B23 and accumulate in transcriptionally 
active nucleoli. J Cell Sci 118, 211-222. 
15. Mortusewicz, O., Rothbauer, U., Cardoso, M. C., and Leonhardt, H. (2006) 
Differential recruitment of DNA Ligase I and III to DNA repair sites. Nucleic Acids Res 
34, 3523-3532. 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-44- 
16. Rothbauer, U., Zolghadr, K., Muyldermans, S., Schepers, A., Cardoso, M. C., 
and Leonhardt, H. (2007) A versatile nanotrap for biochemical and functional studies 
with fluorescent fusion proteins. Mol Cell Proteomics. 
17. Tsukamoto, T., Hashiguchi, N., Janicki, S. M., Tumbar, T., Belmont, A. S., and 
Spector, D. L. (2000) Visualization of gene activity in living cells. Nat Cell Biol 2, 871-
878. 
18. Janicki, S. M., Tsukamoto, T., Salghetti, S. E., Tansey, W. P., 
Sachidanandam, R., Prasanth, K. V., Ried, T., Shav-Tal, Y., Bertrand, E., Singer, R. 
H., and Spector, D. L. (2004) From silencing to gene expression: real-time analysis in 
single cells. Cell 116, 683-698. 
19. Phair, R. D., and Misteli, T. (2000) High mobility of proteins in the mammalian 
cell nucleus. Nature 404, 604-609. 
20. Caldecott, K. W., McKeown, C. K., Tucker, J. D., Ljungquist, S., and 
Thompson, L. H. (1994) An interaction between the mammalian DNA repair protein 
XRCC1 and DNA ligase III. Mol Cell Biol 14, 68-76. 
21. Wei, Y. F., Robins, P., Carter, K., Caldecott, K., Pappin, D. J., Yu, G. L., 
Wang, R. P., Shell, B. K., Nash, R. A., Schar, P., and et al. (1995) Molecular cloning 
and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, 
an enzyme active in DNA repair and recombination. Mol Cell Biol 15, 3206-3216. 
22. Fan, J., Otterlei, M., Wong, H. K., Tomkinson, A. E., and Wilson, D. M., 3rd 
(2004) XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res 
32, 2193-2201. 
23. Schreiber, V., Ame, J. C., Dolle, P., Schultz, I., Rinaldi, B., Fraulob, V., 
Menissier-de Murcia, J., and de Murcia, G. (2002) Poly(ADP-ribose) polymerase-2 
(PARP-2) is required for efficient base excision DNA repair in association with PARP-
1 and XRCC1. J Biol Chem 277, 23028-23036. 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-45- 
24. Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J., 
and de Murcia, G. (1998) XRCC1 is specifically associated with poly(ADP-ribose) 
polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 
18, 3563-3571. 
25. Chuang, L. S., Ian, H. I., Koh, T. W., Ng, H. H., Xu, G., and Li, B. F. (1997) 
Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for 
p21WAF1. Science 277, 1996-2000. 
26. Easwaran, H. P., Leonhardt, H., and Cardoso, M. C. (2005) Cell Cycle 
Markers for Live Cell Analyses. Cell Cycle 4. 
27. Cardoso, M. C., Joseph, C., Rahn, H. P., Reusch, R., Nadal-Ginard, B., and 
Leonhardt, H. (1997) Mapping and use of a sequence that targets DNA ligase I to 
sites of DNA replication in vivo. J Cell Biol 139, 579-587. 
28. Montecucco, A., Savini, E., Weighardt, F., Rossi, R., Ciarrocchi, G., Villa, A., 
and Biamonti, G. (1995) The N-terminal domain of human DNA ligase I contains the 
nuclear localization signal and directs the enzyme to sites of DNA replication. Embo J 
14, 5379-5386. 
29. Goehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., Worm, U., 
Droege, A., Lindenberg, K. S., Knoblich, M., Haenig, C., Herbst, M., Suopanki, J., 
Scherzinger, E., Abraham, C., Bauer, B., Hasenbank, R., Fritzsche, A., Ludewig, A. 
H., Bussow, K., Coleman, S. H., Gutekunst, C. A., Landwehrmeyer, B. G., Lehrach, 
H., and Wanker, E. E. (2004) A protein interaction network links GIT1, an enhancer 
of huntingtin aggregation, to Huntington's disease. Mol Cell 15, 853-865. 
30. Rothbauer, U., Hofmann, S., Muhlenbein, N., Paschen, S. A., Gerbitz, K. D., 
Neupert, W., Brunner, M., and Bauer, M. F. (2001) Role of the deafness dystonia 
peptide 1 (DDP1) in import of human Tim23 into the inner membrane of 
mitochondria. J Biol Chem 276, 37327-37334. 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-46- 
31. Tranebjaerg, L., Schwartz, C., Eriksen, H., Andreasson, S., Ponjavic, V., Dahl, 
A., Stevenson, R. E., May, M., Arena, F., Barker, D., and et al. (1995) A new X linked 
recessive deafness syndrome with blindness, dystonia, fractures, and mental 
deficiency is linked to Xq22. J Med Genet 32, 257-263. 
32. Hofmann, S., Rothbauer, U., Muhlenbein, N., Neupert, W., Gerbitz, K. D., 
Brunner, M., and Bauer, M. F. (2002) The C66W mutation in the deafness dystonia 
peptide 1 (DDP1) affects the formation of functional DDP1.TIM13 complexes in the 
mitochondrial intermembrane space. J Biol Chem 277, 23287-23293. 
33. Tumbar, T., Sudlow, G., and Belmont, A. S. (1999) Large-scale chromatin 
unfolding and remodeling induced by VP16 acidic activation domain. J Cell Biol 145, 
1341-1354. 
34. Dietzel, S., Zolghadr, K., Hepperger, C., and Belmont, A. S. (2004) Differential 
large-scale chromatin compaction and intranuclear positioning of transcribed versus 
non-transcribed transgene arrays containing {beta}-globin regulatory sequences. J 
Cell Sci 117, 4603-4614. 
35. Vazquez, J., Belmont, A. S., and Sedat, J. W. (2001) Multiple regimes of 
constrained chromosome motion are regulated in the interphase Drosophila nucleus. 
Curr Biol 11, 1227-1239. 
 
 
under revision at Molecular & Cellular Proteomics (MCP) Zolghadr et al.  
 
-47- 
Figure Legends 
Figure 1 
Schematic outline of the fluorescent two-hybrid (F2H) assay. (a) Outline of pF2H-
prey and pF2H-bait expression vectors coding for fluorescently labeled prey- and 
bait- proteins used for the F2H assay (b) The LacI domain of the bait-protein 
mediates binding to the chromosomally integrated lac operator array, which is visible 
as a fluorescent spot in nuclei of transfected cells. If the differentially labeled prey 
interacts with the bait it becomes enriched at the same spot resulting in co-
localization of fluorescent signals at the lac operator (visible as yellow spot in the 
overlay image). (c) If the prey does not interact with the bait protein it remains 
dispersed in the nucleus and the lac operator array is only visualized by the bait 
protein (red spot). FP1 and FP2 refer to two distinguishable fluorescent proteins, e.g. 
GFP or YFP and mCherry or mRFP. 
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Figure 2 
Specific interaction of DNA Ligase III with XRCC1 revealed by the F2H assay. (a) 
Transgenic BHK cells containing a chromosomal lac operator array were co-
transfected with XRCC1-LacI-RFP and GFP-tagged DNA Ligase III or DNA Ligase I 
constructs. The lac repressor part of the XRCC1-LacI-RFP fusion protein mediates 
binding to the lac operator array (visible by fluorescence microscopy as red spot). 
DNA Ligase III is recruited to the lac operator array through interaction with XRCC1. 
Note that the highly homologous DNA Ligase I does not accumulate at the lac 
operator array indicating that it does not interact with XRCC1. Scale bars 5 m. (b) 
Comparison of F2H results and co-immunoprecipitation (Co-IP) experiments. Co-IPs 
were performed with HEK 293T cells co-expressing RFP-XRCC1 and GFP-Ligase III 
or GFP-Ligase I, respectively. For interaction mapping the GFP-tagged BRCT 
domain of DNA Ligase III and a deletion construct lacking the BRCT domain were 
used. Immunoprecipitations were performed with a GFP-nanotrap (16) (as shown 
before (15)). Precipitated fusion proteins were then detected with specific antibodies 
against RFP and GFP on western blots. RFP-XRCC1 was co-precipitated with GFP-
Ligase III but not with GFP-Ligase I. RFP-XRCC1 was also co-precipitated with GFP-
Ligase III BRCT but not with GFP-N-Ligase III BRCT. For comparison of F2H 
results the input (left) and bound (right) bands from Co-IPs were aligned with 
corresponding signals from the F2H assay. The LacI spot of the XRCC1-LacI-RFP 
bait construct shown in red and the bound fraction was aligned with the respective 
signal of the GFP-tagged prey constructs. Whole cell images of the respective F2H 
experiments are shown in (a) and supplementary Fig. 1. 
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Figure 3 
F2H analysis of cell cycle independent interaction of Dnmt1 with PCNA. (a) 
Schematic outline of full-length mouse Dnmt1 and fusion proteins. PBD, PCNA 
binding domain; NLS, nuclear localization signal; TS, targeting sequence; ZnF, Zn2+-
binding region; BAH 1 and 2, two Bromo Adjacent Homology domains. (b) Outline of 
binding possibilities of fusion proteins at the lac operator (lac op) array and at the 
replication fork. (c) Transgenic BHK cells containing a chromosomal lac operator 
array were co-transfected with PBD-LacI-YFP and RFP-PCNA constructs. RFP-
PCNA shows the characteristic cell cycle dependent distribution (dispersed in non S 
phase cells (top row) and focal patterns in S phase (bottom row)). The lac repressor 
part of the PBD-LacI-YFP fusion protein mediates binding to the lac operator array 
(visible as green spot and highlighted by arrowheads) and the PBD mediates binding 
to PCNA at replication sites (focal pattern in S phase). Notice, RFP-PCNA is 
localized at the lac operator array in S and non S phase cells indicating an interaction 
of the PBD of Dnmt1 with PCNA throughout the cell cycle and independent of the 
replication machinery. (d) BHK cells were transfected with expression vectors for 
PBD-LacI-YFP and RFP-PCNA. As above, RFP-PCNA shows a dispersed 
distribution in non S phase (top row) and redistributes to replication sites in S phase 
(bottom row). The PBD-LacI-YFP fusion protein binds to the lac operator array 
(green spot marked by arrowhead) but does not bind to replication sites in S phase 
since it lacks the PBD. Importantly, in these cells RFP-PCNA (prey) is not localized at 
the lac operator array (marked by arrowheads) indicating that binding depends on the 
presence of the PBD, which is absent in PBD-LacI-YFP (bait). Scale bars 5 m 
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Figure 4 
Analysis of Huntington´s disease related interactions by F2H. Reported interactions 
between (a) SUMO3 and HZFH and (b) HZFH and Vimentin revealed by the F2H 
assay. (c) F2H analysis shows no interaction between SUMO3 and Vimentin as 
previously described (29). In (b) the nucleus is outlined by a dashed line and in (c) 
the lac operator array is indicated (arrowheads). Scale bars 5 m. 
 
Figure 5 
Analysis of mitochondrial protein-protein interactions and the effect of a mutation 
associated with the Mohr-Tranebjaerg Syndrome. (a) Schematic overview of the 
hexameric DDP1-TIMM13 complex in the intermembrane space (IMS) of 
mitochondria. (b + c) BHK cells expressing the bait-protein mCherry-LacI-TIMM13 
together either with GFP-DDP1 (b) or the loss-of-function mutant GFP-DDP1C66W (c). 
While the functional wt fusion GFP-DDP1 shows interaction with TIMM13 revealed by 
co-localization of fluorescent signals at the lac operator array (b), the GFP-DDP1C66W 
mutant is dispersedly distributed throughout the nucleus indicating no interaction (c). 
Scale bars 5 m. 
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Supplementary Information 
 
Supplementary Figure 1 
BRCT mediated interaction of DNA Ligase III with XRCC1 revealed by the F2H 
assay. Transgenic BHK cells containing a lac operator array were co-transfected with 
XRCC1-LacI-RFP and various GFP-tagged DNA Ligase III constructs. The lac 
repressor part of the XRCC1-LacI-RFP fusion protein mediates binding to the lac 
operator array (visible as red spot). The BRCT domain is necessary and sufficient for 
targeting of DNA Ligase III to the lac operator array through interaction with XRCC1. 
Note that the highly homologous DNA Ligase I does not accumulate at the lac 
operator array indicating that it does not interact with XRCC1. Scale bars 5 m. 
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Supplementary Figure 2 
The F2H assay reveals the interaction of XRCC1 with PCNA, PARP-1 and PARP-2. 
BHK cells containing a lac operator array were transfected with expression vectors 
for XRCC1-LacI-RFP and either GFP-PARP-1, GFP-PARP-2 or GFP-PCNA. The lac 
repressor part of the XRCC1-LacI-RFP fusion protein mediates binding to the lac 
operator array (visible as red spot). GFP-PARP-1, GFP-PARP-2 and GFP-PCNA are 
targeted to the lac operator array indicating an interaction with XRCC1. Scale bar 
5 m. 
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Supplementary Figure 3 
The F2H assay reveals the PBD-mediated interaction of DNA Ligase I with PCNA. 
Transgenic U2OS cells containing a lac operator array were co-transfected with NLS-
PCNA-LacI-RFP and various GFP-tagged DNA Ligase I constructs. The lac 
repressor part of the NLS-PCNA-LacI-RFP fusion protein mediates binding to the lac 
operator array (visible as red spot). The PBD is necessary and sufficient for targeting 
of DNA Ligase I to the lac operator array through interaction with PCNA. 
Scale bar 5 m. 
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Supplementary Figure 4 
Interaction of various replication and repair proteins with PCNA revealed by the F2H 
assay. Transgenic BHK cells containing a lac operator array expressing NLS-PCNA-
LacI-RFP and various GFP-tagged replication and repair proteins. All proteins tested 
interact with PCNA. Scale bar 5 m. 
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Targeting and tracing
antigens in live cells with
fluorescent nanobodies
Ulrich Rothbauer1,5, Kourosh Zolghadr1,5,
Sergei Tillib2, Danny Nowak3, Lothar Schermelleh1,
Anja Gahl3, Natalija Backmann4, Katja Conrath4,
Serge Muyldermans4, M Cristina Cardoso3 &
Heinrich Leonhardt1
We fused the epitope-recognizing fragment of heavy-chain
antibodies from Camelidae sp. with fluorescent proteins
to generate fluorescent, antigen-binding nanobodies
(chromobodies) that can be expressed in living cells. We
demonstrate that chromobodies can recognize and trace antigens
in different subcellular compartments throughout S phase and
mitosis. Chromobodies should enable new functional studies, as
potentially any antigenic structure can be targeted and traced in
living cells in this fashion.
Antibodies are valuable tools for visualizing cellular components in
fixed cells, but their use in living cells is limited owing to the
inefficient folding and assembly of their variable heavy and light
chains. So far, intracellular applications have mostly relied on direct
microinjection of antibodies, which is technically demanding and
stressful for cells. Fluorescent fusion proteins can easily be
expressed in cells and whole organisms and provide information
on protein localization and dynamics in living cells1,2, but endo-
genous proteins, their post-translational modifications and non-
protein cell components remain invisible and cannot be studied. To
overcome these limitations, we fused the antigen-binding fragment
of a heavy-chain antibody with fluorescent proteins. Heavy-chain
antibodies3 from Camelidae sp. are devoid of light chains and
recognize antigens via their variable domain (referred to as VHH or
nanobody; Fig. 1a and Supplementary Fig. 1 online), which
represents the smallest intact antigen-binding fragment4. On the
basis of their chimeric nature, we termed these fluorescent antigen-
binding nanobody fusions ‘chromobodies’.
We chose green fluorescent protein (GFP) as a first target
molecule to test the feasibility of this approach. GFP has previously
been fused to a variety of proteins with well-characterized sub-
cellular localization, providing ‘visible’ antigens to directly test
chromobodies in different subcellular compartments. We isolated
lymphocytes from an alpaca (Lama pacos) immunized with pur-
ified GFP. We amplified the coding sequence of the VHH by PCR,
cloned it into a phage display vector and identified a highly specific
GFP-binding antibody fragment, a-GFP VHH, after panning
(Supplementary Methods online). Surface plasmon resonance
measurements indicated a fast kinetic association rate of 7.68 
105 M–1s–1 and a slow dissociation rate of 1.74  10–4 s–1 for the
interaction of a-GFP VHH with the GFP antigen. The low dis-
sociation constant (Kd¼ 0.23 nM) calculated from these values was
consistent with the interaction of an affinity-matured antibody
recognizing its cognate antigen.
To test the distribution of a-GFP VHH in living cells, we fused it
to the monomeric red fluorescent protein (mRFP) to generate a
‘visible’ GFP-binding antibody termed the ‘GFP-chromobody’
(Fig. 1a). Gel filtration, immunoblotting and confocal microscopy
showed that the GFP-chromobody was stable and dispersely
distributed in mammalian cells and that there were no detectable
signs of protein degradation (Supplementary Fig. 2 online). We
did not detect any aggregates such as have been described for
intrabodies like scFvs5.
We then investigated the ability of the GFP-chromobody to
access and bind its epitope in different subcellular compartments
and structures in living cells. As a typical epitope in the cytoplasm,
we used GFP–b-actin (Supplementary Fig. 3 online), which is
incorporated into growing actin filaments and allows direct visua-
lization of actin-containing structures6. We cotransfected HeLa
cells with GFP–b-actin and GFP-chromobody expression vectors
and analyzed them by live cell microscopy (Supplementary
Methods). A representative confocal image of a double-transfected
cell showed green and red fluorescence at the cytoskeleton
(Fig. 1b), indicative of correct incorporation of GFP–b-actin into
the actin filaments and efficient recognition by the GFP-chromo-
body. The efficient epitope binding of the a-GFP VHH
domain of the chromobody indicated that its intrinsic stability
(DG ¼ 30 kJ/mol)7 was sufficient for proper folding and intra-
cellular function.
We next chose three well-characterized GFP fusions to test
antigen binding in different nuclear structures, by cotransfecting
HeLa cells with GFP fusion proteins and the GFP-chromobody. We
used a GFP–lamin B1 fusion that assembles into nuclear lamina of
mammalian cells8 (data not shown), a GFP fusion of proliferating
cell nuclear antigen (PCNA) as an example of a nucleoplasmic
epitope9 (Fig. 1c), and an epitope embedded in chromatin using a
HeLa cell line stably expressing a histone H2B-GFP fusion that
assembles into nucleosomes10 (Fig. 1d). In all experiments, the
GFP-chromobody colocalized with the GFP fusion proteins. More-
over, the images of the untransfected cells clearly showed that no
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fluorescence bleed-through occured under these experimental
conditions (Fig. 1d; see arrows). These results demonstrated that
the GFP-chromobody efficiently recognizes and binds its epitope in
different structures and subcellular compartments.
We then tested the ability of the GFP-chromobody to trace its
antigen throughout the cell cycle, again using H2B-GFP and GFP-
PCNA. Time-lapse microscopy of transfected HeLa cells showed
that colocalization of the GFP-chromobody with H2B-GFP per-
sisted through various chromatin condensation states during
mitosis (Fig. 1e and Supplementary Video 1 online). GFP-
PCNA constitutes a special challenge to live cell microscopy because
it is an essential component of the replication machinery that
concentrates at replication foci in S phase and shows a diffuse
pattern in G1 and G2 (ref. 9). We followed the subcellular
distribution of GFP-PCNA and GFP-chromobody from early S
until G2 phase by taking confocal three-dimensional image stacks
every 20 min (Supplementary Fig. 4 and Supplementary Video 2
online). Both GFP-PCNA and the chromobody showed typical
punctate patterns followed by a disperse distribution, indicating
progression through S phase and transition to G2 phase. These
time-lapse analyses show that chromobodies can trace integral
chromatin components such as H2B as well as essential compo-
nents of the replication machinery without major impact on cell
cycle progression and viability.
To test whether chromobodies can also recognize and trace
endogenous epitopes, we generated chromobodies against cyto-
plasmic and nuclear antigens. We selected VHHs that specifically
bind to cytokeratin-8 and lamin Dm0, fused them to mRFP and
tested the subcellular distribution of the resulting chromobodies in
a variety of higher eukaryotic cells. The cytokeratin-8-chromobody
highlighted cytoplasmic filaments, indicative of binding to the
endogenous cytokeratin structures (Fig. 2a). In contrast, the
lamin-chromobody was localized at the nuclear rim in Drosophila
melanogaster S2 and HeLa cells (Fig. 2b), indicating efficient
recognition of endogenous lamina lining the nucleus in cells
derived from two organisms as different as insect and humans.
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Figure 1 | Generation and characterization of a
GFP-binding chromobody. (a) Schematic outline of
a conventional IgG antibody in comparison with a
Camelidae-derived heavy-chain IgG antibody and a
generic chromobody. The putative structure of the
chromobody, based on the known crystal structures
of a VHH and mRFP, is shown at right, with the
three antigen-binding loops in yellow, cyan and
green. (b–d) Targeting of the GFP-chromobody to
GFP fusion proteins localizing in different cellular
compartments and structures in HeLa cells.
(b) GFP-chromobodies colocalize with GFP–b-actin
on cytoskeletal actin filaments. (c) GFP-
chromobodies bind to GFP-PCNA at replication
foci; a cell in mid S phase is shown. (d) GFP-
chromobodies bind to the histone H2B-GFP
incorporated into chromatin. The cell transfected
with the GFP-chromobody was in prometaphase
and condensed chromosomes are visible. Untrans-
fected cells in metaphase and interphase (marked
by arrows) that did not express the chromobody
indicate that no unspecific bleed-through of green
fluorescence occured under these experimental
conditions. Confocal mid-sections (b–c) and
z-projection (d) of living cells are shown. Scale bars, 5 mm. (e) Tracing of a chromatin protein throughout mitosis. Time-lapse imaging of a HeLa cell stably
expressing histone H2B-GFP transfected with GFP-chromobody. Selected frames from this time series are shown. At the time imaging was started (0 h), this cell
was in late G2 phase. Scale bars, 10 mm. (See also Supplementary Video 1.)
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Figure 2 | Recognition of subcellular structures by chromobodies raised
against endogenous epitopes. (a) Confocal microscopy images of mouse
myoblast cells (C2C12) fixed and stained with 4¢,6-diamino-2-phenylindole
dihydrochloride (DAPI) 24 h after transfection with the cytokeratin-8-
chromobody. The red fluorescence on cytoplasmic filaments indicates the
recognition of cytokeratin fibers. Scale bar, 20 mm. (b) Confocal microscopy
images of D. melanogaster S2 cells and human HeLa cells fixed and stained
with DAPI 24 h and 48 h after transfection with the lamin-chromobody
expression plasmid. The red fluorescence of the chromobody highlights
a nuclear rim structure that is characteristic of the nuclear lamina.
Scale bars, 5 mm.
888 | VOL.3 NO.11 | NOVEMBER 2006 | NATURE METHODS
BRIEF COMMUNICATIONS
Finally, we investigated the antigen-binding dynamics of
chromobodies by measuring the fluorescence recovery after
photobleaching (FRAP). We compared the binding of the lamin-
chromobody and the GFP-chromobody with the recovery rate of
the GFP–lamin B1 fusion, which is a stable component of the
nuclear lamina with practically no turnover11. As expected, GFP–
lamin B1 showed no detectable recovery after photobleaching and
the GFP-chromobody showed very little recovery of fluorescence at
the nuclear lamina, indicating high-affinity binding of its epitope
(Fig. 3a,b). In contrast, the lamin-chromobody showed a quick
recovery of fluorescence, with a halftime (t1/2) ofB1.9 s, indicating
transient lamin binding with rapid turnover (Fig. 3a,b). These
results demonstrate that chromobodies can be raised with different
binding affinities and that even transient binding can be sufficient
for visualization of cellular structures. Transient binding of chro-
mobodies is likely to be less harmful to cells than permanent fusion
with a fluorescent protein.
Chromobodies combine the wide target range of antibodies with
the live cell capabilities of fluorescent protein fusions and thus
potentially allow tracing of any cellular epitope, including endo-
genous proteins, their post-translational modifications and various
conformational states as well as non-protein components in living
cells. Recent work describing the detection of a specific protein
conformation with scFvs12 exemplifies new applications made
possible with recombinant antibody technologies. As chromobo-
dies can be selected against the entire antigen surface and their
affinities adjusted by mutagenesis, it should be possible either
to minimize functional interference for antigen tracing or to
deliberately target catalytic or regulatory sites for functional studies.
The small size and compact structure of the antigen-binding
domain of the chromobodies supports their intracellular stability
and should allow access to epitopes that are not reached by larger,
conventional antibodies (Supplementary Fig. 1). This smaller size
could, however, limit the maximally possible binding interface and
strength of chromobodies.
The single VHH domain required for chromobodies can be
amplified in one step from bulk lymphocyte mRNA to generate
libraries from naive or immunized animals for rapid selection of
specific binders13,14. Thus in generating chromobodies one can take
advantage of the affinity maturation occurring during the immu-
nization process, which involves somatic mutations and in vivo
selection of high-affinity binders. By comparison, Fab and scFv
molecules require two matching fragments from heavy and light
chains (Supplementary Fig. 1), which are usually obtained from
monoclonal cell lines. The alpacas used in this study are the least
demanding of all Camelidae and alpaca immunization is readily
available in most countries. The availability of VHH libraries,
combined with continually improving maturation and selection
techniques, will further facilitate the generation of new chromo-
bodies. We anticipate that chromobodies and related tools will
expand the possibilities of live cell microscopy and make entirely
new functional studies possible, as potentially any antigenic cellular
structure can be targeted and traced in living cells.
Note: Supplementary information is available on the Nature Methods website.
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Figure 3 | In vivo binding properties of various chromobodies analyzed by
FRAP. (a) FRAP of GFP–lamin B1 (top; green) and GFP-chromobody (middle;
red) coexpressed in a HeLa cell. Photobleaching of a small region (box)
resulted in no recovery of GFP–lamin B1 and only slow recovery of GFP-
chromobody during the observation period. FRAP of lamin-chromobody
(bottom; green) expressed in a different HeLa cell revealed a quick recovery
of lamin chromobody within less than 20 s. Scale bars, 5 mm. (b) Quantitative
evaluation of FRAP data showing mean curves, n ¼ 10. Error bars, s.d.
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Supplementary Figure 1. Schematic comparison of a conventional IgG and a Heavy-chain 
IgG from Camelidae and various antigen-binding fragments derived thereof. The antigen 
binding domains of a conventional antibody are Fabs (fragment antigen binding) and Fv 
fragments. The Fab fragments are the antigen binding domains of an antibody molecule, 
containing VH + CH1 and CL + VL. The CL and CH1 are connected through an intrachain 
disulfide bond. The molecular weight of the heterodimer is around 50 kDa. Fab fragments can 
be prepared by papain digestions of whole antibodies. Normally, recombinant Fv fragments 
composed of both the variable heavy chain (VH) and the variable light chain (VL) are unstable 
since the non-covalently associated domains tend to dissociate. To remediate this unstable 
behavior, the VH and VL domains are tethered by hydrophilic and flexible peptide linker 
(Gly4Ser)3. Such scFv (single chain Fv fragments) are the minimal fragments that still contain 
the whole antigen-binding site of an IgG antibody. Heavy-chain IgGs from Camelidae are 
only composed of the heavy chains and lack the light chain completely. Also the first constant 
region (CH1) is missing in these Heavy-chain antibodies (spliced out during mRNA 
processing due to loss of a splice consensus signal). The antigen-binding domain, referred to 
as VHH (15 kDa) to distinguish it from a VH of the conventional IgG, contains some key 
mutations that prevent all pairing to possible VL domains. The isolated VHHs are the smallest 
available intact antigen-binding fragment that can be cloned after PCR amplification of one 
single exon, whereas a scFv requires separate VH and VL amplification and subsequent 
joining. The affinities of VHHs to their cognate antigen are in the nanomolar range and 
comparable with those of Fab and scFv fragments. In contrast to other fragments, VHHs are 
highly soluble and stable under challenging conditions as high salts, detergents or at elevated 
temperatures. 
 
  
Supplementary Figure 2. The GFP-chromobody is present as a stable monomeric protein in 
mammalian cells. (a) Total cell extracts of GFP-chromobody expressing 293T cells or mock 
treated cells were prepared 72 h after transfection and were analyzed by SDS-PAGE and 
immunostaining. Lane 1: 30 g of protein extract of mock transfected cells; lane 2-4: 10, 20 
and 30 g of protein extract of GFP-chromobody expressing cells. The predicted size of the 
chimeric protein is 41 kDa (upper panel). As a loading control, the blot was reincubated with 
an antibody against PCNA (lower panel). (b) Gel filtration analysis of extracts of mammalian 
cells expressing the chromobody. The GFP-chromobody elutes from the column in peak 
fractions corresponding to an apparent molecular mass of ~40 kDa. Arrowheads indicate the 
elution of calibration standards. (c) Expression of the GFP-chromobody in HeLa cells in the 
absence of any antigen shows a dispersed distribution of the protein throughout the cytoplasm 
and the nucleus (upper panel), which is comparable to the distribution of non-fused mRFP in 
the same cell type (lower panel). 
 Supplementary Figure 3. Schematic representation of the fusion proteins used in this study. 
 Supplementary Figure 4. Antigen tracing with chromobodies. Tracing of a component of the 
replication machinery throughout S phase until G2. Time lapse imaging of cotransfected 
HeLa cell expressing GFP-PCNA and GFP-chromobody. Selected frames from this series are 
shown. At the start of imaging (0 h) the cell was in early to mid S phase. Scale bar, 10 µm. 
(See also Supplementary Video 2.) 
Supplementary Methods 
GFP expression, purification and llama immunization. Escherichia coli BL21DE3 cells 
were transformed with pRSETB-GFPS65T
1
 (kindly provided by Roger Y. Tsien, UCSD) and 
overexpressed (His6)-tagged GFPS65T was purified using ion-metal affinity chromatography 
according to the manufacturer's instructions (Talon, Clontech, CA, USA). One llama alpaca 
(Lama pacos) was immunized with recombinant purified GFP in Gerbu adjuvant according to 
the following scheme: day 0, 250 g GFP; days 7, 14, 21, 28 and 35, 100 g GFP; day 42, a 
bleed of 150 ml was collected. 
 
VHH library construction and selection of the antigen specific VHH. Heparinized blood 
(36 ml) was diluted with prewarmed RPMI and layered on Lymphoprep
TM
 (AXIS-Shield, 
Oslo, Norway) to purify the PBL cells according to the manufacturer’s instructions. A total of 
2107 PBL cells were isolated and stored at -80°C in aliquots of 6106 cells. The mRNA was 
extracted from 6106 lymphocytes and cDNA was synthesized with SuperscriptII RNaseH- 
reverse transcriptase (Invitrogen, CA, USA) using an oligo-dT primer. The first PCR on the 
cDNA template was performed using CALL001 (5´-GTC CTG GCT GCT CTT CTA CA 
AGG-3´) and CALL002 (5´-GGT ACG TGC TGT TGA ACT GTT CC-3´) primers annealing 
at the leader sequence and at the CH2 exon of the heavy chains of all llama IgGs, 
respectively. The PCR products lacking the CH1 sequences (i.e. fragments with sizes between 
650 -750 bp) were purified from an agarose gel using QIAquick PCR gel extraction kit 
(Qiagen-GmbH, Hilden, Germany). A nested PCR was done with an equimolar mixture of 
primers SM017 and SM018 (5´-CCA GCC GGC CAT GGC TCA GGT GCA GCT GGT 
GGA GTC TGG-3´and 5´-CCA GCC GGC CAT GGC TGA TGT GCA GCT GGT GGA 
GTC TGG-3´, respectively) and CALL002 primer, and the PCR product repurified from 
agarose gel as described before. The VHH genes were finally re-amplified with primers 
A4short (5´-CAT GCC ATG ACT CGC GGC CAC GCC GGC CAT GGC-3´) and 38 (5´-
GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT-3´) and digested with 
restriction enzymes NcoI and NotI to obtain sticky DNA ends. The fragment was purified 
with QIAquick, ligated into pHEN4 vector 
2
 cut with the same enzymes and the ligation 
mixture used to transform Escherichia coli TG1 cells. After overnight growth on 
LB/ampicillin plates, the bacterial colonies were scraped from the plates in LB, washed in the 
same medium and stored in LB/15% glycerol at -80°C until further use. A VHH library of 10
6
 
individual clones was obtained in Escherichia coli TG1 cells. A representative aliquot of this 
library was used to inoculate LB/ampicillin until cells reached the exponential growth phase 
before infection with M13K07 helper phages to display the cloned VHH at the tip of the 
virions. The phage displayed VHH library was panned for the presence of -GFP VHH on 
solid phase coated GFP (0.1 g GFP / 100 l per well) for three consecutive rounds. After the 
third round of selection, individual colonies were picked and expression of their soluble 
periplasmic protein was induced with 1 mM IPTG. The recombinant VHH extracted from the 
periplasm was tested for antigen recognition in an ELISA. For further investigation of the 
binding specificity of the -GFP VHH, a C-terminal histidine (His6)-tagged bacterial 
expression plasmid was constructed and the soluble recombinant antibody fragment was 
purified from Escherichia coli WK6 cells. The -GFP VHH was highly expressed and yielded 
0.7 - 1 mg of soluble VHH per 200 ml of IPTG-induced bacterial culture. The cytokeratin-8 
and Drosophila lamin Dm0 specific VHH’s were obtained from an immunized camel using a 
similar protocol as for retrieving the -GFP VHH. 
 
Expression and purification of the single-domain antibody fragment. The VHH gene of 
the clone that scored positive in ELISA (-GFP VHH) was recloned into the pHEN6 
expression vector and used to transform Escherichia coli WK6 cells. Large scale production 
and purification followed the protocol described by Saerens et al.
3
 
 
Generation of chromobodies. The plasmid construct encoding a translational fusion of 
-GFP VHH and mRFP was derived by PCR amplification of the -GFP VHH coding region 
with primers gfp4#F (5´-GGG GGC TCG AGC CGG CCA TGG CCG ATG TGC AG-3´) 
and gfp4#RC (5´-GGG GGA ATT CCT TGA GGA GAC GGT GAC-3´). In the case of the 
-lamin-VHH and the -cytokeratin VHH the corresponding cDNA, was amplified by PCR 
with primers VHH (BglII)#F (5´-GGG GAG ATC TCC GGC CAT GGC TCA GGT GCA G-
3´) and gfp4#RC (5´-GGG GGA ATT CCT TGA GGA GAC GGT GAC-3´). The PCR 
product was purified as described and digested with restriction enzymes XhoI and EcoRI or 
BglII and EcoRI and ligated into a modified pEYFP-N1 vector (Clontech, CA, USA) where 
the YFP sequence had been replaced by the mRFP1 coding region 
4
. 
 
Affinity measurements. Affinity measurements were done by addition of different 
concentrations of GFP, ranging from 500 nM to 7.5 nM, to purified his-tailed -GFP VHH 
attached on a nickel-nitrilo triacetic acid biochip (Biacore International AB, Uppsala, 
Sweden) according to the manufacturer’s description. The kinetic binding parameters kon, koff 
and Kd were determined with the BIAevaluation software (version 3.0). 
 
Mammalian expression constructs. The plasmid constructs encoding translational fusions of 
GFP were as follows: GFP-ß-actin (Clontech, CA, USA), GFP-lamin B1 
5
, GFP-PCNA 
6
. 
 
Mammalian cell culture and transfection. 293T cells, HeLa cells, HeLa cells stably 
expressing H2B-GFP 
7
 and C2C12 mouse myoblasts, were cultured in DMEM supplemented 
with 10% FCS and 20% FCS for C2C12. 293T cells were transfected with plasmid DNA 
using TransFectin™ reagent (Bio-Rad Laboratories, Hercules, CA, USA) according to the 
manufacturer's guidelines and incubated overnight, 48 h or 72 h respectively before 
performing the immunoblots. For microscopy HeLa cells were grown to 50-70 % confluence 
either on 1818 mm glass coverslips, 40 mm round glass coverslips, in -Slides (ibidi®, 
Munich, Germany) or on Lab-Tek™ Chambered Coverglass (Nunc-GmbH, Wiesbaden, 
Germany) and were transfected with the indicated expression constructs using Polyplus 
transfection reagent jetPEI™ (BIOMOL GmbH, Hamburg, Germany) according to the 
manufacturer’s instructions. After 4-6 hours the transfection medium was changed to fresh 
culture medium and cells were then incubated for another 24 hours before performing live cell 
microscopy or fixation with 3.7 % formaldehyde in PBS for 10 min at room temperature. 
Fixed cells were permeabilized with 0.2 % Triton X-100 in PBS for 3 min, counterstained 
with DAPI and mounted in Vectashield (Vector Laboratories, CA, USA). 
 
Drosophila cell culture and transfection. Schneider S2 cells were cultured in Schneider´s 
Drosophila Medium containing 10% heat inactivated FBS at 26°C. Cells were transfected 
using Effectene™ reagent (QIAGEN Inc, Valenica, CA, USA) according to the 
manufacturer's guidelines and incubated for 48 hours at 26°C. After resuspension S2 cells 
were seeded on 1818 mm glass coverslips. After 2 hours cells were fixed with 2.5% 
formaldehyde in PBS for 7 min on ice. Fixed cells were permeabilized with 0.2 % Triton X-
100 in PBS for 3 min, counterstained with DAPI and mounted in Vectashield (Vector 
Laboratories, CA, USA). 
 
Western blot analysis. Increasing protein amounts of total cell extracts of 293T cells either 
mock transfected or expressing the GFP-chromobody were separated on a 12% SDS–PAGE 
and then electrophoretically transferred to nitrocellulose membrane
 
(Bio-Rad Laboratories, 
CA, USA). The membrane was blocked
 
with 3% milk in PBS and incubated overnight at 4°C 
with an mRFP rabbit polyclonal
 
antibody. After washing
 
with PBS containing 0.1% Tween-
20, the blots were incubated
 
with rabbit IgG antibody conjugated with horseradish peroxidase. 
Immunoreactive bands were visualized
 
with ECL plus Western Blot Detection Kit 
(Amersham Biosciences,
 
NJ, USA). As a loading control, membranes were reprobed with 
PCNA antibody. 
 
Gel filtration. Extracts from 293T cells expressing the GFP-chromobody were subjected to 
gel filtration analysis. Briefly, 1107 cells were homogenized in 500l lysis buffer (20 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 2 mM PMSF, 0.5% NP40). After a 
centrifugation step (10 min, 20,000g, 4°C) the clear supernatant was loaded on a Superose-
12 column (Amersham Pharmacia Biotech, NJ, USA) and chromatographed at a flowrate of 
0.4 ml/min in column buffer (20 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA). 
Fractions (500l each) were analyzed by SDS-PAGE and proteins were either stained with 
Coomassie Brilliant Blue R-250 or probed further by western blotting followed by incubation 
with an antibody against mRFP as described above. As calibration standards bovine serum 
albumin (66 kDa), carbonic anhydrase (29.5 kDa) and cytochrome c (12.5 kDa) were used. 
 
Microscopy. Live or fixed cells expressing fluorescent proteins were analyzed using a Leica 
TCS SP2 AOBS confocal microscope equipped with a 63/1.4 NA Plan-Apochromat oil 
immersion objective. Fluorophores were excited with a 405 nm Diode laser, a 488 nm Ar 
laser, a 561 nm Diode-Pumped Solid-State (DPSS) laser. Confocal image stacks of living or 
fixed cells were typically recorded with a frame size of 512512 pixels, a pixel size of 70-160 
nm, a z step size of 280 nm and the pinhole opened to 1 Airy unit. A maximum intensity 
projection of several mid z-sections was then performed using ImageJ (Version 1.34, 
http://rsb.info.nih.gov/ij/). For long term live cell observation 40 mm diameter glass 
coverslips were mounted in a FCS2 live-cell chamber (Bioptechs, Butler, PA, USA) and 
maintained at 37°C. Light optical sections were acquired with a Zeiss LSM410 confocal laser 
scanning microscope using the 488 nm Ar laser line and the 543 nm HeNe laser line. Three 
mid z-sections at 1 m intervals and the pinhole opened to 2 Airy Units were taken at 
indicated time intervals. Cells were followed up to 12 hours. Focus drift over time was 
compensated with a macro, which uses the reflection at the coverslip to medium interface as 
reference. After image acquisition, a projection of the three z-sections was performed from 
each time point. For colocalization analysis the “colocalization-finder” plug-in (Version 1.1) 
for ImageJ written by C. Laummonerie was used. For FRAP analysis, a region of interest was 
selected and photobleached by an intense laser beam (laser lines 458 nm, 476 nm, 488 nm, 
496 nm, 514 nm and 561 nm set to maximum power at 100% transmission) for 300 ms. 
Before and after bleaching, confocal image series were recorded at 300 ms time intervals 
(typically 5 prebleach and 60 postbleach frames) with the pinhole opened to 1.5 Airy units. 
Mean fluorescence intensities of the bleached region were corrected for background and for 
total nuclear loss of fluorescence over the time course and normalized to the mean of the last 
4 prebleach values. For the quantitative evaluation of FRAP experiments, data of 10 nuclei 
were averaged and the mean curve as well as the standard deviation was calculated. 
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A Versatile Nanotrap for Biochemical and
Functional Studies with Fluorescent Fusion
Proteins*□S
Ulrich Rothbauer‡, Kourosh Zolghadr‡, Serge Muyldermans§, Aloys Schepers¶,
M. Cristina Cardoso, and Heinrich Leonhardt‡**
Green fluorescent proteins (GFPs) and variants thereof
are widely used to study protein localization and dynam-
ics. We engineered a specific binder for fluorescent pro-
teins based on a 13-kDa GFP binding fragment derived
from a llama single chain antibody. This GFP-binding pro-
tein (GBP) can easily be produced in bacteria and coupled
to a monovalent matrix. The GBP allows a fast and effi-
cient (one-step) isolation of GFP fusion proteins and their
interacting factors for biochemical analyses including
mass spectroscopy and enzyme activity measurements.
Moreover GBP is also suitable for chromatin immunopre-
cipitations from cells expressing fluorescent DNA-binding
proteins. Most importantly, GBP can be fused with cellular
proteins to ectopically recruit GFP fusion proteins allow-
ing targeted manipulation of cellular structures and pro-
cesses in living cells. Because of the high affinity capture
of GFP fusion proteins in vitro and in vivo and a size in the
lower nanometer range we refer to the immobilized
GFP-binding protein as GFP-nanotrap. This versatile
GFP-nanotrap enables a unique combination of micro-
scopic, biochemical, and functional analyses with one
and the same protein. Molecular & Cellular Proteomics
7:xxx–xxx, 2008.
After the identification of most components of the cell,
further insights into their regulation and function require infor-
mation on their abundance, localization, and dynamic inter-
actions. Green fluorescent proteins (GFPs)1 and spectral vari-
ants thereof became popular tools to determine protein
localization and, in combination with fluorescence photo-
bleaching techniques, provided unique information on protein
dynamics in living cells (1–4). Necessary additional informa-
tion on DNA binding, enzymatic activity, and complex forma-
tion can be obtained with various methods including chroma-
tin immunoprecipitation (ChIP) and affinity purification (5, 6).
These methods, however, are hampered by the limited avail-
ability of specific antibodies. Those limitations are often by-
passed by fusing the protein of interest to specific epitope or
protein tags including hemagglutinin, c-Myc, FLAG, or GST (7,
8). Curiously GFP, the most widely used labeling tag in cell
biology, is rarely used for biochemical analyses, although
various mono- and polyclonal antibodies have been de-
scribed (9, 10). This may be due in part to limited availability
and specificity as well as co-eluted heavy and light antibody
chains that interfere with subsequent analyses. An alternative
to conventional antibodies are variable single domain anti-
body fragments, also referred to as VHH, derived from heavy
chain antibodies of Camelidae (11). These VHH fragments,
which present the smallest intact antigen-binding units with a
molecular mass of about 15 kDa are highly soluble and
stable and can be efficiently produced in heterologous sys-
tems (12, 13). VHH fragments have been used like conven-
tional antibodies for various immunological applications
(14–16).
Here we describe a novel application of a 13-kDa GFP
binding fragment derived from a llama single chain antibody
(17). This GFP-binding protein (GBP) has a small (2.5  4.5-
nm) barrel-shaped structure and can easily be produced in
bacteria. We immobilized the GBP to generate a GFP-nano-
trap, which enables a fast and efficient isolation of GFP fusion
proteins and their interacting factors for biochemical and ChIP
analyses. Moreover we demonstrated that the GFP-binding
protein can be fused with structural proteins to ectopically
recruit GFP fusion proteins and interacting factors at defined
regions in living cells.
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EXPERIMENTAL PROCEDURES
Expression and Purification of the GBP—Llama immunization, VHH
library construction, and selection of the GBP were described previ-
ously (17). The coding sequence of the GFP-binding VHH domain was
cloned into the pHEN6 (18) vector using the NcoI and NotI restriction
sites adding a C-terminal histidine (His6) tag, and chemically compe-
tent Escherichia coli BL21 cells were transformed. For expression and
purification a 500-ml E. coli culture was induced with 1 mM isopropyl
-D-1-thiogalactopyranoside for 20 h at room temperature. Bacterial
cells were harvested by centrifugation (10 min at 5000  g), and the
pellet was resuspended in 10 ml of binding buffer (1 PBS, pH 8.0,
0.5 M NaCl, 20 mM imidazole, 1 mM PMSF, 10 g/l lysozyme). The
cell suspension was incubated for 1 h at 4 °C in a rotary shaker and
then sonified (6  10-s pulse) on ice. After centrifugation (20 min at
20,000  g) soluble proteins were loaded on a preequilibrated 1-ml
HiTrap column (GE Healthcare) and purified. The His-tagged GBP
was eluted by a linear gradient ranging from 20 to 500 mM imidazole.
Elution fractions containing the GBP were pooled and dialyzed into
PBS. Protein concentration was adjusted to 1 g/l. The yield of
purified GBP/liter of bacterial culture was in the range of 10–15 mg.
Expression Plasmids—For bacterial expression and purification of
GFP we used the bacterial expression plasmid pRSet5D containing
the GFP coding sequence with a C-terminal His6 tag kindly provided
by B. Steipe. For mammalian cells we used the following expression
vectors encoding different fluorescent fusion proteins: pEGFP-C1,
pEYFP-C1, pECFP-C1, GFP--actin (all from Clontech), GFP-Lamin
B1 (19), GFP-PCNA (20), mRFP-PCNA, GFP-Dnmt1, and GFP-
Dnmt1(P1229W) (21). We also used mammalian expression vectors
containing cDNAs coding for mRFP1 (22), mCherry, or mOrange (23)
kindly provided by R. Tsien. Overlap extension PCR was performed to
construct the CFP I147N and the CFP T154M using mutagenic prim-
ers CFP-I147N-FW (5-GAGTACAACTACAACAGCCACAACGTCTA-
TA-3) in combination with CFP-I147N-Rev (5-AACGTCTATATCAT-
GGCCGACAAGCAG-3) and CFP-T154M-FW (5-AACGTCTATATC-
ATGGCCGACAAGCAG-3) in combination with CFP-T154M-Rev (5-
CTGCTTGTCGGCCATGATATAGACGTT-3), respectively, and the fl-
anking primer CFP FW (5-GATCCGCTAGCGCTACCGGTCGCCAC-
CATG-3) and CFP-Rev (5-AACGTCTATATCATGGCCGACAAGCA-
G-3). The PCR fragment was cloned into the NheI/BsrGI site of the
pECFP-C1 vector. For GBP-Lamin B1, the Lamin B1 was amplified
from GFP-Lamin B1 by PCR with primers LaminB1EcoRV#F (5-CC-
CCGATATCGGCGACTGCGACCCCC-3) and LaminB1HisNotI#R (5-
GGGGGCGGCCGCCTAGTGATGGTGATGGTGGTGTTACATAATTG-
CACAGCTTC-3). The PCR product was purified, digested with
EcoRV and NotI, and ligated into the EcoRV/NotI sites of the GFP
chromobody vector. All resulting constructs were sequenced and
tested for expression in HEK 293T cells followed by Western blot
analysis.
Antibodies—For immunoprecipitation and immunoblotting a mix-
ture of two anti-GFP monoclonal antibodies (clones 7.1 and 13.1)
from Roche Diagnostics and an affinity-purified polyclonal anti-GFP
antibody raised in rabbit (a kind gift from D. Nowak, Berlin, Germany)
were used. Precipitated proteins were detected with antibodies
against GFP, mRFP, Lamin B (H-90, Santa Cruz Biotechnologies),
-actin (monoclonal anti--actin, Sigma), and PCNA (monoclonal anti-
PCNA, clone 16D10). Promyelocytic leukemia protein (PML) bodies
were detected with a monoclonal anti-PML antibody (5E10).
Immunoprecipitation—1  106–1  107 HeLa, HeLa H2B-GFP, or
HEK 293T cells either mock-treated or transiently transfected with
expression vectors coding for GFP, YFP, CFP, mRFP, mCherry, mO-
range, GFP--actin, GFP-Lamin B1, GFP-PCNA, or GFP-Dnmt1 were
homogenized in 200 l of lysis buffer (20 mM Tris/HCl, pH 7.5, 150 mM
NaCl, 0.5 mM EDTA, 2 mM PMSF, 0.5% Nonidet P-40). For extraction
of GFP-Lamin B1 or H2B-GFP the lysis buffer was modified by adding
0.5 M NaCl, 1 g of DNase I, 5 mM MgCl2, and 0.1% SDS. After a
centrifugation step (10 min at 20,000 g at 4 °C) the supernatant was
adjusted with dilution buffer (20 mM Tris/HCl, pH 7.5, 150 mM NaCl,
0.5 mM EDTA, 2 mM PMSF) to 1 ml. 20 l (2%) were added to
SDS-containing sample buffer (referred to as input). 1 g of purified
GBP or 2 g of anti-GFP antibodies were added and incubated for
5–60 min on an end-over-end rotor at 4 °C. For pulldown of immu-
nocomplexes 25 l of an equilibrated mixture of protein A/G-Sepha-
rose (Amersham Biosciences) were added, and incubation continued
for 60 min. After a centrifugation step (2 min at 5000  g at 4 °C)
supernatant was removed, and 2% was used for SDS-PAGE (referred
to as flow-through). The bead pellet was washed two times in 1 ml of
dilution buffer containing 300 mM NaCl. After the last washing step the
beads were resuspended in 2 SDS-containing sample buffer and
boiled for 10 min at 95 °C.
Column-based GFP Purification—1 mg of purified GBP was co-
valently coupled to 1 ml of N-hydroxysuccinimide-Sepharose (GE
Healthcare), according to the manufacturer’s instructions, generating
the GFP-nanotrap. Subsequently 50 l of the GFP-nanotrap was
transferred to a 1-ml column (MoBiTec) and preequilibrated with 5 ml
of dilution buffer. Protein extracts of GFP-producing cells were pre-
pared as described above, and the soluble protein fraction was
loaded onto the column. The protein solution (1 ml) passed through
the column at 100–200 l/min flow rate. Subsequently the column
material was washed (two times) with 1 ml of dilution buffer containing
300 mM NaCl, and bound proteins were eluted with 100 l 0.1 M
glycine, pH 3.2. 2% of the input and flow-through and 10% of bound
material were resuspended in 2 SDS-containing sample buffer and
analyzed by SDS-PAGE and Coomassie Blue and by immunostaining.
Enzymatic Activity Test—Soluble protein extracts of HEK 293T
cells producing GFP-Dnmt1 or GFP-Dnmt1(P1229W) were prepared,
and immunoprecipitation was performed as described above. Beads
containing the GBP-GFP-Dnmt1 complexes were washed extensively
in dilution buffer containing 300 mM NaCl, and after centrifugation the
beads were resuspended in 500 l of assay buffer (100 mM KCl, 10
mM Tris, pH 7.6, 1 mM EDTA, 1 mM DTT). Beads were washed (two
times) in assay buffer, and after centrifugation (1000  g for 1 min) 30
l of methylation mixture (0.1 Ci of S-[3H]adenosylmethionine (Am-
ersham Biosciences), 1.67 pmol/l hemimethylated double-stranded
35-bp DNA (50 pmol/l), 160 ng/l BSA) were added. As a positive
control 2 g of recombinant purified DNA methyltransferase I
(DNMT1) was used. Incubation was carried out for 2.5 h at 37 °C, and
the reactions were spotted onto DE81 cellulose filters. Subsequently
filters were washed (three times) with 0.2 M (NH4)HCO3, once with
H2O, and once with 100% EtOH. After drying at 80 °C the filter was
transferred into a Mini-Poly-Q vial with 5 ml of Ultima Gold LSC
Mixture (PerkinElmer Life Sciences), and each sample was measured
for 1 min in a scintillation counter (Beckman LS1801). A sample
without enzyme addition was used as negative control.
Chromatin Immunoprecipitation Assay and Real Time PCR Analy-
sis—For chromatin immunoprecipitation experiments, formaldehyde
was diluted to 1% in serum-free medium, and 15 ml were added to
monolayers of C2C12 and C2C12/HMGA1a-GFP cells for 10 min at
room temperature. The cross-link was stopped by adding 1.5 ml of
1.25 M glycine. After removal of the medium, cells were washed (two
times) on plates with cold 1 PBS, scraped off, and washed again in
cold 1 PBS and once with hypotonic LSB buffer (10 mM Hepes, pH
7.9, 10 mM KCl, 1.5 mM MgCl2). Cells were resuspended in 2.7 ml of
LSB buffer and lysed by adding 300 l of 20% Sarkosyl. The chro-
matin was carefully layered onto a 40-ml sucrose cushion (LSB buffer
plus 100 mM sucrose) and centrifuged (10 min at 4 °C at 4000  g).
Supernatant was removed, and the chromatin was resuspended in 2
ml of TE (10 mM Tris, 0.5 mM EDTA, pH 8.0) and sonicated (Branson
sonifier 250-D, 35% amplitude, 2 min in 1-s intervals). For each
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immunoprecipitation, 500 g of the nucleoprotein were adjusted with
1⁄10 volume of 1 NET (50 mM Tris, 150 mM NaCl, 0.5 M EDTA, 0.5%
Nonidet P-40). 10 g of two anti-GFP monoclonal antibodies (clones
7.1 and 13.1; Roche Diagnostics), a mouse IgG1 isotype control, and
5 g of GFP-nanotrap were incubated overnight at 4 °C. The purifi-
cation of co-precipitated DNA was performed as described above.
Real time PCR was performed with the Light Cycler instrument
(Roche Diagnostics) using a ready-to-use “hot start” reaction mixture
(FastStart DNA Master SYBR Green I; Roche Diagnostics). Real time
PCR analysis was performed according to the manufacturer’s instruc-
tions using the same parameters as described previously (24). The list
of primer pairs is given in Supplemental Table 1.
RESULTS
Ideally the subcellular localization and binding dynamics of
fluorescent fusion proteins should be complemented with
biochemical data on interacting factors, enzymatic activity,
and DNA binding properties (Fig. 1). To generate a nanotrap
for fast and efficient purification of GFP fusion proteins we
used a small recombinant 13-kDa GBP comprising the
epitope recognition domain of a heavy chain antibody raised
in an alpaca (Lama pacos) against GFP (17). The GBP was
fused with a C-terminal histidine (His6) tag, produced in
E. coli, and purified by IMAC (Supplemental Fig. S1A). Sub-
sequent gel filtration analysis showed a single elution peak at
about 13 kDa indicating that the GBP can easily be produced
and purified as a stable monomer (Supplemental Fig. S1B).
For a first functional analysis we tested the binding capacity of
the GBP to purified GFP. Equimolar amounts of both proteins
were mixed and incubated for about 20 min. Subsequent gel
filtration analysis showed that the GBP and its antigen rapidly
assemble into a stable, stoichiometric complex with a corre-
sponding native molecular mass of 41 kDa (Supplemental Fig.
S2). We then tested the ability of GBP to precipitate its antigen
from cell extracts and directly compared its performance with
mono- and polyclonal anti-GFP antibodies. GBP and anti-
GFP antibodies were added to protein extracts of HEK 293T
cells expressing GFP. Precipitated proteins were separated
by SDS-PAGE and visualized by Coomassie Blue or immuno-
blot analysis (Fig. 2A). After precipitation with GBP only two
protein bands (GFP at 28 kDa and the GBP itself at 13
kDa) were detectable, whereas additional bands correspond-
ing to the light and heavy chains of the denatured IgGs as well
as unspecifically precipitated proteins could be observed in
immunoprecipitations with the mono- and polyclonal anti-
GFP antibodies. The quantitative comparison of precipitated
GFP in relation to antibody input showed that the GBP is
clearly more efficient than established mono- and polyclonal
antibodies (Fig. 2A and Supplemental Fig. S3).
Conveniently GBP complexes can be immobilized and pre-
cipitated with protein A-agarose just like conventional anti-
bodies (Fig. 2A, left panel). However, to prevent elution of the
GBP itself and to avoid any interference with subsequent
analyses we covalently coupled GBP to N-hydroxysuccinimide-
Sepharose beads generating a stable GFP-binding matrix
(GFP-nanotrap). This GFP-nanotrap allowed a very fast (5-
min) column-based purification of GFP from total cell extracts
yielding a single protein band without any visible unspecific
protein contamination (Fig. 2B, right panel). Moreover the
immunoblotting analysis revealed a quantitative precipitation
of the antigen visible as depletion of GFP from the flow-
through fraction.
To analyze the specificity of GBP we performed immuno-
precipitation with a set of different fluorescent proteins. Be-
sides GFP itself, GBP recognizes the yellow variant YFP but
not CFP or any derivatives of DsRed like mRFP, mCherry, or
mOrange (Supplemental Fig. S4). To further characterize the
binding properties of GBP we tested different salt, tempera-
ture, and pH conditions. First, we increased the NaCl molarity
of the binding buffer from 0.15 to 2 M and found that GBP
precipitates its antigen even under high salt conditions (Sup-
plemental Fig. S5A). Second, we tested different incubation
temperatures and observed quantitative precipitation of GFP
even at 65 °C (Supplemental Fig. S5B) demonstrating the
temperature-stable folding and binding of GBP. Third, we
tested the elution of bound epitope at different pH conditions.
GFP was stably bound in the range from pH 4 up to pH 11.
Lowering the pH to 3.2 caused quantitative release of GFP
providing a fast and efficient method to elute bound antigen
complexes from the GFP-nanotrap (Supplemental Fig. S5C).
To investigate whether GBP also precipitates GFP fusion
proteins we chose four well characterized constructs from
different subcellular compartments: GFP--actin (25), GFP-
Lamin B1 (26), GFP-PCNA (20), and H2B-GFP (27). Cells
transiently or stably expressing the fusion proteins were an-
alyzed by confocal microscopy to determine the subcellular
localization of the GFP fusion protein (Fig. 2B, upper panel).
Subsequently cells were harvested, and GFP fusion proteins
FIG. 1. Outline of possible GFP fu-
sion protein applications with the
GFP-nanotrap. FRAP, fluorescence re-
covery after photobleaching; FRET, flu-
orescence resonance energy transfer.
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were precipitated with the GFP-nanotrap followed by Coo-
massie staining and Western blot analysis (Fig. 2B, lower
panel). The results show that GBP efficiently precipitated N-
or C-terminal GFP fusion proteins from different subcellular
compartments and structures.
One of the most interesting applications of the GBP is the
possibility to correlate subcellular localization, dynamics, and
complex formation of specific proteins and mutants thereof.
We had previously identified a deletion mutant of Dnmt1
lacking the PCNA interaction domain (Dnmt1-PBD) (28). In
comparison with wild-type Dnmt1 (GFP-Dnmt1) the fluores-
cent labeled mutant (GFP-Dnmt1-PBD) showed no colocal-
ization with the red fluorescent PCNA (mRFP-PCNA) during S
phase (Fig. 2C, upper panel). We then compared this obser-
vation from living cells with biochemical data. Cells were lysed
immediately after microscopic analysis and subjected to im-
munoprecipitation with the GFP-nanotrap. Immunoblot anal-
ysis showed that mRFP-PCNA co-precipitates with GFP-
Dnmt1 but not with GFP-Dnmt1-PBD (Fig. 2C, lower panel).
The unbound mRFP-PCNA fraction reflects the transient na-
ture of the Dnmt1-PCNA interaction during S phase (21). In
addition, we also detected endogenous PCNA co-precipitat-
ing with GFP-Dnmt1 but not with GFP-Dnmt1-PBD, demon-
strating that GBP can also pick up interacting endogenous
proteins. These results show that the GFP-nanotrap is suita-
ble to identify (even) transiently interacting factors and cell
cycle-dependent complexes. Taking advantage of its avid and
specific binding we now routinely use the GFP-nanotrap to
identify interacting factors by MALDI mass spectrometry.
A critical question in live cell studies is whether the fluores-
cent fusion proteins are enzymatically active and have bio-
chemical properties similar to their endogenous counterparts.
For fast determination of enzymatic activity we chose fluores-
cent fusion constructs of the murine Dnmt1, which are ac-
tively investigated in our laboratory. With live cell microscopy
we could not distinguish the active GFP-Dnmt1 (wild type)
and an enzymatically inactive version, GFP-Dnmt1(P1229W)
(Fig. 3, upper panel). After visualization of the fluorescent
Dnmt1 constructs in nuclei of mammalian cells both proteins
were one step-purified from cell extracts with the GFP-nano-
trap (Fig. 3, middle panel) and directly assayed for enzymatic
taining GBP directly coupled to Sepharose (GFP-nanotrap), and
bound proteins were eluted. B, one-step purification of GFP fusion
proteins with the GFP-nanotrap. Representative images of HeLa cells
producing GFP--actin, GFP-Lamin B1, GFP-PCNA, or H2B-GFP are
shown (upper panel). Cells were lysed, and GFP fusion proteins were
one step-purified with the GFP-nanotrap. C, co-precipitation of GFP
fusion proteins and interacting factors. HeLa cells coexpressing either
GFP-Dnmt1 or a deletion mutant of Dnmt1 (GFP-Dnmt1-PBD) to-
gether with the red fluorescent version of PCNA (mRFP-PCNA) were
analyzed by live cell microscopy. Representative confocal images of
two cells in early-to-mid S phase are shown (scale bar, 5 m). Sub-
sequently cells were lysed and subjected to immunoprecipitation with
the GFP-nanotrap. wt, wild type.
FIG. 2. One-step purification of fluorescent proteins. A, immu-
noprecipitation of GFP. Left panel, comparison of GBP with mono-
and polyclonal anti-GFP antibodies. Protein extracts of GFP-produc-
ing HEK 293T cells were subjected to immunoprecipitation with GBP,
mono-, or polyclonal anti-GFP antibodies. Throughout (A–C) aliquots
of input (I), flow-through (FT), and bound fraction (B) were separated
by SDS-PAGE and visualized either by Coomassie Blue (top) or by
immunoblot analysis (bottom). Precipitated GFP, denatured heavy
(hc) and light chains (lc) of the IgGs, and the GBP are marked by
arrows. Right panel, column-based purification with the GFP-nano-
trap. GFP-containing protein extracts were loaded on a column con-
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measurements. GFP-Dnmt1 showed a specific DNA methyl-
transferase activity similar to that of purified recombinant
DNMT1 (Fig. 3, lower panel). The comparison with the cata-
lytically inactive GFP-Dnmt1(P1229W) revealed that the en-
dogenous DNA methyltransferase activities of mammalian
cells were efficiently removed by this quick one-step purifica-
tion. These results demonstrate that the GFP-nanotrap is a
highly efficient tool for quick and reliable biochemical charac-
terization of fluorescent fusion proteins.
To investigate whether the GFP-nanotrap has the required
specificity to function in chromatin immunoprecipitations we
performed ChIP experiments using a mouse myoblast cell line
stably expressing a GFP fusion of the high mobility group
protein A1a (HMGA1a-GFP).2 We analyzed the promoter re-
gions of the Interleukin 6 and Igf-binding protein 1 genes that
are known to preferentially bind HMGA1a (29–32). 500 g of
formaldehyde-cross-linked nucleoprotein were subjected to
immunoprecipitation with the GFP-nanotrap and comparison
with commercially available GFP-specific antibodies. Only the
GFP-nanotrap showed a reproducible 3-fold enrichment of pro-
moter fragments over distal sites. This preferential binding of
HMGA1a-GFP at the specific promoter sites was not detectable
with conventional GFP-specific antibodies (Fig. 4). The parental
C2C12 cells not expressing HMGA1a-GFP showed no specific
enrichment of any sequences in comparison with the isotype
control (data not shown). These data confirm the high speci-
ficity and sensitivity of the GFP-nanotrap.
These experiments show in vitro applications of the GFP-
binding protein. In a second step we explored potential in vivo
applications and placed the coding region of the GFP-binding
protein at a defined position within the cell by fusing it to a
structural component of the nuclear envelope. We fused the
GBP with Lamin B1 (GBP-Lamin B1) to generate a cellular
nanotrap at the nuclear lamina. As described above, GBP
efficiently recognized and bound YFP but not the blue variant
CFP in vitro (Supplemental Fig. S10). To compare these bio-
chemical data with binding specificity in living cells we trans-
fected HeLa cells with GBP-Lamin B1, GFP, and CFP and
determined the distribution of GFP and CFP with respect to
the GFP-nanotrap positioned at the nuclear lamina. Confocal
microscopy showed that only GFP was exclusively localized
at the nuclear lamina, whereas CFP showed a strikingly dif-
ferent, disperse distribution throughout the cell (Fig. 5A). Se-
quence alignment of GFP, YFP, and CFP showed that CFP
differs from the two other fluorescent proteins at two relevant
amino acid positions (Fig. 5B). To define the epitope recog-
nized by GBP we introduced single mutations reverting step-
wise CFP to GFP. We found that the exchange of isoleucine at
position 147 to asparagine (I147N) restored binding to the
GFP-nanotrap, whereas mutating methionine at position 154
to a tryptophan (T154M) did not restore any detectable bind-
ing (Fig. 5C). This demonstrates the high selectivity and spec-
ificity of the GBP in vitro and in vivo even allowing detection of
single amino acid substitutions. Finally we analyzed whether
the GFP-nanotrap can be used to manipulate endogenous
factors and cellular structures. As a target we chose the
endogenous PML. The PML is organized in nuclear PML
bodies, which play a role in regulation of gene expression,
apoptosis, DNA repair, and proteolysis (33, 34). We could
detect 10–30 PML bodies by immunofluorescence staining of
PML in HeLa cells where PML bodies are evenly distributed
throughout the nucleus (data not shown). In transiently trans-
fected cells PML bodies are highlighted by the green fluores-
cence of the GFP-PML (35) fusion protein and immuno-
staining with a specific antibody against PML (Fig. 6A). Upon
expression of GBP-Lamin B1 green fluorescent labeled PML
bodies were exclusively found at the nuclear rim, and subse-
quent antibody staining confirmed the depletion of endoge-
nous PML from the nuclear interior (Fig. 6C). These results
demonstrate the potential of the GFP-nanotrap not only to
recruit GFP fusion proteins but also interacting endogenous
factors.2 . Brocher and . Hock, manuscript submitted.
FIG. 3. GFP fusion proteins retain their enzymatic activity after
purification with the GFP-nanotrap. Representative images of nu-
clei from HeLa cells show the endogenous Dnmt1, GFP-Dnmt1, or
catalytically inactive mutant GFP-Dnmt1(P1229W) (top). Soluble pro-
tein extracts containing GFP-Dnmt1 or GFP-Dnmt1(P1229W) were
one step-purified with the GFP-nanotrap and analyzed by SDS-PAGE
followed by Coomassie Blue staining (middle). DNA methyltransferase
activity of purified GFP fusion proteins (4 g each) and recombinant
DNMT1 (2 g) were determined (bottom). n  4; error bars show
standard deviation.
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DISCUSSION
One challenge of the postgenomics era is the effective
integration of genetic, biochemical, and cell biological data.
This integration has in part been impeded by the simple fact
that different protein tags are used for different applications.
Here we present a GBP as a simple, robust, and versatile tool
for biochemical analyses of GFP fusion proteins and even
functional studies in vivo. The small and stable GBP has
several decisive advantages over the conventional, 10 times
larger, mono- and polyclonal antibodies. First, the GBP can
be produced in bacteria in unlimited quantities and with re-
producible quality and can easily be coupled to beads or
matrices. Second, the high affinity of single chain GBP allows
short (5–30-min) incubations to isolate fluorescent fusion pro-
teins and even transiently bound factors from different cellular
compartments. Third, its small size of about 13 kDa minimizes
unspecific binding and entirely avoids contamination by heavy
and light chains of conventional antibodies (50 and 25 kDa)
that normally interfere with subsequent analyses.
The specificity of the GFP-nanotrap was further underlined
by ChIP experiments with stable cells expressing a HMGA1a-
GFP fusion. Analyzing DNA binding at two gene loci with the
FIG. 5. Specificity of the GFP-nanotrap. A, in HeLa cells expressing GFP, CFP, and GBP-Lamin B1 GFP is exclusively localized at the
nuclear lamina, whereas CFP is dispersedly distributed. B, amino acid sequence alignment of GFP, CFP, CFP I147N, and CFP T154M.
Non-conserved residues are marked in red. The crystal structure of GFP (36) is shown, and the asparagine at position 147 is displayed as a
blue sphere using PyMOL Version 0.99 (DeLano Scientific LLC). C, soluble protein extracts of HEK 293T cells expressing GFP, CFP, CFP
I147N, and CFP T154M were subjected to one-step purification with the GFP-nanotrap. Input (I) and bound fractions (B) were separated by
SDS-PAGE and analyzed by Coomassie Blue staining and by immunoblotting with anti-GFP antibody.
FIG. 4. ChIP analysis with the GFP-nanotrap. For ChIP experiments, 500 g of C2C12/HMGA1a-GFP cells were subjected to immuno-
precipitation using 5 g of GFP-nanotrap, 10 g of anti-GFP antibody (monoclonal), and 10 g of mouse IgG1 isotype control, respectively.
Co-precipitated DNA was quantified by real time PCR analysis using primer pairs of the IgfBP1 and Il6 promoter regions and indicated
downstream regions (distal region 1/2). Results obtained for the Interleukin 6 and IgfBP1 promotor are shown in dark gray. Column heights
indicate the relative enrichment obtained in two independent experiments as the difference between PCR values obtained with the GFP-
nanotrap and anti-GFP antibodies over mouse IgG1 isotype control antibodies.
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GFP-nanotrap we detected a preferential binding of HMGA1a
at the promoter regions that was far less evident with estab-
lished anti-GFP antibodies.
In conclusion, this versatile GFP-nanotrap together with the
widespread use of fluorescent fusion proteins now enables a
fast and direct correlation of the subcellular localization and
mobility of fluorescent fusion proteins with their enzymatic
activity, interacting factors, and DNA binding properties com-
bining cell biology and biochemistry with mutual benefits.
Unlike conventional antibodies, the GFP-nanotrap can also be
used for functional studies in vivo. We demonstrated that GBP
can be fused with cellular proteins to set a GFP-nanotrap at a
defined subcellular site to either ectopically recruit GFP fusion
proteins and their associated factors or deplete them from
their native surroundings. In one example we anchored the
GBP at the nuclear lamina to capture nuclear bodies. Multiple
other applications are possible because any GFP fusion pro-
tein can be combined with any cellular anchor point. The use
of GBP as a nanotrap in living cells opens up an entire
spectrum of new types of functional studies to probe and
manipulate cellular processes and structures.
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SUPPLEMENTAL DATA 
EXPERIMENTAL PROCEDURES 
Mammalian cell culture and transfection 
HeLa, HeLa H2B-GFP (Kanda et al., 1998) and HEK 293T cells were cultured in 
DMEM containing 50 g/ml gentamicin supplemented with 10% FCS. HEK 293T cells were 
transfected with plasmid DNA using TransFectin™ reagent (Bio-Rad Laboratories) according 
to the manufacturers guidelines and incubated either overnight, 48 h or 72 h before 
performing immunoprecipitation. Cells grown on coverslips were cotransfected with jetPEI, 
(Poly Plus Transfection) according to the manufacturer’s instructions, 24 h prior to fixation.  
C2C12 and C2C12-GFP, a subclone of a mouse myoblast cell line, were cultivated in 
DMEM, 4.5 g/l glucose, 1% L-Glutamine, and 10 FCS (Blau et al., 1985). 
Immunofluorescence 
Cells were fixed in 3.7% formaldehyde for 10 min and permeabilized with 0.5% 
Triton X-100 in PBS. For immunofluorescence an anti-PML (5E10) mouse primary antibody 
(diluted in PBS containing 2% BSA) was used. For detection a secondary antibody (diluted 
1:400 in PBS containing 2% BSA) conjugated to Alexa Fluor 555 (Molecular Probes) was 
then used. Cells were counterstained with DAPI and mounted in Vectashield (Vector 
Laboratories). 
Confocal Microscopy 
Confocal microscopy was carried out with a Leica TCS SP2 AOBS confocal laser 
scanning microscope equipped with a HCX PL 63x/1.4 NA oil immersion objective. 
Fluorophores were exited using a 405 nm diode laser line, a 488 nm Ar laser line and a 
561 nm diode-pumped solide-state (DPSS) laser line. Confocal image series were typically 
recorded with a frame size of 512x512 pixels, a pixel sizes between 50 - 100 nm, a typical z-
step size of 250 nm and the pinhole opened to 1 Airy unit. A maximum intensity projection of 
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several confocal mid z-sections was then performed using ImageJ (Version 1.37, 
http://rsb.info.nih.gov/ij/). 
Gel filtration 
10 g IMAC purified GBP were loaded on a Superdex-75 column (Amersham 
Pharmacia Biotech) and chromatographed at a flowrate of 0.5 ml/min in column buffer 
(1xPBS, 0.5 mM EDTA). BSA (66 kDa), carbonic anhydrase (29.5 kDa) and cytochrome c 
(12.5 kDa) were used as calibration standards. For complex analysis 2 mg of GBP were 
incubated for 20 min with 2 mg of purified GFP in 500 l column buffer and subsequently 
subjected to gel filtration analysis. Eluted proteins were subjected to SDS-PAGE followed by 
staining with Coomassie Blue (Invitrogen). 
SDS-PAGE and Western blot analysis 
Indicated protein fractions were separated on an SDS–PAGE (12% - 15%) or on a 
4% – 12% NuPAGE Novex bis-Tris precast gel subsequently stained with Coomassie Blue 
(Invitrogen) or electrophoretically transferred to nitrocellulose membrane
 
(Bio-Rad 
Laboratories). The membrane was blocked
 
with 3% milk in PBS containing 0.1% Tween 20 
(T-PBS) and incubated for 1 h at RT or overnight at 4°C with the indicated antibodies. After 
washing
 
with T-PBS the membrane was incubated
 
with secondary antibodies conjugated with 
horseradish peroxidase (HRP). Immunoreactive bands were visualized
 
with ECL Western 
Blot Detection Kit (Amersham Biosciences). 
Binding assays under high selective condition  
The soluble protein extract of HEK 293T cells expressing GFP were adjusted with 
5 M NaCl to final concentrations of 150 mM, 0.5 M, 1 M and 2 M NaCl prior adding the 
GFP-nanotrap. Binding occurs for 10 min at 4°C and constant rotation. After a centrifugation 
step (2 min, 5000xg, 4°C) the supernatant was removed and 2% was used for SDS-PAGE 
(referred to as flow through). The bead pellets were washed (2x) in 1 ml dilution buffer 
containing 300 mM NaCl. Bound proteins were eluted by resuspending the beads in 2x SDS-
A GFP-binding Protein for Biochemical and Functional Studies Rothbauer et al. 
 
 -89- 
containing sample buffer and boiling for 10 min at 95°C. For analyzing different temperature 
conditions immunoprecipitation were carried out as described. After the last washing step the 
beads pellet was resuspended in 100 l dilution buffer and incubated at 25°C, 45°C and 65°C 
respectively for 30 min. Beads were harvested by centrifugation (2 min, 5000xg), the 
supernatant containing the released protein (R) was removed and 50 l 3x SDS-containing 
sample buffer was added. Proteins remaining bound to the beads were eluted as described. To 
test increasing pH-values the bead pellet was resuspended after immunoprecipitation in 
dilution buffer adjusted to pH 8, pH 9, pH 10 or pH 11 and incubated for 1 h at room 
temperature. Subsequently the samples were treated as described. For decreasing pH-
conditions, the beads pellet was incubated for 1 min with 0.1 M glycine pH 4.0, 3.2 or 2.5 and 
subsequently neutralized by adding 2 l of 1 M Tris-base. 
Sequences of oligonucleotides for ChIP experiments 
Table 1 
oligo name Sequence location 
IL6 promoter_forward CCACCCTCCAACAAAGATTTTTATC 1175-1199; acc.: M20572 
Il6 promoter_reverse CTGCCTCACACTCCTCTCTCACAG 1390-1413; acc.: M20572 
Il6 control1_forward AACAAGAAAGACAAAGCCAGAGTCC 6123-6147; acc.: M20572 
Il6 control1_reverse AAACCCCAAAGTAAAACAAAGCAAG 6304-6328; acc.: M20572 
Il6 control2_forward TCTTCCCACAGCCCAGAACAC 7373-7393; acc.: M20572 
Il6 control2_reverse TGGATGGTCTTGGTCCTTAGCC 7535-7556; acc.: M20572 
IgfBP1 promoter1_for GTCGCTTAGGTTTTCTGTGAGCC 2233-2255; acc.: AL607124 
IgfBP1 promoter1_rev TGGGTGGAAGGGGGTAAAGG 2394-2413; acc.: AL607124 
IgfBP1 control1 for F11 CAGCAAATAGCCAGGGTCGG  5241-5260; acc.: AL607124 
IgfBP1 control1 revB15 TGAGACAGAGCAGGAGCAGCC 5440-5460; acc.: AL607124 
IgfBP1 control2 forF285 AAGCAGGAAGGATGGAGGGG 46095-46114; acc.: AL607124 
IgfBP1 control2 revB299 TTTTGTGGCTGAATCGGTGTTC 46305-46284; acc.: AL607124 
 
Table1: Sequence and location of oligonucleotides used for quantitative PCR-analysis of ChIP experiments 
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SUPPLEMENTAL FIGURES 
 
 
Supplemental Fig. S1. Purification of recombinant GBP by immobilized affinity 
chromatography (IMAC). (A) Soluble E.coli protein extract was subjected to IMAC. 
Supernatant (SN), pellet (P) and pooled elution fractions (E) were analyzed by SDS-PAGE 
and coomassie staining. (B) Gel filtration analysis of IMAC purified GBP. Purified GBP (10 
g) was subjected to gel filtration on a Superdex-75 column. GBP elutes from the column in 
peak fractions corresponding to an apparent molecular mass of ~13 kDa. Arrows indicate the 
elution of calibration standards: BSA (66 kDa), carbonic anhydrase (29.5 kDa) and 
cytochrome C (12.5 kDa). 
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Supplemental Fig. S2. Determination of the native molecular weight of the recombinant 
GFP-GBP complex. Purified GFP was mixed with GBP in stoichometric amounts, and 
subjected to gelfiltration analysis on a Superdex-75 column. Elution fractions were subjected 
to SDS-PAGE and analyzed by Coomassie Blue staining (left panel). The elution profile of 
the complex is shown in the right panel. Arrows indicate the elution of calibration standards: 
BSA (66 kDa), carbonic anhydrase (29.5 kDa) and cytochrome C (12.5 kDa). 
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Supplemental Fig. S3. Comparison of GBP with mono- and polyclonal anti-GFP 
antibodies (A) Intensity profile of bound fractions (B) obtained with GBP, mono- and 
polyclonal GFP antibodies as shown in Figure 2A. Peaks corresponding to GFP, heavy (hc) 
and light antibody chains (lc) and GBP are indicated. (B) Quantification of GFP precipitated 
with GBP, mono- and polyclonal anti-GFP antibodies. Relative amounts were determined by 
densitometry of Coomassie Blue stained gels (dark grey bars) and immunostained blots (light 
grey bars) using ImageJ software (Version 1.34, http://rsb.info.nih.gov.ij/). 
A GFP-binding Protein for Biochemical and Functional Studies Rothbauer et al. 
 
 -93- 
 
Supplemental Fig. S4. Specificity of the GFP-nanotrap. Protein extracts of HEK 293T 
cells expressing either GFP, YFP, CFP, mRFP, mCherry or mOrange were subjected to one-
step purification with the GFP-nanotrap. Input (I), flow through (FT) and bound fractions (B) 
were separated by SDS-PAGE and visualized by Coomassie Blue staining and 
immunoblotting using an anti-GFP antibody recognizing GFP, YFP, CFP and an anti-mRFP 
antibody recognizing mRFP, mCherry, mOrange respectively.  
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Supplemental Fig. S5. The GFP-nanotrap efficiently binds its epitope even under 
extreme conditions. Protein extracts of HEK 293T cells expressing GFP were subjected to 
one-step purification at (A) increased NaCl molarity or (B) rising temperature or (C) different 
pH conditions. Aliquots of released (R) and bound (B) fractions were separated by SDS-
PAGE and visualized by Coomassie Blue staining. 
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Supplemental Fig. S6. Schematic representation of all proteins used in this study. 
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Trapped in action: direct visualization of DNA
methyltransferase activity in living cells
Lothar Schermelleh1, Fabio Spada1, Hariharan P Easwaran2, Kourosh Zolghadr1, Jean B Margot2,
M Cristina Cardoso2 & Heinrich Leonhardt1,2
DNA methyltransferases have a central role in the complex
regulatory network of epigenetic modifications controlling gene
expression in mammalian cells. To study the regulation of DNA
methylation in living cells, we developed a trapping assay using
transiently expressed fluorescent DNA methyltransferase 1
(Dnmt1) fusions and mechanism-based inhibitors 5-azacytidine
(5-aza-C) or 5-aza-2¢-deoxycytidine (5-aza-dC). These nucleotide
analogs are incorporated into the newly synthesized DNA at
nuclear replication sites and cause irreversible immobilization,
that is, trapping of Dnmt1 fusions at these sites. We
measured trapping by either fluorescence bleaching assays or
photoactivation of photoactivatable green fluorescent protein
fused to Dnmt1 (paGFP-Dnmt1) in mouse and human cells;
mutations affecting the catalytic center of Dnmt1 prevented
trapping. This trapping assay monitors kinetic properties and
activity-dependent immobilization of DNA methyltransferases
in their native environment, and makes it possible to directly
compare mutations and inhibitors that affect regulation and
catalytic activity of DNA methyltransferases in single living cells.
DNA methylation has a central role in the epigenetic control of
mammalian gene expression during development and is required
for X inactivation, genomic imprinting and silencing of retroviral
elements1,2. Until now, four DNA methyltransferases, Dnmt1,
Dnmt2, Dnmt3a and Dnmt3b, are known in mammals, although
the functional significance of the weak activity of Dnmt2 is still
unclear3–7. Dnmt3a and Dnmt3b are de novo methyltransferases
implicated in setting up DNA methylation patterns during devel-
opment1. The major mammalian DNA methyltransferase, Dnmt1,
maintains the methylation patterns after DNA replication and
associates with the replication machinery during S phase8.
Dnmt1 has been shown to interact with several different proteins
including PCNA, HDACs, SUV39H1, HP1, MeCP2, DMAP1,
E2F1, pRb and p53 (refs. 9–14). Changes in DNA methylation
patterns, that is, general hypomethylation and local hypermethyla-
tion, are commonly found in cancerous cells15, and hypomethyla-
tion has been directly shown to cause genome instability and
tumors in mice16. The regulatory mechanism(s) responsible for
these methylation changes are still unknown. Notably, maintenance
of methylation patterns has been observed in the human HCT116
colorectal carcinoma cell line after inactivation of both DNMT1
alleles, indicating possible differences in the regulation of DNA
methylation in mouse and human or in transformed cells17.
The basic enzymatic mechanism of the methylation reaction has
been worked out in vitro by biochemical studies with purified
enzymes18,19. The regulation of DNA methylation in mammalian
cells, however, is still far from being understood, mostly owing to
the fact that multiple methyltransferases are involved that interact
with each other as well as with many nuclear factors. Moreover, the
substrate itself, the cytosine residue, is embedded in highly dynamic
and regulated chromatin structure. Here we describe a method
to assay the activity of Dnmt1 in defined chromatin domains of
single living cells. The method is based on the ability of Dnmt1 to
form a stable covalent complex with the mechanism-based inhibi-
tors 5-aza-C and 5-aza-dC upon their incorporation into DNA
during replication. Trapping of GFP-Dnmt1 fusions is measured by
fluorescence recovery after photobleaching (FRAP) analysis and
reflects the enzymatic activity of the fusion protein. This assay can
be used for studying the activity and targeting of Dnmt1 mutants,
and for testing candidate catalytic inhibitors in living cells.
RESULTS
Rationale of the DNA methyltransferase trapping assay
To directly test the enzymatic activity of DNA methyltransferases in
single living cells we developed an assay based on FRAP measure-
ments in the presence of 5-aza-C and 5-aza-dC. The assay takes
advantage of the transient covalent complex formation of the
methyltransferase with the C6 position of the cytosine base ring
to activate the C5 position for methyl group transfer20,21. After
methyl group transfer the enzyme is released from the complex by
b elimination with the proton at the C5 position (Fig. 1a). The
DNA methyltransferase inhibitors 5-aza-C and 5-aza-dC are widely
used in research and clinical applications as demethylating drugs22.
Both inhibitors are incorporated during DNA replication instead of
cytosine residues throughout the genome including at potential
methylation sites. The absence of the proton at the C5 position of
the 5-aza analog prevents b elimination, the final step of the
methylation reaction, leaving the methyltransferase trapped
RECEIVED 11 JULY; ACCEPTED 12 AUGUST; PUBLISHED ONLINE 22 SEPTEMBER 2005; DOI:10.1038/NMETH794
1Ludwig Maximilians University Munich, Department of Biology II, Grohaderner Str. 2, 82152 Planegg-Martinsried, Germany. 2Max Delbrueck Center for Molecular
Medicine, FVK, Wiltbergstr. 50, 13125 Berlin, Germany. Correspondence should be addressed to H.L. (h.leonhardt@lmu.de).
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(Fig. 1b). Consequently, the free enzyme pool is depleted with
progressing S phase, and existing methylation patterns cannot be
maintained leading to global genome demethylation.
Direct visualization of DNA methyltransferase trapping
To visualize the distribution and mobility of Dnmt1 in living cells,
we constructed a GFP-Dnmt1 fusion comprising the ubiquitously
expressed long isoform of the mouse Dnmt1 tagged at the amino
terminus with enhanced GFP23. GFP-Dnmt1 is catalytically active
as it is able to restore cytosine methylation levels when transiently
expressed in mouse embryonic stem (ES) cells deficient of Dnmt1
(Supplementary Fig. 1 online). Coexpression in mouse myoblast
cells of GFP-Dnmt1 and proliferating cell nuclear antigen (PCNA)
fused to red fluorescent protein (RFP-PCNA) that labels sites of
DNA replication24 showed that the GFP-Dnmt1 localizes at S phase
replication foci just like endogenous Dnmt1 (Fig. 2a and ref. 23).
After bleaching of single or multiple replication foci, we observed
nearly complete recovery of the GFP signal within about 90 s
indicating a rapid recruitment of new, fluorescent Dnmt1 fusion
proteins at these sites. In contrast, the recovery of RFP-PCNA
fluorescence was much slower, and the partial recovery after several
minutes is likely to be caused by a de novo assembly of the trimeric
PCNA ring at adjacent replication sites rather than by a constant
protein exchange25. After the incubation with 5-aza-C, however, we
observed no recovery of GFP-Dnmt1 fluorescence at bleached
replication foci (Fig. 2b) reflecting the depletion of the mobile
fraction caused by trapping of the active
fusion protein at the newly synthesized
DNA. This is consistent with the observa-
tion that after incubation with 5-aza-C
GFP-Dnmt1 no longer colocalized with
RFP-PCNA but seemed to be retained at
earlier, adjacent replication sites. These
results demonstrate a 5-aza-C–dependent
immobilization of GFP-Dnmt1 at sites of
DNA replication.
Enzyme trapping depends on catalytic
activity
Because 5-aza-C is a mechanism-based in-
hibitor, immobilization of the GFP-Dnmt1
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Figure 1 | Schematic representation of the DNA methylation reaction. (a) A covalent complex is formed between the sulfhydryl group of cysteine in the Pro-Cys
motif of DNA methyltransferase (Dnmt) and the C6 position of cytosine base ring. Then a methyl group is transferred from S-adenosyl-L-methionine (SAM)
followed by the release of the enzyme. (b) The absence of a proton at the N5 position of the 5-aza-C base ring prevents b elimination and thus causes trapping
of the enzyme. Green dots represent GFP fused to the enzyme.
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Figure 2 | Trapping of active Dnmt1 after 5-aza-C
treatment. (a) FRAP of GFP-Dnmt1 and RFP-PCNA
coexpressed in mouse myoblasts without drug
treatment. Late S phase nucleus with GFP-Dnmt1
(green) and RFP-PCNA (red) largely colocalize at
replication sites. Inset shows the replication focus.
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300 mM 5-aza-C for 2 h. (c) Comparative FRAP
of wild-type RFP-Dnmt1 and the GFP-Dnmt1 PW
mutant after treatment with 300 mM 5-aza-C for
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(d) Quantitative evaluation of FRAP data showing
mean curves. Error bars represent standard
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representation of the fusion proteins. PBD,
PCNA binding domain; NLS, nuclear localization
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fusion should be a direct measure of methyltransferase activity. To
directly test this, we introduced a site-specific mutation inactivating
the catalytic center of Dnmt1. We mutated the conserved Pro-Cys
motif, which is involved in the covalent complex formation21, by
exchanging the cysteine for a tryptophan (Dnmt1 C1229W, here
referred to as PW mutant). For direct comparison we generated an
RFP-tagged wild-type Dnmt1 and cotransfected cells with the wild-
type and mutant construct. Both fusion proteins localized at
replication foci in S-phase cells as observed for the native protein.
In sharp contrast to the wild-type Dnmt1 fusion, the PW mutant
did still recover after photobleaching even after 2 h of incubation
with 300 mM 5-aza-C (Fig. 2c). This indicates that the mutant
protein does not form a covalent complex with the DNA, which is
consistent with earlier biochemical studies on bacterial DNA
(cytosine-5) methyltransferases26. In control experiments without
5-aza-C treatment, we determined a mobile fraction ofB90% for
both, wild-type Dnmt1 and PW mutant (Fig. 2d). After
90–120 min incubation with 5-aza-C, however, the mobile
fraction of the active wild-type fusion dropped toB5%, whereas
the mobility of the PW mutant was not affected. Half-times of
recovery (t1/2) were 15 s and 34 s for wild type and PW mutant,
respectively, without 5-aza-C treatment, and 40 s for the PW
mutant after 5-aza-C treatment (300 mM, 120 min). The slower
recovery of the PW mutant as compared to the wild-type fusion in
untreated cells may be due to altered dissociation kinetics of the
mutant. The decelerated recovery of the PW mutant in the presence
of 5-aza-C is likely due to a general slowdown of the replication and
methylation machinery caused by trapping of the endogenous
Dnmt1 protein. The fusion proteins are schematically represented
in Figure 2e. Taken together, the catalytic activity of a Dnmt1
fusion construct can be directly assayed as covalent complex
formation rate by FRAP in the presence of 5-aza-C.
Trapping rate is inhibitor-, dose- and time-dependent
To evaluate the trapping assay we compared different incubation
times and concentrations of the two widely used demethylating
drugs 5-aza-C and 5-aza-dC (Fig. 3). In comparison, 5-aza-dC was
more potent than 5-aza-C in depleting the nucleoplasmic pool of
GFP-Dnmt1. About threefold lower concentrations and threefold
shorter incubation times were sufficient to reach the same levels of
depletion with 5-aza-dC as compared to 5-aza-C (Fig. 3a,b). With
longer incubation times the nucleoplasmic GFP-Dnmt1 pool
became progressively immobilized in cells treated with 300 mM
5-aza-C or 30 mM 5-aza-dC, until complete depletion was reached
after about 90 min or 40 min, respectively (Fig. 3c,d and
Supplementary Video 1 online). Direct comparison of the same
concentration of the two inhibitors showed that 5-aza-dC is about
fivefold more potent than 5-aza-C in depleting the nucleoplasmic
pool of GFP-Dnmt1 (Fig. 3e). This is consistent with the fact that
5-aza-dC is directly incorporated into DNA, whereas 5-aza-C has to
be modified before incorporation and can also be incorporated into
RNA27,28. These results demonstrate that the assay is sensitive to the
type of inhibitor, its dose and incubation time.
Experiments with human DNMT1 fused to GFP expressed in
human neuroblastoma cells also showed trapping of the fusion
protein upon treatment with 5-aza-dC, thus demonstrating the
general applicability of the trapping assay not only in mouse but
also in human cells (Supplementary Fig. 2 online).
Direct visualization of trapping with paGFP-Dnmt1
For further dynamic studies we fused Dnmt1 to photoactivatable
GFP (paGFP-Dnmt1) and coexpressed with RFP-PCNA to mark
replication sites. Photoactivatable GFP has a low initial absorbance
at 488 nm, which increases B100-fold by photoconversion after
excitation with B400-nm light29. Photoactivation of paGFP-
Dnmt1 at replication sites in an untreated control cell revealed
rapid dissociation of paGFP-Dnmt1 (Fig. 4a). Upon treatment
with 5-aza-dC we observed no dissociation of paGFP-Dnmt1,
directly showing the trapping of the enzyme (Fig. 4b). In contrast,
local activation of paGFP-Dnmt1 in a G1 nucleus was followed by a
quick redistribution throughout the entire nucleus as no incor-
poration of 5-aza-dC can take place at this cell cycle stage (Fig. 4c).
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These fundamental differences in Dnmt1 dissociation kinetics are
underscored by the quantitative evaluation (Fig. 4d). Without
treatment paGFP-Dnmt1 dissociates with a t1/2 of ~12 s to reach
a level of ~15% at the end of the observation period. After 5-aza-dC
treatment fluorescence levels drop to ~80% of the initial fluores-
cence and then remain constant during the rest of the observation
period. In G1 nuclei, paGFP-Dnmt1 shows a very rapid dissocia-
tion to 0% with a t1/2 of ~0.5 s. This application of paGFP is the first
direct demonstration of the action of mechanism-based inhibitors
and covalent complex formation with DNA methyltransferases in
living cells.
DISCUSSION
We owe most of our basic knowledge about DNA methylation to
classical biochemical approaches, which cannot reproduce the
complexity of living, mammalian cells. Recent biochemical studies
of DNA methyltransferase activity involved detection of either
lowered DNA methyltransferase levels in nuclear extracts30,31 or of
elevated levels of DNA methyltransferase–DNA adducts in genomic
DNA extracts after 5-aza-dC treatment in both cases by immuno-
blotting analysis32. The trapping assay described here makes it
possible for the first time to study Dnmt1 in its natural environment
with its natural substrate in the context of dynamic chromatin
structures and simultaneously ongoing DNA replication. Both
activity and subnuclear targeting of DNA methyltransferases can
be analyzed in situ at different cell cycle stages in single living cells.
The basic principle of the trapping assay and its application to
test catalytic mutants and potential inhibitors of the catalytic
domain is illustrated in Figure 5. The method takes advantage of
the covalent complex formation of DNA methyltransferases with
cytosine residues during catalysis. By using a catalytic mutant of
Dnmt1 we show that trapping depends on catalytic activity,
providing direct evidence that the technique can be used to
monitor DNA methyltransferases actively engaged in the methyla-
tion reaction. Comparing different concentrations and incubation
times of known DNA methyltransferase inhibitors, 5-aza-C and
5-aza-dC, we demonstrate the sensitivity of this assay.
The assay can be applied to all DNA (cytosine-5) methyltrans-
ferases that form a covalent complex with cytosine residues and
have a mobile nuclear distribution. Here we focus on Dnmt1 as it is
of major clinical relevance. Unlike de novo methyltransferases,
Dnmt1 is ubiquitously expressed in proliferating cells in which it
Figure 5 | Postreplicative action of Dnmt1 and
rationale of the trapping assay. (a) Regulatory and
catalytic domains of Dnmt1 are in lighter and
darker shades of green, respectively. For simplicity
only events at the leading strand are shown.
Methylated and nonmethylated cytosines
are depicted as black and white hexagons,
respectively. The trimeric PCNA ring (red) is shown
as part of the replication complex (grey circle).
Dnmt1 transiently interacts with PCNA at the
replication site, binds to CpG sites and forms a
transient covalent complex with the cytosine
residue (red line). After methyl group transfer the
enzyme is released and becomes available for
another round of methylation (dotted arrow).
(b) Mechanism-based inhibitors (orange
hexagons) are incorporated into DNA during
S phase. Dnmt1 forms a stable complex with these inhibitors and becomes trapped. (c) In contrast, trapping is eliminated if the catalytic domain of Dnmt1
is mutated (black dot). (d) Likewise, blocking the catalytic site of Dnmt1 with new types of small-molecule inhibitors (filled orange circles) would prevent
covalent complex formation.
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Figure 4 | Direct visualization of trapping by photoactivation of paGFP-
Dnmt1. (a–c) Mouse myoblast cells were cotransfected with RFP-PCNA to
identify cell cycle stage and replication sites of S-phase cells. Photoactivated
paGFP-Dnmt1 dissociates from the irradiated site (indicated by arrows) and
associates with neighboring replication sites (indicated by arrowheads)
until a new equilibrium is reached (94 s; a). Upon treatment with 30 mM
5-aza-dC for 1 h, no dissociation of paGFP-Dnmt1 is observed (arrow; b). The
arrowhead indicates a replication focus irradiated a few minutes earlier. Note
that fluorescence intensity of trapped paGFP-Dnmt1 at this site also does not
change during the time course. Local activation of paGFP-Dnmt1 (arrow) in
a G1 nucleus is followed by a quick redistribution throughout the entire
nucleus, as no incorporation of 5-aza-dC can take place in this cell cycle stage
(c). (d) Quantitative evaluation of the fluorescence activation experiments
shown in a–c.
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maintains normal as well as aberrant methylation patterns through
DNA replication. In cancer cells tumor-suppressor genes are fre-
quently silenced by methylation. Thus, pharmaceutical strategies
aim at transient inhibition of Dnmt1 to reactivate such epigeneti-
cally silenced genes and re-establish normal cell cycle and growth
control22. Mechanism-based inhibitors presently under clinical
trials, however, generate Dnmt1-DNA adducts that may lead to
cytotoxic effects33. Therefore, small-molecule inhibitors targeting
the catalytic domain of Dnmt1 are actively sought after, and
candidate molecules can now be directly tested by their ability to
prevent 5-aza-dC–mediated trapping of GFP-Dnmt1 (Fig. 5d). It
should be noted that some compounds may affect cell cycle
progression or DNA replication, which would reduce the incor-
poration of 5-aza-dC and thus indirectly prevent trapping of DNA
methyltransferases. Such unspecific cell cycle progression effects
can, however, be identified using the changing subnuclear GFP-
Dnmt1 and RFP-PCNA patterns to monitor cell cycle progres-
sion23,34. In any case, newly identified compounds need to be
further characterized in vitro with additional biochemical DNA
methyltransferase activity assays.
In summary, the mechanism-based trapping assay provides a new
approach to directly study the regulation of DNA methylation and
to test the effect of mutations and interacting factors in living cells.
In addition, this method now makes it possible to directly inves-
tigate the cellular effects of demethylating drugs like 5-aza-dC that
are widely used in basic research and in cancer therapy and offers an
approach to test new types of DNA methyltransferase inhibitors.
METHODS
Cell culture and transfections. We cultured mouse C2C12 myo-
blast cells in DMEM containing 25 mM HEPES and supplemented
with 20% fetal calf serum and 50 mg/ml gentamycin. We grew cells
to 30–40% confluence on Lab-Tek chamber slides (Nunc) and then
cotransfected them with the indicated expression constructs by
standard Ca2PO4 DNA coprecipitation followed by a glycerol
shock35, or using TransFectin transfection reagent (Bio-Rad) accord-
ing to the manufacturer’s instructions. We then incubated cells
overnight before performing drug treatment and live-cell analysis.
For culture, transfection and 5-methylcytosine staining of mouse
ES and human cell lines, see Supplementary Methods online.
Expression constructs. We visualized replication sites using a red
fluorescent fusion with full-length human PCNA (RFP-PCNA)36.
To generate GFP-Dnmt1 (previously referred to as GMT1L) we
cloned the full-length mouse cDNA of the long Dnmt1 isoform in
the pEGFP-C1 vector (Clontech)23. To generate RFP-Dnmt1 and
paGFP-Dnmt1 we replaced the sequence encoding GFP with those
encoding mRFP137 and paGFP29, respectively. We introduced the
C1229W mutation (PW mutant) into the Dnmt1 cDNA by site-
directed mutagenesis (QuikChange Kit, Stratagene) and confirmed
it by DNA sequencing. We tested all fusion constructs by expres-
sion in COS-7 or 293T cells and subsequent western blot analysis34.
Live-cell microscopy, FRAP analysis and photoactivation. We
added 5-Aza-C or 5-aza-dC (Sigma) at indicated final concentra-
tions and incubated cells as indicated before starting live-cell
observations. We performed FRAP experiments using a Zeiss
LSM 510 confocal laser scanning microscope with a 63, 1.4 NA
Plan-Apochromat oil immersion objective. We excited
fluorophores with a 488-nm Ar laser and a 543-nm HeNe laser.
We typically recorded confocal image series with a frame size of 256
 256 pixels and a pixel size of 70–90 nm. The laser power
was typically set to 1–5% transmission with the pinhole opened
to 2 Airy units. For FRAP analysis, we selected a region of interest
and photobleached it by an intense 488-nm Ar laser beam (laser set
to maximum power at 100% transmission) for 1 s. Before and after
bleaching, we recorded confocal image series at 2–5 s intervals
(typically 6 prebleach and 50–100 postbleach frames). Mean
fluorescence intensities of the bleached region were corrected for
background and for total nuclear loss of fluorescence over the time
course, and normalized to the mean of the last 4 prebleach values.
For the quantitative evaluation of FRAP experiments, we averaged
data of 4–6 nuclei, calculated the mean curve as well as the standard
deviation and displayed these using GraphPad Prism 4.01 software.
We calculated the t1/2 of recovery from the average curves.
We performed photoactivation experiments using a DeltaVision
widefield epifluorescence microscope system (Applied Precision)
equipped with a 60, 1.4 NA Plan-Apochromat objective and
appropriate filter sets. Photoactivatable GFP was activated using a
405 nm diode laser coupled into the light path of the microscope.
After laser photoactivation for 1 s (100% transmission), we
acquired epifluorescence time series at 0.6-s intervals. For quanti-
tative evaluation, we corrected the mean fluorescence intensities
of the activated area for background and for the increase of
fluorescence in a nonirradiated nuclear control region, and then
normalized it to the value of the first time point after activation.
Note: Supplementary information is available on the Nature Methods website.
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Supplementary Figure 1. GFP-Dnmt1 fusion protein restores methylation at chromocenters in  
dnmt1–/– ES cells. Mouse minor and major satellite sequences are heavily methylated in wild type cells 
and severely hypomethylated in dnmt1–/– ES cells1. These sequences can be visualised in situ as 
DAPI-bright chromocenters that are heavily stained with an antibody to 5-methylcytosine (5mC) in wild 
type cells (a), but not in dnmt1–/– ES cells (b, c). The latter cells were transiently transfected with 
constructs driving the expression of GFP-Dnmt1 wild type (b) and PW mutant (c). 60 hours after 
transfection cells were stained with the 5mC antibody (red) and DAPI (blue) and imaged by confocal 
microscopy. Cells expressing GFP-Dnmt1 showed a clear increase in 5mC staining at chromocenters 
compared to non transfected cells, indicating that the fusion protein is functional in vivo. As a control, 
cells expressing the catalytically inactive PW mutant did not show any increase of 5mC staining. 
Shown are projections of optical sections. Bars: 5 µm. 
 
1. Lei, H. et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122, 
3195-3205 (1996). 
 
 
 
Supplementary Figure 2. Trapping of DNMT1 after 5-aza-dC treatment in human SH-EP N14 
neuroblastoma cells. S phase cell nuclei with a replication pattern typical for early to mid S phase are 
shown. (a) FRAP of transiently expressed human DNMT1 fused to GFP without drug treatment. After 
photobleaching full recovery of GFP-DNMT1 can be observed within less then 50 sec. (b) No recovery 
can be observed over the time course after bleaching of GFP-DNMT1 in cells incubated 2.5 hours with 
30 µM 5-aza-dC. Bars: 5 µm.  
 
 Supplementary Methods 
 
The fusion of the human DNMT1 to GFP was generated by cloning the full length human cDNA of the 
long isoform1 (kindly provided by P. Vertino) in the pEGFP-C1 vector (Clontech). SH-EP N14 
neuroblastoma cells were cultured in RPMI 1640 medium supplemented with 10% FCS and 50 µg/ml 
gentamycine and transfected with JetPEI (Polyplus-Transfection). Dnmt1s/s J1 ES cells2 were cultured 
on gelatin coated plastic dishes with 1000 U/ml of LIF and were transfected with FuGene6 (Roche) 
according to the manufacturer’s instructions. 48 hours after transfection cells were seeded on gelatin 
coated coverslips and 12 hours later they were fixed with 3.7% formaldehyde for 10 min at RT. Cells 
were then permeabilized with 0.5% Triton X-100 for 5 min at RT and 5mC was exposed by digestion 
with 10 mU/ml of DNase I for 1hr at 37°C in PBS containing 0.1% Tween 20, 3% BSA and 5 mM 
MgCl2. After extensive washing with PBS containing 0.1% Tween 20 and 1 mM EDTA 5mC was 
detected with a specific mouse monoclonal antibody (Eurogentec) and an anti-mouse secondary 
antibody conjugated with rhodamine Red-X (Jackson Immunoresearch Laboratories). Samples were 
stained with DAPI and mounted in Vectashield (Vector Labs). 
 
1. Yoder, J. A., Yen, R. W., Vertino, P. M., Bestor, T. H. & Baylin, S. B. New 5' regions of the murine and human genes for 
DNA (cytosine-5)-methyltransferase. J Biol Chem 271, 31092-31097 (1996). 
2. Lei, H. et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122, 
3195-3205 (1996). 
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Regulation of DNA methyltransferase 1
Fabio Spada, Ulrich Rothbauer, Kourosh Zolghadr,
Lothar Schermelleh, Heinrich Leonhardt
Biocenter, Department of Biology II, Ludwig Maximilians University Munich, Germany
Introduction
Although essentially all cells of a mammalian organism contain the same genetic
information they may differ dramatically in form and function. This cellular differentia-
tion is established during development by cascades of transcription factors driving the
expression of cell-type speciﬁc sets of genes. These cell type speciﬁc gene expression
patterns are established, maintained and changed in conjunction with epigenetic
mechanisms including DNA methylation, histone modiﬁcation and chromatin structure.
The most tangible epigenetic mark is DNA methylation, a postreplicative modiﬁcation,
which in vertebrates is mainly catalyzed by DNA methyltransferases (Dnmts: EC 2.1.1.37)
1, 3a and 3b at palindromic CpG sites. The DNA methylation pattern changes along with
cellular differentiation and is generally inversely correlated with transcriptional activity.
Over the past decade, several functional links between DNA methylation, histone
modiﬁcation, chromatin structure and transcriptional regulation have been discovered.
In mammalian cells Dnmt1 is the major and ubiquitously expressed Dnmt. By direct and
indirect interactions Dnmt1 plays a central role in the epigenetic networks controlling gene
expression in development and disease. We will outline results and open questions
concerning the regulation of Dnmt1 and discuss novel approaches to study Dnmts in living
cells.
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Regulation of Dnmt1 and its effects on DNA methylation patterns
The importance of Dnmt1 in maintaining genomic methylation is underscored by
studies on cell lines and mice carrying dnmt1 homozygous null mutations. Dnmt1 null ES
cells have reduced but stable levels of DNA methylation and are impaired in their
differentiation potential, while the corresponding null mice die prior to the 8-somite stage
(Lei et al., 1996). In addition, somatic cells with conditional homozygous dnmt1 null
mutations display genomic hypomethylation and die by apoptosis within 5–6 days
(Jackson-Grusby et al., 2001). These data indicate that de novo methylation activity
mainly provided by the Dnmt3a and b enzymes is sufﬁcient for survival of undifferentiated
ES cells, while proper differentiation and survival of differentiated cells requires
maintenance of DNA methylation patterns by Dnmt1. This is consistent with the concept
that differential DNA methylation patterns in differentiated cells contribute to their
speciﬁc gene expression programs. Although de novo methyltransferases are necessary for
the establishment of genomic methylation patterns, setup and maintenance of speciﬁc
expression programs depend on maintenance of DNA methylation patterns.
Given the central role of DNA methylation in the epigenetic control of gene expression
it is to be expected that the activity and cellular levels of Dnmt1 are strictly regulated. The
postreplicative maintenance of methylation patterns in a large part of the genome is
mediated and secured by recruitment of Dnmt1 to replication foci (Chuang et al., 1997;
Leonhardt et al., 1992). This major role of Dnmt1 is mostly restricted to the S phase of the
cell cycle suggesting that Dnmt1 levels could cycle in a way similar to that observed for
replication factors like PCNA. Indeed, evidence for cell cycle-dependent control of Dnmt1
levels comes from the observations that Dnmt1 transcript levels correlate positively with
normal cell proliferation and that the dnmt1 promoter is under control of the Rb/E2F
pathway (Bestor and Ingram, 1985; Kimura et al., 2003; McCabe et al., 2005; Robertson et
al., 2000a, b). Consistent with these data, both Dnmt1 transcript and protein levels were
shown to be minimal in quiescent cells (G0) and peak during S phase in human cells
(Robertson et al., 2000a, b; Tatematsu et al., 2000). However, in mouse cells Dnmt1 was
also detected at (peri-)centromeric heterochromatin from late S-phase till M and early G1
phase (Easwaran et al., 2004). Consistent with this, Dnmt1 transcript levels were shown to
increase steadily through S to G2 in synchronized mouse cells (Kimura H. et al., 2003).
Interestingly, Dnmt1 protein levels comparable to those present in proliferating cells were
found in postmitotic neurons indicating the presence of cell-type speciﬁc regulatory
mechanisms (Inano et al., 2000). The general theme, however, seems to be a proliferation-
dependent expression of Dnmt1 and two independent mechanisms for subnuclear
recruitment to replication sites and (peri-)centromeric heterochromatin to secure efﬁcient
maintenance of DNA methylation patterns (Fig. 1).
In contrast, a special situation with respect to Dnmt1 levels, subcellular localization and
genomic methylation levels is found in mammalian oocytes and preimplantation embryos.
In the mouse zygote there is a drastic decrease of DNA methylation in the paternal genome
within a few hours after fertilization (active demethylation) and both the maternal and
paternal genomes undergo progressive demethylation during segmentation stages (Mayer
et al., 2000; Oswald et al., 2000; Rougier et al., 1998; Santos et al., 2002). At these stages
only the 118 amino acids shorter, maternal Dnmt1 isoform can be detected, which is
present in large amounts but is sequestered in the cytoplasm. As the short Dnmt1 enters
embryonic nuclei only transiently at the 8-cell stage it is believed that its retention in the
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cytoplasm of preimplantation embryos prevents maintenance of gamete-speciﬁc methyla-
tion patterns (passive demethylation) and thus contributes to epigenetic reprogramming of
the embryo (Cardoso and Leonhardt, 1999; Carlson et al., 1992; Grohmann et al., 2005;
Mertineit et al., 1998). Also, it has been proposed that the presence of the long Dnmt1
isoform in donor somatic nuclei used in animal cloning would result in defective epigenetic
reprogramming, thus explaining the low survival rates of cloned embryos (Chung et al.,
2003). However, it is far from clear how methylation patterns at imprinted loci,
transposable elements and satellite sequences are maintained throughout mouse
preimplantation development and how Dnmt1 levels and subcellular localization are
regulated in mammalian species with little passive demethylation during early embryonic
development (Young and Beaujean, 2004).
Alterations of DNA methylation patterns are a general feature of cancer cells (Jones and
Baylin, 2002). Typically, both tumors and cancer cell lines display a global reduction of
genomic methylation and at the same time local hypermethylation of selected CpG islands.
Local hypermethylation often involves regulatory regions of tumor-suppressor genes and
effects their silencing. This epigenetic alteration may thus contribute to tumorigenesis by
disturbing the balance of growth control. Dnmt1 is an obvious candidate for a role in this
epigenetic deregulation. Indeed, overexpression of Dnmt1 resulted in increased CpG island
methylation in human cells (Vertino et al., 1996) and increased global methylation and
oncogenic transformation of NIH3T3 cells (Wu et al., 1993). Also, elevated levels of
Dnmt1 have frequently been found in tumors and cancer cell lines compared to the
respective normal tissues (Choi et al., 2003; Fang et al., 2003; Kanai et al., 2001; Li et al.,
2003; Mizuno et al., 2001; Nagai et al., 2003; Patra et al., 2002; Saito et al., 2001) and
correlated with progression of pancreatic carcinoma (Peng et al., 2005). However, this
correlation does not seem to be consistent for a given type of tumor cell and alterations of
Dnmt1 abundance often do not correlate with variations in DNA methylation levels in the
same cancerous tissue (Eads et al., 1999; Kimura F. et al., 2003; Li et al., 2003; Saito et al.,
2001). In addition, homozygous deletion of the DNMT1 locus in the human colorectal
cancer cell line HCT116 led to a surprisingly minor reduction in DNA methylation levels,
apparently involving only classical satellite 2 and 3 sequences. Interestingly, a drastic
reduction of genomic methylation was observed only after additional ablation of DNMT3b
(Rhee et al., 2000; Rhee et al., 2002). Although these data suggest an unexpected level of
cooperativity between the two methyltransferases, it should be noted that the starting cell
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Fig. 1. PBD and TS-mediated association of Dnmt1 with chromatin during the cell cycle. PBD directs association
of Dnmt1 with replication foci throughout the S phase and TS mediates association with (peri-)centromeric
heterochromatin from mid/late S till M phase.
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type used in these studies was already a transformed one and that functional knock out of
DNMT1 in other types of cancer cell lines led to more substantial alteration of methylation
patterns. This suggests that the effects of DNMT1 ablation depend on the speciﬁc genetic
and epigenetic background (Leu et al., 2003; Suzuki et al., 2004).
Besides local hypermethylation most tumors show a general hypomethylation. To test
also whether lowered levels of Dnmt1 may contribute to oncogenic transformation, mice
carrying a hypomorphic dnmt1 allele were generated, reducing Dnmt1 expression to about
10% of wild-type levels. These mice have substantially reduced genomic methylation levels,
develop aggressive T-cell lymphomas and show chromosomal instability (Eden et al., 2003;
Gaudet et al., 2003). These effects are likely due to the mobilization of endogenous
retroviral elements normally silenced by DNA methylation (Gaudet et al., 2004) and to
instability of hypomethylated satellite sequences (Chen et al., 1998; Eden et al., 2003;
Gaudet et al., 2003; Kim et al., 2004). Thus, model studies on altered Dnmt1 expression
levels demonstrate that both alterations of DNA methylation patterns commonly found in
spontaneous tumors, i.e. global hypomethylation and local hypermethylation, can
contribute to oncogenic transformation. However, it is not yet clear how either increased
or lowered Dnmt1 levels found in tumors may simultaneously cause the establishment of
global hypomethylation and local hypermethylation.
Nevertheless, methyltransferase inhibitors like 5-aza-2’-deoxycytidine are actively
pursued as anti-cancer treatment. The hope of such treatments is that transient inhibition
of methyltransferase activity would lead to demethylation and consequent reactivation of
silenced tumor-suppressor genes, although this has actually been documented in very few
cases (Brueckner and Lyko, 2004; Brueckner et al., 2005). These demethylating drugs are
highly cytotoxic and, although they have been used in numerous clinical trials, promising
results were obtained with low and repeated doses only in leukemia patients. Studies
employing Dnmt1 deﬁcient ES cells and mice support the idea that their cytotoxic effects
are mainly due to covalent complex formation of Dnmt1 with the DNA substrate rather
than to the consequent global demethylation (Juttermann et al., 1994). This and the
frequent occurrence of tumors and chromosomal rearrangements in hypomethylated
animal models mentioned above have raised concern about the long-term exposure to such
agents. For these reasons alternative small molecule inhibitors of Dnmts that lack the
undesired cytotoxic effects of cytosine analogs are intensively sought after (Brueckner et
al., 2005).
Interactions controlling Dnmt1 activity
These ﬁndings that changes in DNA methylation patterns may have severe consequences
for human health have raised strong interest in the regulation of the activity of Dnmt1. In
vitro assays with puriﬁed Dnmt1 showed a preference for hemi-methylated CpG sites,
which on one hand led to its classiﬁcation as the maintenance methyltransferase (Bestor et
al., 1988; Leonhardt and Bestor, 1993), but on the other hand can hardly explain the
faithful inheritance of epigenetic information over countless cell division cycles throughout
the lifespan of an organism.
Dnmt1 is composed of a large N-terminal, regulatory domain and a C-terminal,
catalytic domain that is closely related to the bacterial C5-methyltransferases (Bestor et al.,
1988; Bestor, 1992; Leonhardt and Bestor, 1993). The regulatory domain is essential for
the complex regulation of Dnmt1 in the context of a dividing cell. Despite its striking
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homology to prokaryotic methyltransferases, the catalytic portion of Dnmt1 alone is not
sufﬁcient for the enzymatic activity. Methyltransferase activity could only be observed in
the presence of a substantial part of the N-terminal domain (Fatemi et al., 2001; Margot et
al., 2000; Zimmermann et al., 1997). Consistent with these data a physical interaction
between the N- and the C-terminus could be detected (Fatemi et al., 2001; Margot et al.,
2003). It is assumed that intramolecular interactions induce a conformational change of
the catalytic domain leading to an allosteric activation of the enzyme. In this context it was
suggested, that upon binding to hemimethylated DNA the zinc binding domain (aa
613–748) interacts with the catalytic domain and stimulates DNA methylation (Fatemi et
al., 2001). However, the precise mechanism through which the regulatory domain can
activate the enzymatic process remains unknown.
The preference of Dnmt1 for hemi-methylated CpG sites, which are produced by semi-
conservative DNA replication, is matched by its subnuclear localization at replication foci
throughout S phase (Leonhardt et al., 1992). In addition, live cell microscopy using
ﬂuorescent fusion constructs recently revealed an association with (peri-)centromeric
heterochromatin (Easwaran et al., 2004). This complex and cell cycle dependent
localization of Dnmt1 is mediated by two independent domains within the N-terminus
of Dnmt1 (Fig. 1). The association with replication sites during S phase is mediated by the
PCNA binding domain (PBD, aa 158–171) while prolonged binding to heterochromatin
from late S phase through mitosis is mediated by the targeting sequence (TS, aa 256–629;
Chuang et al., 1997; Leonhardt et al., 1992; Easwaran et al., 2004). Therefore, substrate
speciﬁcity and subcellular localization are both likely to contribute to the faithful,
postreplicative maintenance of genomic methylation patterns in mammalian cells. This cell
cycle dependent localization of ﬂuorescent Dnmt1 fusion proteins has also been used to
distinguish cell cycle phases in living cells (Easwaran et al., 2005).
The binding of Dnmt1 to late replicating heterochromatin beyond S phase may either
represent an additional mechanism to ensure complete maintenance of the dense
methylation in these genomic regions and/or point to a novel role of Dnmt1 in the
maintenance of transcriptionally repressed chromatin (Easwaran et al., 2004). In this
context it is interesting to note that the N-terminal portion of Dnmt1 has been shown to
interact with a range of chromatin-associated proteins including pRb, DMAP1, HDAC 1/
2, MeCP2, SUV39H1 and HP1b and the nucleolar chromatin remodelling complex Tip5/
Snf2h (Fuks et al., 2000; Fuks et al., 2003; Geiman et al., 2004a, b; Kimura and Shiota,
2003; Robertson et al., 2004; Robertson et al., 2000a, b; Santoro et al., 2002). A summary
of interacting factors and their reported binding sites is outlined in Fig. 2. These
interactions indicate several independent mechanisms by which Dnmt1 could cause
transcriptional repression. First, Dnmt1 interacts with the retinoblastoma (Rb) tumor-
suppressor gene product, a cell cycle regulator protein that represses transcription by
recruiting the histone deacetylase HDAC1 (Pradhan and Kim, 2002; Robertson et al.,
2000a, b). The Dnmt1-Rb complex also associates with the transcription factor E2F1
(Robertson et al., 2000a, b), resulting in transcriptional repression of E2F1-responsive
promoters. Second, Dnmt1 is reported to establish transcriptional repression by a direct
interaction with DMAP1 (DNMT1-associated protein) and the histone deactetylase
HDAC2 (Rountree et al., 2000). DMAP1 has an intrinsic silencing activity and binds to
the transcriptional co-repressor TSG101 and the transcriptional co-regulator Daxx
(Muromoto et al., 2004). In contrast to DMAP1, which associates with Dnmt1 throughout
S phase, the interaction of HDAC2 with Dnmt1 occurs speciﬁcally at replication foci in
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the regulation of the survivin gene by stabilizing the HDAC1–DNMT1–p53 complex on
the survivin promotor leading to a hypermethylation of its CpG sites (Esteve et al., 2005).
In summary, the sheer number of all reported Dnmt1 interactions makes it clear that not
all of them may occur at all times. It is now necessary to establish which of them occur
when and what their functional consequences are. A common theme of these interactions is
transcriptional repression and involves different types of proteins ranging from
transcription factors to histone methyltransferases. These observations place Dnmt1 at
the center of a complex network connecting two epigenetic pathways, DNA methylation
and histone modiﬁcation which result in the establishment and maintenance of
transcriptionally inactive chromatin.
Analysis of Dnmt1 activity and regulation in living cells
The fact that Dnmt1 interacts with numerous cellular protein, shows a cell cycle and
development speciﬁc subcellular localization and—last but not least—works on a substrate
as complex and dynamic as DNA packaged into chromatin clearly indicates that any real
understanding of its regulation will require in vivo studies. The basic enzymatic mechanism
of the methylation reaction is shared by all eukaryotic and prokaryotic C5-cytosine
methyltransferases and has been worked out in vitro with puriﬁed enzymes (Bestor and
Verdine, 1994; Cheng and Roberts, 2001). These assays, however, miss most, if not all,
interacting factors and are carried out with ‘naked’ and often artiﬁcial DNA substrates.
As outlined above, the control of DNA methylation in the context of highly regulated
and dynamic chromatin in mammals is extraordinarily complex and far from being
understood. The establishment and maintenance of genomic methylation in mammals is
accomplished by multiple methyltransferases, which interact with each other as well as
with numerous nuclear factors via their regulatory domains. Even though many
interaction partners and subdomains within the regulatory domains of methyltransferases
have been described, it is still largely unknown how they control and modulate the
enzymatic activity during cell cycle and development.
As in vitro assays do not reproduce the complexity of living cells it would be ideal to
directly study the regulation of DNA methyltransferases in their natural environment.
Unfortunately, the methylation reaction is not suited for chromogenic substrates that
could provide an optical readout of enzyme activities.
To overcome this limitation a novel in vivo assay was recently developed that utilizes
ﬂuorescent GFP-Dnmt1 fusions (or mutants thereof) in combination with a mechanism-
based inhibitor (Schermelleh et al., 2005). The assay takes advantage of the rather complex
catalytic mechanism of C5-methyltransferases which form a transient, covalent complex
with the base ring to facilitate methyl group transfer.
The mechanism-based inhibitor, the cytosine analogue 5-aza-2’-deoxycytidine (5-aza-
dC), gets incorporated into DNA during replication just like deoxycytidine itself and
Dnmts form a covalent complex but cannot be released due to the nitrogen substitution in
the base ring. In other words the enzyme gets trapped as a result of its enzymatic activity
(Fig. 3). The time dependent immobilization of Dnmt1 (trapping) can be measured by
ﬂuorescence recovery after photobleaching (FRAP) analysis and reﬂects the enzymatic
activity of the fusion protein. This assay makes it now possible to study the regulation of
Dnmts in situ at different cell cycle stages and to directly study the effect of mutations and
interacting factors in its natural environment with its natural substrate in the context of
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dynamic chromatin remodelling and ongoing DNA replication. In addition, this method
offers a novel approach to test new types of small molecule inhibitors targeting the
catalytic domain of Dnmt1 by their ability to prevent 5-aza-dC-mediated trapping of GFP-
Dnmt1. Such inhibitors are actively sought after as transient blocking of the catalytic
activity of Dnmt1 is expected to reactivate epigenetically silenced tumor-suppressor genes
(Brueckner et al., 2005).
Summary
DNA methylation plays a central role in the control of gene expression, chromatin
condensation and genome stability. In mammalian cells DNA methylation patterns are
established and maintained by DNA methyltransferases 1, 3a and 3b. The regulation of
DNA methylation by these enzymes requires interactions with other cellular factors
involved in histone modiﬁcation, chromatin structure and transcription and interference
with either of these DNA methyltransferases severely impairs viability and development.
Although hypo- and hypermethylation have both been linked with cancer, very little is
known about the regulation of DNA methylation during development and disease.
The best system to study this complex regulation should be living cells and organisms
where both the native substrate and all potential interaction partners are available.
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Fig. 3. Postreplicative action of Dnmt1 and rational of the trapping assay. Methylated and non-methylated
cytosines are depicted as black and white hexagons, respectively. Dnmt1 is depicted in gray shade. (a) Dnmt1
binds to hemimethylated CpG sites produced during DNA replication and forms a transient covalent complex
with the cytosine residue (gray line). After methyl group transfer the enzyme is released and becomes available for
another round of methylation (dotted arrow), which is visualized as ﬂuorescence recovery after photobleaching of
GFP-Dnmt1 in the outlined region (bottom row). (b) Mechanism-based inhibitors such as 5-aza-dC (hexagons
with N at position 5) are incorporated into DNA during S phase. Dnmt1 forms a stable covalent complex with 5-
aza-dC (black line) and becomes trapped. Immobilization of GFP-Dnmt1 is detected as lack of recovery after
photobleaching (bottom row).
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CHAPTER III. Discussion 
In the course of this work presented here we designed and improved new cell biological assays 
to analyze protein interactions, function and mobility in their natural environment. We 
developed versatile tools and techniques to visualize and manipulate endogenous proteins in 
living cells and to isolate proteins together with their interacting partners for biochemical 
approaches. The results were presented in three articles that are accepted for publication in 
peer-review scientific journals until now. A fourth manuscript presenting a new fluorescent 
protein-protein interaction assay was also submitted to a peer-review journal and is prepared to 
be accepted with minor revisions. An additional publication is a review article subsuming the 
current state of the regulation of DNA methyltransferase 1 (Dnmt1) at that time. In principle, we 
designed the new assays and tools to study proteins promoting DNA methylation particularly 
Dnmt1. The ultimate goal is to combine and integrate in vivo and in vitro data to gain a deep 
insight into the regulation of DNA methylation in living cells. 
 
III.1. A new assay to visualize protein-protein interactions in 
vivo 
The substantial importance of protein interactions and complex protein networks for almost all 
cellular processes has driven the development of numerous technologies to monitor such 
interactions. These technologies range from biochemical approaches to measure protein 
binding to genetic tools such as the yeast two-hybrid assay or fluorescent-based approaches to 
analyze protein associations within a living cell. Despite the broad assortment of assays, work 
in this field is constrained by the fact that virtually all methods require some perturbation or 
manipulation of the physiological situation to allow assessment of interaction. As fluorescent 
proteins are being constantly improved microscopic techniques encounter increasing 
popularity and more and more methods are developed. Still, they are often not generally 
applicable since mostly expensive instrumentation or advanced technical expertise is required. 
As an alternative to present methods we designed a simple fluorescent two-hybrid (F2H) assay 
based on the immobilization of a fluorescently labeled bait protein at a distinct subcellular 
structure. This enables the detection of protein-protein interactions as co-localization of signal 
of a differently labeled prey protein at this defined structure in real-time (Fig. 10a). In case the 
analyzed proteins do not interact, the prey protein fluorescence remains dispersed throughout 
the nucleus without being enrichment at that structure (Fig. 10b). In the work presented here 
we took advantage of cell lines with 200-1000 copies of a lac operator array stably integrated at 
one chromosomal site to which the bait protein binds (Janicki et al., 2004; Tsukamoto et al., 
2000). 
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Fig. 10Schematic outline of the fluorescent two-hybrid (F2H) assay. (a) The bait-protein binds to the 
chromosomally integrated lac operator array, which is visible as a red fluorescent spot in the nucleus. In 
case of interaction of the differentially labeled prey protein (green) with the bait it becomes enriched at 
the same spot resulting in co-localization of fluorescent signals at the lac operator (visible as yellow spot 
in the overlay image). (b) If the prey does not interact with the bait protein, it remains dispersed in the 
nucleus (green) and the lac operator array is only visualized by the bait protein (red spot). 
We have demonstrated the reliability of the assay by testing and visualizing protein-protein 
interactions from different cellular compartments such as the nucleus, the cytoplasm or the 
mitochondria. The F2H assay allows detection of interactions in real-time and is independent of 
dynamic processes the studied proteins are involved in such as DNA replication, DNA repair or 
mitochondrial import. Furthermore, we were able to analyze specific disruptions of protein-
protein interactions by deletions of dedicated domains or single point mutations. With the F2H 
assay we investigated more than 20 protein-protein interactions from different subcellular 
compartments. Notably, we obtained in all cases corresponding results as previously described 
with other genetic or biochemical methods. The interactions could be detected independently 
of the combination of the used fluorescent proteins (GFP/RFP; YFP/RFP; GFP/mCherry). 
Furthermore, the F2H assay could successfully be applied irrespectively of the order of the 
individual protein parts in the bait vector (bait-LacI-FP or FP-LacI-bait). Consequently, we could 
demonstrate that the interaction between Dnmt1 and PCNA is exclusively mediated through 
the PCNA binding domain (of Dnmt1) and occurs also outside S phase (and is therefore 
replication independent). However, in rare cases the prey protein may bind to the anchoring 
structure by itself. Such prey proteins can quickly be identified with an initial screen without 
the presence of the bait protein. Analyzing those proteins as baits only easily circumvents this 
limitation. 
Our results demonstrate the simplicity, reliability and versatility of the F2H assay and make it 
therefore generally interesting to study protein-protein interactions. The only prerequisite of the 
assay is a simple fluorescent microscope equipped with a filter set good enough to distinguish 
two fluorescent proteins e.g. GFP and RFP and basic experience in cell culture and 
transfections. The simple co-localization read out of the F2H assay could be automated in the 
future and applied in cell-based high-throughput protein-protein interaction screens. 
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III.2. A new antibody-format to follow endogenous antigens in 
living cells 
There are two very common methods to analyze proteins inside cells: either to label them with 
a fluorescent protein or to stain them with specific antibodies. Fluorescent protein-fusions can 
only be N- or C-terminal. This might cause the masking of an important domain or a general 
dysfunction of the studied protein. In addition, the artificial introduction of the expression 
plasmid into cells can lead to un-physiological overexpression of the encoded protein. A major 
drawback of fluorescent fusion proteins is the lack of any information about their 
conformational state or important post-translational modifications. 
In comparison, antibodies are ideal tools to detect proteins and their post-translational 
modifications but only in fixed and permeabilized cells. Our goal was to combine the 
versatility of antibodies with the live cell applications of fluorescent proteins. We therefore took 
advantage of heavy-chain antibodies derived from Camelidae, more precisely alpacas (Lama 
pacos). We isolated the repertoire of antigen-binding fragments (VHH), selected specific VHHs 
by phage display and combined them with a fluorescent protein. According to their chimeric 
nature we termed these fluorescent antigen-binding molecules “chromobodies”. 
With chromobodies we could target and trace endogenous antigens in living cells with minimal 
perturbation. Our results demonstrate that chromobodies efficiently recognize and bind their 
epitope in different structures such as the cytoskeleton, the replication machinery, the 
chromatin or the nuclear envelope as well as in different subcellular compartments like the 
cytoplasm or nucleus. We generated chromobodies with different binding affinities and could 
demonstrate that even transient binding was sufficient for visualization of cellular structures. 
Since low affinity binding of chromobodies to the protein of interest is likely to be less harmful 
than a permanent fusion of the studied protein with a fluorescent protein we aim to modulate 
chromobody affinities through directed in vitro mutagenesis and maturation. As the entire 
antigen surface is available for chromobody selection not only chromobodies with different 
binding/recognition sites can be identified but also chromobodies against post-translational 
modifications can be selected (Fig. 11a). In principle, different conformational states of proteins 
could be distinguished. Moreover, induced gene expression as a cellular response to external 
stimuli could be monitored as spontaneous accumulation of chromobodies at distinct sites or 
overall altered fluorescent intensity distribution. Antigens have not necessarily to be only 
proteins but also could be non-protein components of cells like methylated DNA respectively 
5-methylcytosine. Chromobodies can also be generated by coupling purified VHHs to a 
chemical dye (e.g. Cy5) or directly fusing a VHH to a chromogenic enzyme e.g. horseradish 
peroxidase (HRP) (Fig. 11b). 
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Fig. 11(a) Visualization (tracing) and inhibition (targeting) of proteins with chromobodies. (b) Illustration 
of the conjugated types of chromobodies 
Chromobodies open up new opportunities to specifically and reversibly knocking out protein 
function without depleting the protein from the cellular context. Simultaneously, the 
chromobody would visualize the targeted protein. Other methods such as the use of siRNA 
(small interfering RNA) does not lead to a complete gene knock-out but only to a knock-down 
with largely reduced protein amount and residual activity (Fig. 12). In addition, siRNA down-
regulates gene expression often with unknown off-target or side effects. Alternatively, target 
inhibition with small molecule inhibitors (SMI) usually only blocks catalytic centers of proteins 
without visualizing them (Fig. 12). In summary, chromobodies combine the wide target range 
of antibodies with live cell capabilities of fluorescent protein fusions and thus allow tracing of 
any cellular epitope including endogenous proteins, their post-translational modifications and 
conformational states as well as non-protein components in vivo. 
 
 
Fig. 12Different strategies of protein inhibition and knock-down: small molecule inhibitors (SMI) 
directed against catalytic centers of proteins; down-regulation of protein expression with siRNA; 
chromobodies to simultaneously inhibit protein function and visualize the endogenous protein. 
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III.3. A GFP-binding protein for biochemical and functional 
studies 
In recent years green fluorescent protein (GFP) and spectral variants thereof became popular 
tools to study protein localization, interaction and in combination with fluorescence 
photobleaching techniques, provided unique information on protein dynamics in living cells. 
Necessary further information on DNA binding, enzymatic activity and complex formation of 
the studied proteins can be obtained with various biochemical techniques. These methods, 
however, are often hampered by the limited availability of specific antibodies. A common way 
to bypass that limitation are fusions of the protein of interest to specific epitope- or protein-tags 
including HA, c-Myc, FLAG or GST (Terpe, 2003). Curiously, GFP, the most widely used 
labeling tag in cell biology, is rarely used for biochemical analyses (Cristea et al., 2005; 
Lorkovic et al., 2004). 
We have now engineered a novel tool to isolate GFP, based on the antigen-binding VHH 
domain derived from an alpaca heavy-chain antibody, referred to as the GFP-binding protein 
(GBP). This GBP can easily be produced in bacteria in unlimited quantities and reproducible 
quality and coupled to matrices (referred to as the GFP-nanotrap). The GFP-nanotrap resembles 
the versatile link between cell biological and biochemical approaches where GFP fusion 
proteins can first be studied in vivo and thereafter be easily isolated for in vitro analyses. The 
high affinity of the GFP-nanotrap allows short (5 – 30 min) time incubations to quantitatively 
precipitate GFP fusion proteins with minimized unspecific binding. Furthermore, it entirely 
avoids contamination by heavy and light chains of conventional antibodies (50 and 25 kDa) 
that normally interfere with subsequent analyses. We took advantage of the GFP-nanotrap to 
isolate GFP-labeled wild-type and mutant Dnmt1 for comparison of enzymatic activity or 
interactions assays after having analyzed the distribution of the proteins in cells. 
In an additional approach, we demonstrated that the GFP-nanotrap could be fused with 
structural proteins, like lamins to ectopically capture GFP fusion proteins and their interacting 
endogenous partners to a defined region inside living cells. The use of this intracellular 
nanotrap opens up an entire spectrum of new types of functional studies to probe and 
manipulate cellular processes and structures. Currently we aim to target specific gene loci to 
heterochromatic or euchromatic domains in the nucleus. This would enable direct studies on 
the role and organization of nuclear architecture, in particular the effects of nuclear localization 
of genes on their transcriptional activity. Additionally we try to implement a “switch” in the 
GFP-nanotrap to reversibly induce directed translocations. 
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III.4. Direct visualization of enzyme-activity in living cells 
Faithful replication of genetic and epigenetic information is crucial to ensure the integrity and 
identity of proliferating cells. We owe part of our basic knowledge about DNA methylation to 
classical biochemical approaches, which cannot reflect the complexity of living, mammalian 
cells. 
The trapping assay described in chapter II.4 allows to study Dnmt1 for the first time in its 
physiological environment with its natural substrate in the context of dynamic chromatin 
structures and simultaneously ongoing DNA replication. The method is based on the formation 
of a covalent complex of DNA methyltransferases with cytosine residues during the methylation 
reaction. After the methylation reaction the enzyme is released from DNA by -elimination and 
available for another round of methylation. This mobility of the enzyme can be measured in 
FRAP experiments with fluorescently labeled Dnmt1 as fluorescence recovery when bleaching 
replication foci (Fig. 13a). Incubation of cells with normal growth medium containing the 
cytosine analog 5-aza-2'-deoxycitidine (5-aza-dC) leads to incorporation of 5-aza-dC into 
newly replicated DNA. The subsequent methylation of 5-aza-dC results in a covalent 
nucleotide/protein complex, which cannot be disassembled due to the lack of a proton at 
carbon 5 of the base ring. This trapping of Dnmt1 at the DNA can be visualized since no 
fluorescence of GFP-Dnmt1 at bleached replication sites recovers (Fig. 13b). 
With this trapping assay both, activity and subnuclear targeting of Dnmts can be analyzed in 
situ at different cell cycle stages in single living cells. We show that this technique can be used 
to monitor any fluorescently labeled DNA methyltransferase actively engaged in the 
methylation reaction with a mobile nuclear distribution. In addition, we demonstrate that the 
trapping assay is a new approach to directly test the effects of mutations of Dnmts in living cells 
on account of different fluorescence recovery rates, which reflect the enzymatic activity of the 
fusion proteins (Fig. 13c). Furthermore, this method now enables a direct analysis of the 
consequences of other demethylating drugs than 5-aza-dC, like zebularine (1-(-D-
ribofuranosyl)-1,2-dihydropyrimidin-2-one) (Cheng et al., 2003; Zhou et al., 2002) or 
procainamide (Lin et al., 2001; Scheinbart et al., 1991), which are widely used in basic 
research and in cancer therapy. The trapping assay also offers an approach to test new types of 
target inhibition of Dnmts including treatment with small molecule inhibitors to specifically 
block the catalytic center (Fig. 13d). 
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Fig. 13Rational of the trapping assay. (a) Dnmt1 binds to hemimethylated CpG sites (black and white 
hexagons) and forms a transient covalent complex with the cytosine residue (red line). After methyl group 
transfer the enzyme is released and becomes available for another round of methylation (dotted arrow), 
which is visualized as fluorescence recovery after photobleaching of GFP-Dnmt1. (b) Mechanism based 
inhibitors such as 5-aza-dC (orange hexagons) are incorporated into DNA during S phase. Dnmt1 forms a 
stable covalent complex with 5-aza-dC and becomes trapped. Immobilization of GFP-Dnmt1 is detected 
as lack of recovery after photobleaching. (c) In contrast, fluorescence recovery is observed if the catalytic 
function of Dnmt1 is eliminated by a mutation (black dot in the catalytic domain). (d) Likewise, blocking 
the catalytic site of Dnmt1 with small molecule inhibitors (SMI) would prevent covalent complex 
formation again resulting in fluorescence recovery after photobleaching. 
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III.5. Combinatorial approaches and outlook 
After the development of several new powerful methods and tools to investigate protein 
localization, distribution, dynamics, interactions and function the next challenge is now to 
optimize, expand, automate, integrate and combine them. 
First, to generate new chromobodies, large libraries of potential VHHs have to be screened to 
isolate antigen-recognizing chromobodies. This is classically done with the phage display 
technology followed by an enzyme-linked immunosorbent assay (ELISA). In vitro identified 
chromobodies then have to be tested in vivo where they can have divergent properties on 
account of the natively folded antigen. Instead, high-throughput screening of chromobody-
libraries with the F2H assay in living cells would directly identify “true” chromobodies and 
could also provide data about binding affinities to the antigen by FRAP analysis. By presenting 
either a denatured antigen in the classical systems or an antigen that is properly folded inside 
eukaryotic cells, different chromobodies with different binding properties for different 
applications could be identified. 
Second, generating a chromobody-based target inhibitor specifically directed against the 
catalytic center of Dnmt1 while simultaneously visualizing the endogenous protein and testing 
its ability to prevent 5-aza-dC–mediated trapping is yet another challenge, since in cancer cells 
tumor-suppressor genes are frequently silenced by erroneous methylation. Pharmaceutical 
strategies aim at transient inhibition of Dnmts to reactivate such epigenetically silenced genes 
and re-establish normal cell cycle and growth control (Christman, 2002). Mechanism-based 
inhibitors such as 5-aza-dC presently under clinical trials, generate irreversible Dnmt1-DNA 
adducts that may lead to cytotoxic side-effects (Juttermann et al., 1994). Therefore, our goal is 
to isolate chromobodies recognizing Dnmt1 and identify with the trapping assay those that are 
potentially inhibiting their target. In a subsequent step candidate inhibitors can be further 
analyzed with the F2H assay to exclude those chromobodies that are perturbing any protein-
protein interaction. 
Third, the GFP-binding protein (GBP) - taken advantage of in the GFP-nanotrap - can be 
introduced in a non-fluorescent F2H-bait vector replacing protein X in the bait construct. 
Expressed in living cells, this fusion protein will bind to its associated distinct cellular structure. 
The GBP part of the protein will then immobilize GFP-fusion proteins at the defined structure, 
thus indirectly highlighting that structure. Other proteins labeled with a different fluorescence 
either co-localize at that anchoring structure, in case of interaction with the GFP fusion protein 
or show no local enrichment. With this, essentially any GFP labeled protein can be analyzed 
for interaction with any red fluorescent fusion protein, rendering this GBP-coupled F2H assay a 
versatile, highly flexible method. In initial experiments we have successfully tested the 
feasibility of this approach. We will optimize the assay to screen new chromobody-libraries 
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and to study internal and external interactions of Dnmts, mutant Dnmts or isolated domains. In 
a similar approach we targeted GFP labeled Dnmt1 and mutants thereof to the anchoring 
structure. Preliminary experiments indicate a TS-domain (see Fig. 8) mediated DNA 
decondensation at the locus. This unexpected observation has to be validated and further 
analyzed. In general, this demonstrates that the GBP-based F2H assay can also be used to 
investigate protein-DNA interactions. 
The cell biological applications developed during this work are in principle applicable for in 
vivo high-throughput screenings. However, designing and optimizing large-scale transfection 
methods and engineering a microscopic set-up for high-resolution live cell imaging with 
fluorescence dynamics techniques, i.e. FRAP is a further challenge. Current screening stations 
mostly are based on wide-field fluorescence microscopy, imaging with relatively low-resolution 
air objectives through thick (~1mm) plastic bottom multiwell dishes. Such acquisition settings 
are necessary to gain data from hundreds of thousands of cells on thousands of images. At the 
same time, the image quality is sufficient to discriminate between cytoplasmic and nuclear 
localization of a reporter protein, which is presently a common assay. For a more detailed 
analysis of many cells a confocal or confocal-like illumination with high magnification through 
glass bottom plates with optical properties would be preferable. Currently we are collaborating 
with manufacturers of live cell dishes for high-resolution microscopy. Furthermore we will 
improve large-scale transfection methods. A potential automated On-Chip transfection assay is 
outlined in Fig. 14. A transfection mix containing the expression plasmids is spotted on an in 
vivo imaging chamber and cells are seeded on top of the dried DNA spots. Cells growing on 
one of these spots take up the corresponding DNA, express the protein and will be imaged in 
high resolution through the optical bottom dish. The next step will be a collaboration with 
developer of high-content imaging systems to implement dynamic live-cell applications. 
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Fig. 14 (a) Exemplary illustration of a cell-biological high-content analysis with On-Chip transfection. 
Automated spotting of the DNA-transfection reagent-mix at defined positions on a live cell chamber with 
optical bottom (transfection-chip). When dried, cells are seeded on top and incubated. Those growing in 
one of the spots specifically take up the DNA and express the corresponding fusion protein. (b) From left 
to right: spotting robot with enlarged transfection-chip, magnification of a dried transfection spot with 
cells seeded on top, a live cell imaging station imaging transfected cells in a DNA spot. 
Further projects will involve the direct transduction of the chromobody-protein into cells using 
e.g. chemical compounds. An alternative method is based on chromobody fusion to viral 
proteins and small peptides that have the ability to transduce or travel through biological 
membranes. At present, we are developing chromobodies for immunofluorescent methods. In 
initial experiments we could demonstrate that purified chromobodies - directly coupled to a 
chemical dye - when applied in immunofluorescent stainings in fixed cells, do detect their 
antigen. They do so equally efficient as conventional antibodies without the necessity of 
amplifying the signal intensity with secondary antibodies (Fig. 15). 
 
Fig. 15Principle comparison 
between immunofluorescence staining 
with chromobodies and conventional 
antibody-detection. 
 
 
In summary, during this thesis we developed novel, simple, versatile and efficient methods and 
tools to gain a better understanding of the regulation and function of cellular processes such as 
DNA methylation by direct detection of protein-protein interaction, tracing of endogenous 
proteins, targeted translocation of proteins and visualization of DNA methyltransferase activity 
all in living cells in real-time. These tools are now the basis for intriguing applications and 
further developments. 
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CHAPTER IV. Annex 
IV.1. Abbreviations 
5-aza-dC: 5-aza-2'-deoxycitidine 
5mC: 5-methylcytosine 
AD: activator domain 
B2H: bacterial two-hybrid 
BiFC: bimolecular fluorescence complementation 
CDR: complementarity-determining region 
CFP: enhanced cyan fluorescent protein 
ChIP: chromatin immunoprecipitation 
Co-IP: co-immunoprecipitation 
COBRA: combined bisulfite restriction analysis 
CpG: cytosine-guanine dinucleotide 
DAPI: 4',6-diamidino-2-phenylindole 
DB: DNA-binding domain 
DDP1: deafness dystonia peptide 1 
Dnmt: DNA methyltransferase 
DPSS: Diode-Pumped Solid-State 
ELISA: enzyme-linked immunosorbent assay 
F2H: fluorescent two-hybrid 
Fab: fragment antigen binding 
FCS: fluorescence correlation spectroscopy 
FCCS: fluorescence cross-correlation spectroscopy 
FLIP: fluorescence loss in photobleaching 
FP: fluorescent protein 
FRAP: fluorescence recovery after photobleaching 
FRET: fluorescent resonance energy transfer / Förster radius energy transfer 
Gadd: growth arrest and DNA-damage-inducible protein 
GBP: GFP binding protein 
GFP: enhanced green fluorescent protein 
GST: glutathione S-transferase 
H2B: histone H2B 
HDAC: histone deacetylase 
HEK: human embryonic kidney cell line 
HMGA1a : mobility group protein A1a 
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HPLC: high-performance liquid chromatography 
HRP: horseradish peroxidase 
IMS: intermembrane space 
Igf: Insulin growth factor 
IgG: Immunoglobulin G 
IP: immunoprecipitation 
kDa: kilodalton 
LacI: Lac repressor 
methyl-DIP: methylated DNA immunoprecipitation 
MeCP: methyl CpG binding protein 
NHS: N-hydroxysuccinimide 
NLS: nuclear localization signal 
PBD: PCNA binding domain 
PA: photoactivation 
PARP: Poly (ADP-ribose) polymerase 
PBHD: polybromo homology domain 
PC: photoconversion / proline-cysteine 
PCNA: proliferating cell nuclear antigen 
PML: promyelocytic leukemia protein 
RFP: monomeric red fluorescent protein 1 
SAH: S-adenosyl homocysteine 
SAM: S-adenosyl methionine 
scFv: single chain variable fragment 
siRNA: small interfering RNA 
SMI: small molecule inhibitor 
SMT: single molecule tracking 
SUMO3: small ubiquitin-related modifier 3 
TS: targeting sequence (of Dnmt1) 
VHH: variable domain of heavy-chain antibody 
Vim: Vimentin 
XRCC1: X-ray repair cross-complementing protein 1 
Y2H: yeast two-hybrid 
YFP: enhanced yellow fluorescent protein 
ZnF: Zn2+-binding region 
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IV.2. Contributions 
IV.2.1. Declarations of Contributions to II.1 
Heinrich Leonhardt, Cristina Cardoso and me developed the method, conceived the study laid 
and out the project aims. I generated most of the expression constructs and performed 
corresponding experiments. Oliver Mortusewicz generated the XRCC1-LacI-RFP and PCNA-
LacI-RFP expression constructs and analyzed the respective data together with Regina 
Kleinhans. Ulrich Rothbauer provided cDNA for the mitochondrial proteins while Heike 
Göhler from the laboratory of Erich Wanker provided the Huntington’s disease related cDNAs. 
Together with Heinrich Leonhardt, Oliver Mortusewicz and Ulrich Rothbauer I prepared the 
manuscript and the figures. 
 
 
IV.2.2. Declarations of Contributions to II.2 
The project was started as a collaboration with the laboratory of Serge Muyldermans, where 
Natalija Backmann and Katja Conrath isolated the corresponding VHH. Ulrich Rothbauer 
designed and generated all chromobody expression constructs as well as the molecular 
biological experiments. Sergei Tillib provided anti-Lamin and anti-Cytokeratin8-VHHs. Danny 
Nowak and Anja Gahl from the group of Cristina Cardoso purified GFP and provided several 
expression constructs. I designed, performed and analyzed the cell biological experiments: 
expressing chromobodies in living cells, performing long term live cell microscopy and FRAP 
analysis of binding properties of chromobodies. I prepared the figures and help writing the 
manuscript. 
 
 
IV.2.3. Declarations of Contributions to II.3 
Ulrich Rothbauer and Heinrich Leonhardt developed the method and conceived the study. 
Ulrich Rothbauer performed all molecular biological experiments. Serge Muyldermans 
generated the anti-GFP VHH. Aloys Schepers performed ChIP experiments for Figure 4. All 
fluorescently labeled Dnmt1 and PCNA fusions were provided by Cristina Cardoso. I designed 
and conducted the Lamin-GBP experiments, prepared all figures and helped writing the 
manuscript. 
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IV.2.4. Declarations of Contributions to II.4 
Heinrich Leonhardt and Lothar Schermelleh laid out the project aims and conceived the study. 
Fabio Spada designed and performed the methylation analysis in dnmt1–/– ES cells for 
supplementary Figure 1. Hariharan Easwaran, Jean Margot from the laboratory of Cristina 
Cardoso provided all fluorescently labeled Dnmt1 and PCNA fusions. I performed the 
experiment for supplementary Figure 2 and analyzed the data for Figures 2d and 3 together 
with Lothar Schermelleh and helped setting up the microscopy for the photoactivation 
experiment. In addition, I prepared the Figures 1 and 5 and helped writing the manuscript. 
 
 
IV.2.5. Declarations of Contributions to II.5 
Fabio Spada wrote most of the manuscript. I prepared the figures, discussed and helped writing 
the manuscript together with Ulrich Rothbauer, Lothar Schermelleh and Heinrich Leonhardt. 
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